<SEC-DOCUMENT>0001387131-20-004479.txt : 20200506
<SEC-HEADER>0001387131-20-004479.hdr.sgml : 20200506
<ACCEPTANCE-DATETIME>20200506172331
ACCESSION NUMBER:		0001387131-20-004479
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200506
DATE AS OF CHANGE:		20200506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		20853706

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_033120.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:txmd="http://therapeuticsmd.com/20200331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_P%2D%2D\Clients\TherapeuticsMD\2020\q20%2D01768__10%2DQ\merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" id="xdx2ixbrl0049" name="dei:EntityFilerCategory">Large Accelerated Filer</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-03-31" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-12-31" id="xdx2ixbrl0161" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-03-31" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-03-31" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-01to2020-03-31" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-01-012019-03-31" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-012019-03-31" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-012019-03-31" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-012019-03-31" id="xdx2ixbrl0891" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10057632</ix:nonFraction>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-03-31" id="xdx2ixbrl1322" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="txmd-20200331.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_VitaminsAndImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUSPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticPatentsNonApprovedBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUSPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUSUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUSDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUtilityPatentTx009HRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ForeignPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_DomesticUtilityPatentOperaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-16</xbrli:startDate>
        <xbrli:endDate>2020-02-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_WarrantMember348335407">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_WarrantsCashlessExerciseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_NewSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NewSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RestrictedStockMember_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_PerformanceSharesMember_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SupplierFourConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierFourConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_SupplierOneConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_custom_SupplierFourConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierFourConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_FiveCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FiveCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPharmacyInnovationsPaRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-302013-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-30</xbrli:startDate>
        <xbrli:endDate>2013-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-26</xbrli:startDate>
        <xbrli:endDate>2020-04-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED STATES</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES AND EXCHANGE COMMISSION</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 12pt Times New Roman, Times, Serif"><b>WASHINGTON, D.C. 20549</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 16pt Times New Roman, Times, Serif"><b>FORM <span id="xdx_90C_edei--DocumentType_c20200101__20200331_z9BdsTmyrD4c" title="Document Type"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">(Mark One)</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--DocumentQuarterlyReport_c20200101__20200331_zHMR2U4yQhx8" title="Document Quarterly Report"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0"><span style="font: 12pt Times New Roman, Times, Serif"><b>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
                <p style="margin-bottom: 0; margin-top: 0">

                </p>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in">
        <span style="font: 10pt Times New Roman, Times, Serif">For the quarterly period ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20200101__20200331_zHmKB8FmyD38" title="Document Period End Date"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2020</ix:nonNumeric></span></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">or</span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--DocumentTransitionReport_c20200101__20200331_zRw91GnlR3x4" title="Document Transition Report"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport">&#x2610;</ix:nonNumeric></span></span>
            </td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span>
                </p>
                <p style="margin-bottom: 0; margin-top: 0">

                </p>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><span title="Entity File Number">For the transition period from________ to ___________</span></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">Commission File No. <b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityFileNumber_c20200101__20200331_z3FPJknNcvoc" title="Entity File Number"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityFileNumber">001-00100</ix:nonNumeric></span></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20200101__20200331_zfVHhxxJh4rf" title="Entity Registrant Name"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityRegistrantName">THERAPEUTICSMD, INC.</ix:nonNumeric></span></span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Its Charter)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="width: 21%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20200101__20200331_zV2bogKki6ie" title="Entity Incorporation State Country Code"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 21%; text-align: center">&#160;</td>
            <td style="width: 19%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20200101__20200331_z7d68oechkS7" title="Entity Tax Identification Number"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityTaxIdentificationNumber">87-0233535</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 19%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of Incorporation or Organization)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="width: 12%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 26%; text-align: center"><span id="xdx_902_edei--EntityAddressAddressLine1_c20200101__20200331_zR1Oq4Bkagi2" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityAddressAddressLine1">951
Yamato Road</ix:nonNumeric></b></span><b><span style="font: 10pt Times New Roman, Times, Serif">, <span id="xdx_909_edei--EntityAddressAddressLine2_c20200101__20200331_zOIsSQaWN1p8"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityAddressAddressLine2">Suite
220</ix:nonNumeric></span></span></b><b>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20200101__20200331_zkxjZ2Aou5Y8"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span></b><b>,
<span id="xdx_90D_edei--EntityAddressStateOrProvince_c20200101__20200331_zThlee97DRTe"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></td>
            <td style="width: 12%; text-align: center">&#160;</td>
            <td style="width: 19%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 12%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20200101__20200331_z5gpPS51cHwe" title="Entity Address Postal Zip Code"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityAddressPostalZipCode">33431</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 19%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--CityAreaCode_c20200101__20200331_zD7kVQOlbh44" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:CityAreaCode"><span style="text-decoration: underline">561</span></ix:nonNumeric></b></span><span style="text-decoration: underline"><span style="font: 10pt Times New Roman, Times, Serif">-<span id="xdx_906_edei--LocalPhoneNumber_c20200101__20200331_zU50QFGEG13b"><b><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:LocalPhoneNumber">961-1900</ix:nonNumeric></b></span></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#x2019;s telephone number, including area code)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Not Applicable</span></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">Securities registered pursuant to Section 12(b) of the Act:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 40%; text-align: center"><b>Title
    of Each Class</b></td>
    <td style="border: Black 1pt solid; width: 15%; text-align: center"><b>Trading Symbol</b></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 45%; text-align: center"><b>Name
    of Each Exchange on Which Registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span id="xdx_905_edei--Security12bTitle_c20200101__20200331_z3fWDi4HE8jg" title="Security 12b Title"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20200101__20200331_zfajTwzt0Vhe" title="Trading Symbol"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:TradingSymbol">TXMD</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span id="xdx_901_edei--SecurityExchangeName_c20200101__20200331_zjifRAirs3I1" title="Security Exchange Name"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
</table>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20200101__20200331_zsz2M2H3EJe5" title="Entity Current Reporting Status"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#x2610;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_908_edei--EntityInteractiveDataCurrent_c20200101__20200331_z34P3TU9nle8" title="Entity Interactive Data Current"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#x2612; No &#x2610;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act (Check one):</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 30%"><span title="Entity Filer Category"><span id="xdx_905_edei--EntityFilerCategory_dxL_c20200101__20200331_zxxqr8Q5stW4" title="Entity Filer Category"><span style="-sec-ix-hidden: xdx2ixbrl0049">Large Accelerated Filer</span></span></span> &#9746;</td>
    <td style="width: 20%">&#160;</td>
    <td style="width: 30%">Accelerated filer &#x2610;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>Non-accelerated filer &#x2610;</td>
    <td>&#160;</td>
    <td>Smaller reporting company<span id="xdx_90B_edei--EntitySmallBusiness_c20200101__20200331_zDtmLdn69H9k" title="Entity Small Business"> <ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness">&#x2610;</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20200101__20200331_zZSftc6Crnx8" title="Entity Emerging Growth Company"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#x2610;</ix:nonNumeric></span></td></tr>
</table>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#x2610; <span id="xdx_907_edei--EntityShellCompany_c20200101__20200331_zs2tgZR5Zj4l" title="Entity Shell Company"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <span style="font: 10pt Times New Roman, Times, Serif">The
    number of shares outstanding of the registrant&#x2019;s common stock, par value $0.001 per share, as of May 1, 2020 was <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20200501_zksN9Rj8akNg" title="Entity Common Stock Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-05-01" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,683,266</ix:nonFraction></span>. <br /> </span> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <!-- Field: Page; Sequence: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
    INC. AND SUBSIDIARIES</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="4" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INDEX</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_001">PART
    I - FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">Item. 1.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003">Consolidated Balance Sheets as of March 31, 2020 (Unaudited) and December 31, 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004">Consolidated Statements of Operations for the Three Months Ended March 31, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005">Consolidated Statements of Stockholders' (Deficit) Equity for the Three Months Ended&#160;&#160;March 31, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 (Unaudited) and 2019 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007">Notes to Unaudited Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">7</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008">Item 2.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">22</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009">Item 3.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">39</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010">Item 4.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">39</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_011">PART
    II - OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012">Item 1.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013">Item 1A.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">40</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014">Item 6.</a></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_001"></span>PART
    I - FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="a_002"></span>Item.
    1</span></b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline"><span style="font: 10pt Times New Roman, Times, Serif">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>


<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_003"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_pp0p0_z2UXyPzGzLV2" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49F_20200331_z0TnGRobcRzg" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20191231_z2wRP7Dz3xRf" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>(Unaudited)</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>&#160;</b></td></tr>
<tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zWjksYct1Skf" style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">ASSETS</td></tr>
<tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zBZO7FMaQvqk" style="vertical-align: bottom">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--Cash_i02I_maCzEt6_maACzdfO_z2LpvZU0Ckw3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 68%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,097,813</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzEt6_maACzdfO_zdaj02L9tOKc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accounts receivable, net of allowance for doubtful accounts of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20200331_zafWJ34ET8Nh" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">781,419</ix:nonFraction></span> and
    $<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20191231_zmE2mKUP4mOi" title="Allowance for doubtful accounts"><span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20191231_z76P8fwLykHi" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">904,040</ix:nonFraction></ix:nonFraction></span></span>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,664,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,395,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--InventoryNet_i02I_maCzEt6_maACzdfO_zNFQw3EN8dZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,607,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzEt6_maACzdfO_zvlAZdM4WQg4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,618,367</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_mtCzEt6_maCzBez_mtACzdfO_zzdDiATAWTK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">211,987,642</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">208,416,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzBez_maAz6Rh_zkey6Oba9LA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Fixed assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,330,190</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--OtherAssetsAbstract_i01B_zBLfla8mbaKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--LicenseRights_i02I_maOANzrAT_zNhsVC0o7Bdh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">License rights, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,475,797</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,221,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maOANzrAT_z4ATXTMNREh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,616,832</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maOANzrAT_zXt9Cn9kjHpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,757,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherAssetsMiscellaneousNoncurrent_i02I_uUSD_maOANzrAT_zkq9QBMS9hKi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">473,009</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">473,009</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_i02TI_maCzBez_mtOANzrAT_z5JBdLe9AsIh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,322,805</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,061,682</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--Assets_i01TI_mtCzBez_mtAz6Rh_z5D11lNOTuWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">268,640,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z02a0RCdTiDe" style="vertical-align: bottom; background-color: White">
    <td colspan="9" style="text-align: center">&#160;LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zOM5gqH40Rf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_i02I_maCzYuh_zQRWUus7wWYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,714,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,181,212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzYuh_znIWFrCkM7de" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,924,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_i02TI_mtCzYuh_maCz9gb_zL1RPeW3tC27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,638,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,004,825</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--LongTermDebtNoncurrentAbstract_i01B_z6XHqC4HZbU3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-Term Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_i02I_maLNz1Ez_zSaOCOvyU0cg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,428,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,634,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNz1Ez_zFb50qvYjg68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,782,274</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNz1Ez_maCz9gb_zNjvYiJvoBsl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total long-term liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">252,210,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">203,779,692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--Liabilities_i01TI_mtCz9gb_maCzqJc_maLASEzhH2_zObXYOM1xyzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">313,849,757</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,784,517</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_iI_zFNv3Lbrm20b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and Contingencies - See Note 15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_iB_zHfsnIrWBleg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders' (Deficit) Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_maCzFMB_maSEzfrc_zxizk4vwX8rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Preferred stock - par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20200331_zamDE7d0Qam4" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20191231_zcxeLVpaGuOi" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pii_c20200331_zupZgohe2T8b" title="Preferred Stock, Shares Authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pii_c20191231_zEwNbu0YCKul" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20200331_zds2Taa3u9p2" title="Preferred Stock, Shares Issued"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20191231_zS6ziwZZMFGd" title="Preferred Stock, Shares Issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20200331_zwNXQvhOy7if" title="Preferred Stock, Shares Outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20191231_zCu82I4YDIKg" title="Preferred Stock, Shares Outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued
    and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0161">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--CommonStockValue_i02I_maCzFMB_maSEzfrc_zidepkTP7x4c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Common stock - par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20200331_zChUS7ivObLj" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_z5r7hC8Oemk5" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20200331_zYzveqKq5f3f" title="Common Stock, Shares Authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_z9lSl90HqEVc" title="Common Stock, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized: <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pii_c20200331_zzPGUdxZisU4" title="Common Stock, Shares, Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20200331_zC2Yc0ANIIZ6" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,677,742</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pii_c20191231_zLbb3O3hJaec" title="Common Stock, Shares, Issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20191231_zmKOEqE2ltsj" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></ix:nonFraction></span></span>
    issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzFMB_maSEzfrc_zufAhMDBnqJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">706,789,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzFMB_maSEzfrc_zJtTET89eEXb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">752,270,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_mtSEzfrc_maLASEzhH2_zivn8tsoU9ul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total stockholders' (deficit) equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">45,209,120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,201,120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzhH2_zdS2W7otvDU8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in">Total liabilities and stockholders' equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">268,640,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,985,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_004"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_zsRWYskooF9j" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_492_20200101__20200331_zLVLzanPiaY2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td id="xdx_496_20190101__20190331_zm1W17df5rY1" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Three
    Months Ended</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March
    31,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_maGPzi8w_zb8YxXPZXVQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Product
    revenue, net</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,250,657</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,946,651</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_uUSD_msGPzi8w_ziIGj3GXeMZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost
    of goods sold</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,715,051</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">762,827</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--GrossProfit_iT_pp0p0_uUSD_maCzLQk_mtGPzi8w_zF1MG99U8xYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Gross
    profit</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,535,606</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,183,824</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zeq9raqu3ye4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_uUSD_maCz8md_maOEzENo_z3v7S3y0mkX1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Sales,
    general, and administrative</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,927,021</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,864,082</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_uUSD_maCz8md_maOEzENo_zDRIjU0f0Yih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,268,829</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,317,882</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--DepreciationAndAmortization_i01_pp0p0_uUSD_maCz8md_maOEzENo_zXUkldtI80q" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
    and amortization</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">261,994</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,938</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--OperatingExpenses_i01T_pp0p0_uUSD_mtCz8md_msCzLQk_mtOEzENo_z7tTkpZ14tob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Total
    operating expenses</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,457,844</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,288,902</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_pp0p0_uUSD_mtCzLQk_maILFCOzwtU_zurcSQuOzNN6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Operating loss</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">50,922,238</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">38,105,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zzGLXNlOW9ue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other income (expense)</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--OtherNonoperatingIncome_i01_pp0p0_uUSD_maCzo9M_maNIEzTbj_zRglzONkRnWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Miscellaneous
    income</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">335,482</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">688,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--InterestExpense_i01N_pp0p0_di_uUSD_msCzo9M_msNIEzTbj_zIyogf8lqXS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
    expense</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,262,046</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,090,018</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_uUSD_mtNIEzTbj_maILFCOzwtU_z1BhQLQ1gh0l" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other expense</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,926,564</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,401,297</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_uUSD_maCz8zb_mtILFCOzwtU_zPppmMQsBc4f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Loss before income
    taxes</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_uUSD_msCz8zb_msNILzuXr_zNfDuJmjw7rf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Provision
    for income taxes</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_pp0p0_uUSD_mtCz8zb_mtNILzuXr_zWqh4h4uiBC9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_z5TjW6gthU7k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Loss per share, basic
    and diluted:</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pii_uUSDPShares_zjGMlEInyKm6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss per share, basic and diluted</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.21</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pii_uShares_z7UV6rbY5Mbi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of common shares outstanding, basic and diluted</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,459,522</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,006,032</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_005"></span>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>FOR
THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zgwu9Lo1rRze" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zIqv1y1DvZW1" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zTVRPvCLpp9j" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zZUbBmn5PHm">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_4B3_znLLPrQIAAx9">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Additional</b></td><td><b>&#160;</b></td>
    <td colspan="3"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="3"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>Common Stock</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Paid in</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center"><b>Accumulated</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Capital</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr id="xdx_435_c20190101__20190331_eus-gaap--StockholdersEquity_iS_pp0p0_uUSD_zFQHgrwrIfu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; font-weight: bold">Balance, December 31, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesOutstanding_iS_pii_uShares_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAyFHO1c39kc" title="Beginning balance, shares" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,462,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">616,559,938</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,524,121</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pp0p0_uUSD_z912KXczBEN8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; text-align: left"><p style="margin-top: 0; margin-bottom: 0">Shares issued for exercise of options</p>
                                                      <p style="margin-left: 10pt; margin-top: 0; margin-bottom: 0">and warrants, net</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoqvriP8kN8" title="Shares issued for exercise of options and warrants, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">759,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_pp0p0_uUSD_zSOzChRXvUie" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,575,369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,575,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_pp0p0_uUSD_zEOcALicZxKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--StockholdersEquity_iE_pp0p0_uUSD_z2bqVNMjny9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesOutstanding_iE_pii_uShares_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlxubLvacYHe" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,221,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,222</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">619,234,655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">558,782,655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,693,222</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20200101__20200331_eus-gaap--StockholdersEquity_iS_pp0p0_uUSD_zmPTFUtmmjLg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CommonStockSharesOutstanding_iS_pii_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGsf2785bxt7" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">704,351,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,201,120</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_zy3vAMLHolxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><p style="margin-top: 0; margin-bottom: 0">Shares issued for exercise of options,</p>
        <p style="text-indent: 10pt; margin-left: 0pt; margin-top: 0; margin-bottom: 0">net</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQSs49fmFeFb" title="Shares issued for exercise of options, net (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pp0p0_uUSD_zO2FtWKCw9Qk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">Issuance of shares from release of</p>
                                 <p style="margin-left: 10pt; margin-top: 0; margin-bottom: 0">restricted stock</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXVcJ3vITL4" title="Issuance of shares from release of restricted stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_pp0p0_uUSD_zzzFYnlSUuF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,366,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,366,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_pp0p0_uUSD_zKDLDg51fu39" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--StockholdersEquity_iE_pp0p0_uUSD_zbaOdgmFwgLi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--CommonStockSharesOutstanding_iE_pii_uShares_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4B3enRtZAv2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,677,742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,678</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">706,789,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">752,270,081</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">45,209,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_006"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zGbUfN5G98Q3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20200101__20200331_znROGtiGWQ1c" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20190101__20190331_zuxJrlIRl2Bc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center"><b>Three Months Ended</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zI4AS7eTA3V6" style="vertical-align: bottom">
    <td style="text-align: left"><b>CASH FLOWS FROM OPERATING ACTIVITIES</b></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maCzwgu_zXhE5496ZK7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif; width: 68%">Net loss</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,848,802</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zHSu8FfvY0Xk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Adjustments to
    reconcile net loss to net cash used in operating activities:</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--Depreciation_i02_maCzwgu_zPHPOiZl5sE4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Depreciation of fixed assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AmortizationOfIntangibleAssets_i02_maCzwgu_z5rwU5ckUNTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization of intangible assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--NoncashOperatingLeaseExpense_i02_maCzwgu_zwHeE94rFebi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Non-cash operating lease expense</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i02_maCzwgu_z8kX02H8or11" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">(Recovery of) provision for doubtful accounts</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">122,621</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maCzwgu_zG4HfmmZQtVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,366,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,586,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCosts_i02_maCzwgu_zrHDqx3tQAaj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization of deferred financing fees</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--OtherAmortizationOfDeferredCharges_i02_maCzwgu_ztrGJSgvYnKl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization of license fee</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">745,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zrDmLTdW2N8b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCzwgu_zgxnZUMsaMY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Accounts receivable</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,854,569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,963,214</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msCzwgu_z5JrFjYwxsx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Inventory</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,746,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,688,045</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msCzwgu_zwGJHmSVt2I1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Other current assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,436,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">987,794</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzwgu_zFYnJr5EbX6e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Accounts payable</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,533,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,621,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_maCzwgu_zQgU5XA5AEYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Accrued expenses and other current liabilities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,261,904</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzwgu_maCCERCzntz_zamEyToYzMo6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Net cash used in operating activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39,110,980</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,163,418</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_ztTItcsfxnR1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCz99a_z6EanXqQMFA7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Patent costs</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">421,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,496</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz99a_zuA3IQRIJdzh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Purchase of fixed assets</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,254</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,418</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz99a_maCCERCzntz_zTtZa9brt977" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Net cash used in investing activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">443,029</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">665,914</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zfswFbcUyQVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzBhp_ztHVxErof0dc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from exercise of options and warrants</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ProceedsFromLinesOfCredit_i01_maCzBhp_zKBhz7b4PBA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from Financing Agreement</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msCzBhp_zJ51fTSQ2oUa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Payment of deferred financing fees</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzBhp_maCzSK6_maCCERCzntz_zSJcyZrHhFyh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,822,109</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,107</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzntz_zRLj00hH1PWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Increase (decrease) in cash</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,268,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,729,225</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zSBe7YPeQeC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Cash, beginning of period</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,829,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,613,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zLjrfRChxFo9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Cash, end of period</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,097,813</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,883,852</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z5haJFgd9KGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Supplemental disclosure of cash flow information</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestPaidNet_i01_zAKX5lpIxjM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Interest paid</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,892,639</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,913,956</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;The accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_007"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_803_eus-gaap--NatureOfOperations_zCf0mFzoW4vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
1 &#8211; <span>THE COMPANY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has <span id="xdx_905_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20200331_zg7eQzOXdG8f" title="Number of subsidiaries"><ix:nonFraction name="txmd:NumberOfSubsidiaries" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup> and BIJUVA<sup>&#174;
</sup>are registered trademarks of our company and ANNOVERA&#8482; is a licensed trademark of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nature
of Business</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as
the pandemic began to negatively affect our revenue growth. On July 30, 2018, we entered into an exclusive license agreement,
or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License
Agreement, with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply
agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY
outside of the U.S., excluding Canada and Israel, or the Theramex Territory.</span></p>

</ix:nonNumeric><p id="xdx_818_zMDiTEPPeagi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqs0mBmK3lt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
2 &#8211; <span>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Interim
Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Risks
and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to risks and uncertainties as a result of the&#160;COVID-19 pandemic. The extent of the impact of the&#160;COVID-19
pandemic on our business is highly uncertain and difficult to predict, as the response to the pandemic is in its incipient stages
and information is rapidly evolving. At this time,&#160;we continue to provide an uninterrupted supply of our portfolio of products
for patients. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
have activated virtual options to ensure business continuity. Our VitaCare Prescription Services patient model assists patients
in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice, including via
home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple third-party online
pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time access to both
diagnosis and treatment. We continue to support prescribers&#8217; needs with samples and product materials through our sales
force. If access is restricted, we currently have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for virtual detailing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
have also implemented measures to cut planned marketing expenses for 2020. However, we have the ability to re-accelerate our
planned marketing spend for ANNOVERA and IMVEXXY should market conditions improve, or to extend or expand the cost cuts
throughout 2020. We have also implemented cost savings which include negotiating lower fees or suspending services from third
party vendors; implementing a company-wide hiring freeze; delaying or cancelling non-critical IT projects; and eliminating
travel, entertainment, meeting, and event expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
savings can be extended further throughout 2020 or expanded depending on the impact of the COVID-19 pandemic. We already have
sufficient inventory of finished product in our warehouses to meet anticipated demand through at least early third quarter of
2020. However, capital markets and economies worldwide have also been negatively impacted by the&#160;COVID-19 pandemic, and it
is possible that it could cause a local and/or global economic recession. Such economic disruption could have a material adverse
effect on our business. Policymakers globally have responded with fiscal policy actions to support the healthcare industry and
economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
severity of the impact of the&#160;COVID-19 pandemic on our business will depend on a number of factors, including, but not limited
to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, all of which are uncertain
and cannot be predicted. Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding
receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives
or programs that we may undertake to address financial and operations challenges that we may face. As of the date of issuance
of these condensed consolidated financial statements, the extent to which the&#160;COVID-19 pandemic may materially impact our
financial condition, liquidity, or results of operations is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020 and the adoption did not have a material effect
on our disclosures for the three months ended March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we&#160;adopted&#160;ASU&#160;2016-13&#160;under a modified retrospective approach for all financial assets measured
at amortized cost. There was no adjustment recorded for the cumulative effect of adopting&#160;ASU 2016-13. The adoption expanded
disclosures about our credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

</ix:nonNumeric><p id="xdx_81C_zUw5UH4XkBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zbseyW5Kul43" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
3 &#8211; <span>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcDsiscBqahk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86D_zVfQLBPHJG05">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency.
We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results
of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement,
economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current&#160;COVID-19
pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible
that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.</span></p>

</ix:nonNumeric><p id="xdx_852_z0YGBG7DUQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z11CO1OFronh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_zb5WXYUcbjo3">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of March 31, 2020 (as disclosed in Note 9), approximates fair value based on market activity for other debt
instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority
to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level
3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs,
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b></b>unobservable inputs for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020 and 2019, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the three months ended March
31, 2020 and 2019.</span></p>

</ix:nonNumeric><p id="xdx_856_zv4cHFKehwo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrmNc7Fxmvkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_z2ve2i6okDGd">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share
appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective
service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable
model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the
input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the
risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed
interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term
of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer
entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices </span>over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our
stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January
1, 2020, the average expected life of options was based on the contractual terms of the stock option using the simplified
method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of share-based awards represent our best
estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the
future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value
estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the
employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January
1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with
the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718
to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an
entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued
to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock awards and restricted stock awards for shares of common stock to employees. We value our restricted
stock awards and our performance-based stock awards by reference to our stock price on the date of grant. We have elected to recognize
compensation expense on a straight-line basis over the requisite service period of the entire award. The number of target shares
that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the
awards, restricted stock is issued based on the level of attainment. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at the grant date and through the date the restricted stock vests.</span></p>

</ix:nonNumeric><p id="xdx_858_zjel9ti0dSVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1NAqlekhAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zSAXok5ZTlTc">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains
control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled
to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine
revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect
to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract
with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance
obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we
began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started
selling ANNOVERA in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the
commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent
quarters. We sell our name brand and generic prescription products primarily through wholesale distributors and retail
pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is
to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies,
which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a
fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance
obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when
the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the
use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers
once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from
contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is
typically due between 30 and 60 days after an invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC,
determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated
product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts
earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is
payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to
determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either
utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract
or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to
the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence
that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the
magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may
differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates,
which would affect net product revenue and earnings in the period such changes in estimates become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_900_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200331__srt--RangeAxis__srt--MinimumMember_znIeOi1oJiaj" title="Return period of unsalable prescription products"><ix:nonNumeric contextRef="From2020-01-012020-03-31_srt_MinimumMember" format="ixt-sec:durwordsen" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">six months</ix:nonNumeric></span> prior
to and up to <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200331__srt--RangeAxis__srt--MaximumMember_zo4Ui1stUbal" title="Return period of unsalable prescription products"><ix:nonNumeric contextRef="From2020-01-012020-03-31_srt_MaximumMember" format="ixt-sec:durmonth" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">12</ix:nonNumeric></span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_90B_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zAfK3GGRO4B1" title="Shelf life of prescription products following product expiration"><ix:nonNumeric contextRef="From2020-01-012020-03-31_custom_VitaminsAndImvexxyMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">24</ix:nonNumeric></span> months from the
date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zoUI68K6dNE7" title="Shelf life of prescription products following product expiration"><ix:nonNumeric contextRef="From2020-01-012020-03-31_custom_BijuvaAndAnnoveraMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">18</ix:nonNumeric></span> months from the date of manufacture. We do not allow
product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that
may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue
is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped
to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history
of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the
inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product
returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in other current liabilities on the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based
on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current
liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking
into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons
and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice
discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained
by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions
paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance
based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple
performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require
continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zYG13U0vCP7c">The
following table provides information about disaggregated revenue by product mix</span> for the three months ended March 31, 2020 and
2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" title="Net revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,473,691</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" title="Net revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,935,971</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,392,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,010,680</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" title="Net revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-31_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,111,604</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">ANNOVERA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" title="Net revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,272,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,250,657</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" title="Net revenue" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,946,651</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AB_zui8XJd4ZQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_857_z6Hm98q6Y7Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock"><p id="xdx_845_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zf7maL1AmvPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_zp0XoJVfiNs">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span><span id="xdx_904_ecustom--MilestonePaymentUponFDAApproval_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzdSrj6ijlBd" title="Milestone payment upon FDA Approval"><ix:nonFraction name="txmd:MilestonePaymentUponFDAApproval" contextRef="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span></span>
within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_90E_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_pp0p0_uUSD_c20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzlQOnkG2JM8" title="Milestone payments (payment after release of first commercial batch)"><ix:nonFraction name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="AsOf2020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span>
within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_907_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zLVhFWipFgBk" title="License rights acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span> were recorded
as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once
ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license
rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the
product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic
benefit cannot be reliably determined. During the three months ended March 31, 2020, we recorded $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_uUSD_c20200101__20200331_zTaBPhlRojyd" title="Amortization of Intangible Assets"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">745,511</ix:nonFraction></span>
in amortization expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zI4rHPgDmvrf" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>, a royalty of <span id="xdx_90A_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zvRXnSrtFUQk" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of net sales;
(ii) for annual net sales greater than $<span id="xdx_909_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zEGIcUn3ZIz8" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> and less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zj2zgaONK7Qk" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of <span id="xdx_90E_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_z0pqRGQuYJYb" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of such net sales;
and (iii) for net sales greater than $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z5vITeRv7bT8" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000,000</ix:nonFraction></span>, a royalty of <span id="xdx_906_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zzYyhvS5I8og" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of such net sales. The annual royalty rate will be reduced
to <span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPejB3k4KuBi" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <span title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent">20</span>% of the initial rate. We are required to pay the Population Council milestone payments of $<span title="Required milestone payments upon cumulative net sales of specified levels">40 million</span> upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span title="Specified level one of cumulative net sales for required milestone payments">200 million</span>, $<span title="Specified level two of cumulative net sales for required milestone payments">400 million</span> and
$<span title="Specified level three of cumulative net sales for required milestone payments">1 billion</span>. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies
required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with
such post-approval study exceed $<span id="xdx_909_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zULvFtjWtpu7" title="Maximum costs and expenses for post approval"><ix:nonFraction name="txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid" contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>, half of such excess will be offset against royalties or other payments owed by us
to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible
for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional
desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council.</span></p>

</ix:nonNumeric><p id="xdx_852_zpryRNURyH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_842_eus-gaap--CostOfSalesPolicyTextBlock_zQMqlFiuunV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_866_zi5XzR9WB6vk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

</ix:nonNumeric><p id="xdx_853_zu4iP95ikIj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zrGO2CXOx7me" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zhWkW75RPQ0g">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTRKuo0UCEoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

</ix:nonNumeric></ix:nonNumeric><p id="xdx_814_zJqEbDU3jGFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zx9x6ABSzgO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
4 &#8211; INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z9HcyPKJavwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49E_20200331_zJ6OnGfW0RJ1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20191231_zy54QoRqwAMl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_z1MWAvfmBMF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,956,900</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,976,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_zHqBoUQfxH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,554,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,059</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryRawMaterialsAndSupplies_iI_zeAitBvwQ9qa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,095,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,701,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iI_zJDL3HUjRQP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,607,453</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,860,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zROhD73x8m21" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_816_zpOdMlWVyXR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zDZvXy7VLrS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
5 &#8211; <span>OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zdpQqp1SYAR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_z315oeVj3xmd" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_494_20191231_zvT6CFgvEhGl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_404_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_uUSD_maPEAOAzkyn_zs1RarO2Qbud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">553,789</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFinanceCostsCurrentNet_iI_uUSD_maPEAOAzkyn_z0bbbNByTM9i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_uUSD_maPEAOAzkyn_zSzus1ZnjEr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,064,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,812,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--PrepaidManufacturing_iI_uUSD_maPEAOAzkyn_zxx7GgLpXD74" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">955,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,595,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_uUSD_maPEAOAzkyn_z7QgK5iLgiA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,769,073</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,787,482</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_uUSD_mtPEAOAzkyn_zn3jtKbW7UZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,618,367</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,329,793</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zyRjQ5Y3nUai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_810_z4V7WU2gegB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zARnJqTt9ku" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
6 &#8211; FIXED ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeaPRBKHtSa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zg2PJZsXwO0l" title="TOTAL FIXED ASSETS" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlKfWaau3kT" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4Z0zOt08qw8" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,640,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlZcRsPr7uN2" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFKrqFQ0kLal" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlKp2iyTusak" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpvF7xSYPh7h" title="TOTAL FIXED ASSETS" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQsgGEW8GUb1" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zy5WtSAUOjmk" title="TOTAL FIXED ASSETS" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmAhWN0pXa3h" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,788</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331_zVrOjJE771k2" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,497,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231_zpYZ6SytS7i4" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,476,599</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20200331_zChgcuFWqYH" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,167,663</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_znrt2W1QZK68" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">968,824</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20200331_zjtw6zANLYSf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,330,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20191231_zFWC915SmO9i" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,507,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_zom7GMcTy0m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended March 31, 2020 and 2019 was $<span id="xdx_90F_eus-gaap--Depreciation_c20200101__20200331_zIVpkYmOBeZ5" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,839</ix:nonFraction></span>, and $<span id="xdx_90F_eus-gaap--Depreciation_c20190101__20190331_z01OVoVKKuXi" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,494</ix:nonFraction></span>, respectively.</span></p>

</ix:nonNumeric><p id="xdx_814_zWBgsHDGuVU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zchYb4KgHkol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
7 &#8211; INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_897_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zz26GotF80U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of March 31, 2020 and December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br />Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br />Remaining Amortization<br />
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved hormone therapy
    drug&#160;candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zXYDMwse61td" title="Finite-Lived Intangible Assets, Gross" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,763,022</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaYaXoZo6IQ4" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">542,235</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZXtiuvXLzR6" title="Finite-Lived Intangible Assets, Net" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,220,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zuNk95uCDdvh" title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">12.75</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents&#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zQL8AYkzExfd" title="Finite-Lived Intangible Assets, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,070,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z0LxzXYIEQZj" title="Finite-Lived Intangible Assets, Net" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,070,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedTrademarks_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zPBhk7RG6V7c" title="Indefinite-Lived Trademarks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zG6sPBcYD03f" title="Indefinite-lived Intangible Assets (Excluding Goodwill)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20200331_zq4h23lLuIF8" title="Intangible Assets, Gross (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,159,067</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331_zKOzPdRlfZf4" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">542,235</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20200331_zUUFmVblveIb" title="Intangible Assets, Net (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,616,832</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br />Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br />Remaining Amortization<br />
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved
    hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zWdHV07R0ln5" title="Finite-Lived Intangible Assets, Gross" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,463,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlLY2WFRzgc" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">478,983</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z1w0tlUPrEFk" title="Finite-Lived Intangible Assets, Net" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,984,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z5znApwOIz0b" title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">13</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zC5bjbT3nExd" title="Finite-Lived Intangible Assets, Gross" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zdozuDJ6LcK2" title="Finite-Lived Intangible Assets, Net" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z29Jjza7Nu91" title="Indefinite-Lived Trademarks" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z99mUIIQEEYa" title="Indefinite-lived Intangible Assets (Excluding Goodwill)" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,813</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Finite-Lived Intangible Assets, Remaining Amortization Period" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zCT9dsXR8CKf" title="Intangible Assets, Gross (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,737,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231_ztH7zn4WIg4h" title="Finite-Lived Intangible Assets, Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">478,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zySQa7F4hnLe" title="Intangible Assets, Net (Excluding Goodwill)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,258,211</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zjAVe5tarN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
remaining useful life of approximately <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4AdkH3TiQAl" title="Finite-Lived Intangible Asset, Useful Life"><ix:nonNumeric contextRef="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20 years</ix:nonNumeric></span>, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the three months
ended March 31, 2020 and 2019, there was no impairment recognized related to intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, we had <span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zlYMmPLfutXc" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUSPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">31</ix:nonFraction></span> issued domestic patents and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zF99eSKBW4L1" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">30</ix:nonFraction></span> issued foreign patents, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_ztaC2pG7aWte" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticPatentsBijuvaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">12</ix:nonFraction></span>
                                         domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zDHTu95403lc" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignPatentsBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">six</ix:nonFraction></span> foreign patents that relate to BIJUVA as well as <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zz9qg1mEZT2j" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticPatentsNonApprovedBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa,
                                         and South Korea.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zCHpH7QebU58" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUSPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Eight</ix:nonFraction></span>
                                         domestic patents (<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zshl8nuM7qpc" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUSUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">seven</ix:nonFraction></span> utility and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_z1LgpjXnxlt4" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUSDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span> design) and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zNqvYmWd0nj6" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">13</ix:nonFraction></span> foreign patents (<span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zHw275ubTqX2" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> utility
                                         and <span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zMyw6z8tSNda" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">ten</ix:nonFraction></span> design) that relate to IMVEXXY. These patents establish an important intellectual
                                         property foundation for IMVEXXY and are owned by us. The domestic patents will expire
                                         in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
                                         design patents provide protection expiring no earlier than 2025. In certain countries,
                                         the foreign design patents provide protection through at least 2037. In addition, we
                                         have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia,
                                         Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and
                                         South Korea.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zALZa2wd5yU5" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span>
                                         domestic utility patent that relates to our topical-cream candidates, which is owned
                                         by us. The domestic patent will expire in 2035.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zAp0jQPvCoy4" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span>
                                         domestic utility patent and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_z6AbjCt5eGO9" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">seven</ix:nonFraction></span> foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zxwEj0sV9UVb" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTx009HRMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Three</ix:nonFraction></span>
                                         domestic utility patents that relate to TX-009HR, a progesterone and estradiol product
                                         candidate, which are owned by us and will expire in 2037.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_z7u8Ezm78BP7" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Two</ix:nonFraction></span>
                                         domestic and <span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zeNjMqryknu1" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_ForeignPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033. In addition, we have pending patent applications
                                         with respect formulations containing progesterone in the U.S., Australia, Brazil, Canada,
                                         Europe, and Mexico.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zVQ7EaGrZpF9" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentOperaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span>
                                         domestic utility patent that relates to our OPERA information-technology platform, which
                                         is owned by us and will expire in 2031.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Amortization
expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200331_z311hmLPbDl3" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,155</ix:nonFraction></span>
and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190331_zUPwGLWCClea" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,444</ix:nonFraction></span>
for the three months ended March 31, 2020 and 2019, respectively.</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z8wXdGjBstB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Estimated amortization expense,
based on current patent cost being amortized, for the next five years is as follows:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (9&#160;months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20200331_zc3KUbdVRHV4" title="2020 (9 months)" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,464</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20200331_zzf1CjRqXSY6" title="2021" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20200331_zGgaIHw2eKxh" title="2022" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20200331_zmn5PDCaunmk" title="2023" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20200331_zgrCptqyKUAd" title="2024" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zFb5bb3Ku6s7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



</ix:nonNumeric><p id="xdx_814_zpX0pNYwWAl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zYJU0DTf51nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
8 &#8211; OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zARa1nt0YMu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_zXU6bS3Y7usf" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_491_20191231_zUXEzD95cGAb" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_407_eus-gaap--AccruedSalariesCurrent_iI_maOLCzu3r_zu7w3AR93IA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,087,359</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,040,278</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_pp0p0_maOLCzu3r_zYayDvE07DA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,712,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,316,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0p0_maOLCzu3r_z5SyHQzqD0Xh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">893,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,285,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maOLCzu3r_zDCcuIpSRXeb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,874,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,463,878</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_pp0p0_maOLCzu3r_zBtGcJ050cz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,897,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,347,122</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzu3r_zby3Z8amvHs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">909,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">422,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maOLCzu3r_zSmzDQRsKmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,179,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,049,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLCzu3r_zteRE5GZDNH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,753,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedRebates_iI_pp0p0_maOLCzu3r_zEqtw8txrvNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,794,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,916,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maOLCzu3r_zGmyUO6kHg4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">823,694</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,480,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_mtOLCzu3r_zB9nSjMyVn86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,924,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,823,613</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zP6GSYBCgXwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_81F_zy4E98AFF5u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z82LLu6cLDFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
9 &#8211; <span>DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending, Inc.,
as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors, which provides us with a $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zWPkSvsXL9h1" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000,000</ix:nonFraction></span> first lien secured term loan credit facility,
or the Facility. The Facility provides for availability to us in three tranches: (i) $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3Ll7wDx1wG4" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span> was drawn upon entering into
the Financing Agreement; (ii) $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zYsC9VY9MIPl" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> will be available to us in the Administrative Agent&#8217;s sole and absolute discretion
either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such
earlier date as the Administrative Agent shall have consented to; and (iii) $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pp0p0_uUSD_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zoLD73qIGCig" title="Proceeds from Financing Agreement"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> was drawn on February 18, 2020 following
our achievement of more than $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zGtCJgVwZ2W3" title="Total revenue, net"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,000,000</ix:nonFraction></span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings
under the Facility accrue interest at either (i) <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zN0gfsr3sTQj" title="Debt Instrument, Description of Variable Rate Basis"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">3-month LIBOR</ix:nonNumeric></span> plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKMLQ3reYHj" title="Debt Instrument, Basis Spread on Variable Rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>%, subject to a LIBOR floor of <span id="xdx_90D_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zzvzcptvKy61" title="LIBOR floor rate"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.70</ix:nonFraction></span>% or (ii) the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zDSXBczIiu9c" title="Debt Instrument, Description of Variable Rate Basis"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">prime
rate</ix:nonNumeric></span> plus<span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVaCXkW2EqNg" title="Debt Instrument, Basis Spread on Variable Rate"> <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.75</ix:nonFraction></span>%, subject to a prime rate floor of <span id="xdx_909_ecustom--PrimeRateFloor_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zFKwSneXwckf" title="Prime rate floor"><ix:nonFraction name="txmd:PrimeRateFloor" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></span>% as selected by us. Interest on amounts borrowed under the Facility is payable
quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_pp0p0_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zrSUU2CqKBI8" title="Number of quarterly principal installment payments"><ix:nonFraction name="txmd:NumberOfInstallmentPayments" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Pure">four</ix:nonFraction></span> equal quarterly installments beginning on June
30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or
in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) <span id="xdx_904_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKBjGlANUAa" title="Prepayment fee for first two years funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeForFirstTwoYearsFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span>% for the first two years following
the initial funding date of the applicable borrowing, (ii) <span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zL5GMcTY54E8" title="Prepayment fee third year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeThirdYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% for the third year following the initial funding date of the applicable
borrowing, (iii) <span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zpxVfOTjgUh7" title="Prepayment fee fourth year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeFourthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% for the fourth year following the initial funding date of the applicable borrowing and (iv) <span id="xdx_900_ecustom--PrepaymentFeeFifthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zD71f1AmJPW2" title="Prepayment fee fifth year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeFifthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% for the
fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the
initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to <span id="xdx_909_ecustom--FacilityFeePaidPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJW687VTUUul" title="Facility fee paid (percent)"><ix:nonFraction name="txmd:FacilityFeePaidPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% of the initial amount
borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are
also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses.
The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary
for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of
$<span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo4Eg4yeOU1f" title="Minimum cash balance requirement under credit agreement"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000,000</ix:nonFraction></span>, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY,
BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes
other representations, warranties, indemnities and events of default that are customary for financings of this type, including
an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable
and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries
under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority
perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under
the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zDTdjYS5Aboj" title="Line of Credit Facility, Maximum Borrowing Capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_907_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pp0p0_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3NpDGkghri8" title="Number of tranches under term loan facility"><ix:nonFraction name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Pure">three</ix:nonFraction></span> separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i) <span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zADPCpIJOxxl" title="Debt Instrument, Description of Variable Rate Basis"><ix:nonNumeric contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">one-month LIBOR</ix:nonNumeric></span> (subject to a LIBOR floor of <span id="xdx_90B_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zAGkdJaSJU29" title="LIBOR floor rate"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>%) plus (ii)
<span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZ5k1Fi7hZSl" title="Debt Instrument, Basis Spread on Variable Rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $<span id="xdx_90F_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0p0_uUSD_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zAoKWmSzHmFf" title="Repayment of debt with new credit facility"><ix:nonFraction name="txmd:RepaymentOfDebtWithNewCreditFacility" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,661,000</ix:nonFraction></span> was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of <span id="xdx_90B_ecustom--PrepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zvRGWtRwnkAk" title="Prepayment fee percentage"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, a repayment fee of <span id="xdx_909_ecustom--RepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zi6WrZzuK6E1" title="Repayment fee percentage"><ix:nonFraction name="txmd:RepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% and other fees and expenses payable to the lenders under the Credit Agreement. As
a result of the termination of the Credit Agreement, we recorded $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_uUSD_c20190101__20190331_zNzeyMeQDmKg" title="Loss on extinguishment of debt::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl0891">10,057,632</span></span> in loss on extinguishment of debt in the second quarter
of 2019. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the three
months ended March 31, 2019 related to the Credit Agreement was $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zlpbCVvShyTg" title="Interest Expense, Debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2019-01-012019-03-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,969,872</ix:nonFraction></span>. During the three months ended March 31, 2019, we amortized
$<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zNXj11pAtXag" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-03-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,146</ix:nonFraction></span> of debt issuance costs as interest expense in the accompanying unaudited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
of March 31, 2020, we had $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z66dY4kGWlYg" title="Long-term Debt, Gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-03-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></span>
in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
consolidated financial statements. We incurred $<span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zpSNKaTaHGF1" title="Deferred financing fees"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2020-03-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,902,270</ix:nonFraction></span>
in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing
Agreement have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to
the two tranches of borrowings that we received of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_uUSD_c20200331_zicw1GXgnUYf" title="Debt Instrument, Unamortized Discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,626,891</ix:nonFraction></span>
have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with an unfunded tranche are deferred as assets until such tranche has been drawn. As of March 31,
2020, deferred financing fees related to the unfunded tranche of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20200331__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zI6pEfqmQys1"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2020-03-31_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>
were included in other current assets in the accompanying consolidated financial statements. During the three months ended
March 31, 2020, we amortized $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20200101__20200331__custom--DebtTrancheAxis__custom--TrancheTwoMember_zc8F2LSPivWk" title="Amortization of deferred financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2020-01-012020-03-31_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">319,408</ix:nonFraction></span> <span style="background-color: white">of
deferred financing fees related to the two tranches that have been received as interest expense in the accompanying
consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in
arrears. Interest expense for the three months ended March 31, 2020 was $<span id="xdx_90D_eus-gaap--InterestExpenseBorrowings_pp0p0_uUSD_c20200101__20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zdWYXM1Y1Ql6" title="Interest Expense, Borrowings"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2020-01-012020-03-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,942,639</ix:nonFraction></span>.
The overall effective interest rate under the Financing Agreement was approximately </span><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20200331_zZxV3QA7ITL6" title="Debt Instrument, Interest Rate, Effective Percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span><span style="background-color: white">%
as of March 31, 2020</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zuYWva5GXJfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020 and December 31, 2019, <span>the carrying value of our debt consisted</span> of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zdBxYTuLbYf1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49C_20191231_zpRZ2jcdfYq8" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zapwzyTEff58" title="Long-term Debt, Gross" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-03-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zYDRx6oDWyG3" title="Long-term Debt, Gross" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_uUSD_zA0yZPzpbaal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,571,329</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,365,357</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_uUSD_zFY2FfjOmEPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,428,671</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,634,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zIY9DzQZVFSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
</ix:nonNumeric><p id="xdx_813_zAGgGZetLH17" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_zEhUrHtD0eNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
10 &#8211; NET LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and
disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common
stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_zv65xt6mS1D7" title="Common stock par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average
number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the
period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were
excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net
loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net
loss per share allocable to common stockholders for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC7MnWRDtovb" summary="xdx: Disclosure - NET LOSS PER SHARE (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pp0p0_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGDOUicyDozd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">25,155,221</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZWiLD6NjQF5" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">21,447,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za9GAAGxKxOa" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,832,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNvvkwguDAok" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,832,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock awards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zACf9oP5p4k8" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,858,490</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znscYXL28Ha1" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,040,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331_z9ILmNQb31l5" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">33,846,282</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331_zcJtI3mjRv6i" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">24,320,290</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

</ix:nonNumeric><p id="xdx_81B_zYBsNKa5NOoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1Xqlb9M1Gl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
11 &#8211; STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, we had <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pii_uShares_c20200331_znrHRL9qs4Hc" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of Preferred Stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_za1QWerwgQbb" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>, authorized for issuance, of which <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dco_uShares_c20200331_zKrCmd6DN4Qe" title="Preferred Stock, Shares Outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_dco_uShares_c20200331_zkQ2gUpduxol" title="Preferred Stock, Shares Issued"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of
Preferred Stock were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, we had <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pii_uShares_c20200331_z94hCnJ5EfC3" title="Common Stock, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span> shares of Common Stock authorized for issuance, of which <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pii_uShares_c20200331_zihrDmrHmcY6" title="Common Stock, Shares, Issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pii_uShares_c20200331_zmYcMTHm3u28" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,677,742</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock
were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three Months ended March 31, 2020</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgFFhaU8wdVa"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,666</ix:nonFraction></span> shares
of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxaNWM1oU1xb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,109</ix:nonFraction></span> in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three Months ended March 31, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2019, certain individuals exercised stock options to purchase an aggregate of<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi55ceFgC474"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">276,383</ix:nonFraction></span> shares
of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6Jmo87fggl6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,107</ix:nonFraction></span> in cash. Also, during the same period, stock options to purchase an aggregate of <span id="xdx_90D_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_pii_uShares_c20190101__20190331_z0r9opzOofEl" title="Number of stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,097</ix:nonFraction></span> shares of
Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_90E_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_pii_uShares_c20190101__20190331_zfBXB9X0ObPl" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,834</ix:nonFraction></span> shares
of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, we had warrants outstanding to purchase an aggregate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_uUSD_c20200331_zMyMyga61Fzb" title="Warrants and Rights Outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,832,571</ix:nonFraction></span> shares of Common Stock with a weighted-average
contractual remaining life of approximately <span id="xdx_901_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200331_z5py9rYo5zn5" title="Weighted-average contractual remaining life"><ix:nonNumeric contextRef="From2020-01-01to2020-03-31" format="ixt-sec:duryear" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife">1.70</ix:nonNumeric></span> years, and exercise prices ranging from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zg9qg43sgDcg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-03-31_custom_WarrantsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span> to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zZrlLqRCeP21" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-03-31_custom_WarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.20</ix:nonFraction></span> per share, resulting in
a weighted average exercise price of $<span id="xdx_905_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2HwQfHCzLda" title="Weighted average exercise price of warrants (in dollars per share)"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.62</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, no warrants were granted. During the three months ended March 31, 2019, we granted
warrants to purchase an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z43EwiFLovu" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span>
shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zLu6Ri5v0Ldi" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></span>.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of <span title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term">five </span>years;
volatility of <span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy4rxCZ0thV8" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.8</ix:nonFraction></span>%;
risk free rate of<span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zDsSrF0xkOp9" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate">
<ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.52</ix:nonFraction></span>%; and dividend yield of<span id="xdx_90B_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zkFxhg4ltlai" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate">
<ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%. The grant date fair value of the warrants was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNz27QtBvNph" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span>
per share. The warrants vested ratably over a <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HN4rtQyoAe" title="Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"><ix:nonNumeric contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month
period and have an expiration date of February 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the three months ended March 31, 2020, no warrants were exercised</span><span style="font: 10pt Times New Roman, Times, Serif">.
<span style="background-color: white">During the three months ended March 31, 2019, warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQC1Yf7JAvP8" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-03-31_us-gaap_WarrantMember348335407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span>
shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_90C_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zhsHssI0ZHJf" title="Number of stock issued in cashless exercise of warrants"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2019-01-012019-03-31_custom_WarrantsCashlessExerciseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,184</ix:nonFraction></span>
shares of Common Stock were issued.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zuAfZEz40GZ8" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-03-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,446</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zzM2jcypKTc4" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-03-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">85,716</ix:nonFraction></span> for the three months ended
March 31, 2020 and 2019, respectively, in the accompanying consolidated financial statements. At March 31, 2020, there was no
unrecognized estimated compensation expense related to unvested warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options
to Purchase Common Stock of the Company</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of March 31, 2020, there were non-qualified
stock options to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zXeLwbqbYKqi" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,546,246</ix:nonFraction></span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our
adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made
under the 2009 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of March 31, 2020, there were non-qualified stock options to purchase an aggregate
of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zaH8D5lv078g" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,316,474</ix:nonFraction></span> shares of Common Stock outstanding and an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjStbGeUG8j7" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,000</ix:nonFraction></span> restricted stock awards under the 2012 Plan. Effective
upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, there were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4CqiMq1gYb" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-03-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,970,994</ix:nonFraction></span> shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NewSharesMember_zxxsuA3aeEma"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-03-31_custom_NewSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,354,764</ix:nonFraction></span>
new shares, (ii) <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zGNvI4t8Ib98" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,395,333</ix:nonFraction></span> unallocated shares previously available for issuance under the 2012 Plan that were not then subject
to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii) <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z25uuN8xGTCc" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">220,897</ix:nonFraction></span> unallocated shares previously available for
issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any
shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan
that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for
cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered
or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which
those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance,
again be available for delivery with respect to Awards under the 2019 Plan. As of March 31, 2020, there were non-qualified stock
options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zbPiaDrJqWS9" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,292,501</ix:nonFraction></span> shares of Common Stock outstanding under the 2019 Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--Plan2019Member_z4AxfPTi3V2j" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,584,245</ix:nonFraction></span> restricted stock awards and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--Plan2019Member_zY5W37PTsAS5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,384,245</ix:nonFraction></span>
performance stock awards outstanding under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmiZZrXoInTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and
2019 are set forth in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKT3HpcC3Ctk" title="Weighted average grant date fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKCm4GBhbZ64" title="Weighted average grant date fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAoURtu9Slh2" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.32</ix:nonFraction></span><span style="font: 10pt Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrhE696UcnGe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.68</ix:nonFraction></span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zclHBCYrH4Y8" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.54</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKbbd5VICeke" title="Volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.53</ix:nonFraction></span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyNJb5gWKHf9" title="Volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65.72</ix:nonFraction></span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zp37dwdC0gd" title="Volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.85</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zBqThQyn9EH2" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span>-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zI3qCxPIUrU9" title="Term"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.7</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm4RzCP1iPK" title="Term" style="text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRCbPvXZsR1g" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z97xFrXVFlxg" title="Dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zr8Sxn6nkEO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCouQC6ZD5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual <br />Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF74Vd7stZY6" title="Number of shares under options, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg5erwQ0O0H1" title="Weighted average exercise price, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlNh1WMeN8Tk" title="Weighted average remaining contractual life" style="width: 11%; text-align: right"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nHUxpATmu4" title="Aggregate intrinsic value, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,668,171</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIrW2Q4UU0yl" title="Number of shares under options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">636,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKkPU4yQi8b" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPDM0gLWg4I4" title="Number of shares under options, exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,666</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEkpJ98J88v9" title="Weighted average exercise price, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKMQTcpYeBii" title="Aggregate intrinsic value, exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">725,199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9eD9aqL6MO8" title="Number of shares under options, expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,472</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gOKEtgi3Al" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyA0VXRGp0Xc" title="Number of shares under options, cancelled forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HEMrytqGP7" title="Weighted average exercise price, cancelled forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR85TrJIPS4" title="Number of shares under options, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,155,221</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35NKobVHVH5" title="Weighted average exercise price, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvu9zkcQx5pg" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.77</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjmPJFz78dti" title="Aggregate intrinsic value, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">787,178</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTP5Y15iGVAc" title="Number of shares under options, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,258,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7MNd8qOHPMd" title="Weighted average exercise price, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.02</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ye87I9gl87" title="Weighted average remaining contractual life, vested and exercisable" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.77</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_uUSD_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zucj29CP0SH6" title="Aggregate intrinsic value, vested and exercisable ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">787,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHbMwgnL9hrg" title="Number of shares under options, unvested ending" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,896,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKAsY49mCuXg" title="Weighted average exercise price, unvested ending" style="text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3rZDaT0F483" title="Weighted average remaining contractual life, unvested" style="text-align: right"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">9.05</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_za27Ur5hVJU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, our outstanding options had exercise prices ranging from $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MinimumMember_z2zcK2shnuD8" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span> to $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MaximumMember_zsWv4cXD5p69" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2020-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.92</ix:nonFraction></span> per share. Share-based compensation expense
related to options recognized in our results of operations for the three months ended March 31, 2020 and 2019 was approximately
$<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8Oalng9xOC3" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,836,630</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8ophyRUIDAl" title="Share-based Payment Arrangement, Noncash Expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,143,239</ix:nonFraction></span>, respectively, and it is based on awards vested. At March 31, 2020, total unrecognized estimated compensation
expense related to unvested options was approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_uUSD_c20200331_zRML7RPGHnm5" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,800,000</ix:nonFraction></span>, which may be adjusted for future changes in forfeitures. This
cost is expected to be recognized over a weighted-average period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaONmS9Je3Ak" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.3</ix:nonNumeric></span> years. No tax benefit was realized due to a continued
pattern of operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Restricted
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Performance
stock awards will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into common stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. Based upon the expected
levels of achievement, stock-based compensation is recognized on a straight-line basis over the awards&#8217; requisite service
periods. The expected levels of achievement are reassessed over the requisite service periods and, to the extent that the expected
levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020 and 2019, we recorded $<span id="xdx_907_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20200101__20200331_zymRAM7dloi3" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">503,377</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20190101__20190331_z55Q3WhfHaLb" title="Restricted Stock or Unit Expense"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">346,414</ix:nonFraction></span>, respectively, in share-based compensation expense
related to restricted stock units and performance stock awards. At March 31, 2020, total unrecognized estimated compensation expense
related to unvested restricted stock units and performance stock awards was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_uUSD_c20200331_zGZpPEt96H98" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,830,000</ix:nonFraction></span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7TixGtmu7T2" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"><ix:nonNumeric contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.6</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8Mso4923Ztl" summary="xdx: Disclosure - Restricted stock and performance stock awards (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Restricted
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Performance
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b></b></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b></b></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b></b></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfs80wXB0Y6" title="Number of shares, beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1gikQdahEX7" title="Weighted average grant date fair value, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td title="Number of shares, beginning" style="width: 12%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Weighted average grant date fair value, beginning" style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDPV5o0aOG94" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,384,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgCPBNvZ4a9i" title="Weighted average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8L3oT6dXQG6" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,384,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhdvXun1r73j" title="Weighted average grant date fair value, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Vested/Released</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsSLdiyKRYI7" title="Number of shares, vested/released" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znw5y3XsKQba" title="Weighted average grant date fair value, vested/released" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1kzQucs7e08" title="Number of shares, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,474,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKxgxHQZES9d" title="Weighted average grant date fair value, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zCUDguZmo065" title="Number of shares, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,384,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5SxZglFc9d2" title="Weighted average grant date fair value, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_zDGO2MJCh1H" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zOK9h2MmOi8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
12 &#8211; INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the three months ended March 31, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not
be realized. As of March 31, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</span></p>

</ix:nonNumeric><p id="xdx_819_z2ayXhi6GmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrEhlWxw6pSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
13 &#8211; RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended March 31, 2020 and 2019, we were billed by Catalent approximately
$</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z3oFfM9nGANh" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2020-01-012020-03-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,303,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zpJg8liN9Tx8" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-01-012019-03-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,397,000</ix:nonFraction></span><span style="background-color: white">,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of March 31, 2020 and December 31, 2019, there were amounts due to Catalent of approximately $</span><span id="xdx_90C_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zQme2UgDxVZj" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2020-03-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">755,000</ix:nonFraction></span> <span style="background-color: white">and
$</span><span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zE9PfebzlMbc" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2019-03-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span><span style="background-color: white">, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.</span></span></p>

</ix:nonNumeric><p id="xdx_819_zs4puKAaOZa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80C_eus-gaap--ConcentrationRiskDisclosureTextBlock_z4loBUXUHMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
14 &#8211; BUSINESS CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
purchase our prescription products from several suppliers with approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zbhYELJlr5Uh" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></span>%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zQ1XMiUXW4Id" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zthVxpVKaYK5" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zaoS24yqS4B5" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_custom_SupplierFourConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>% of our purchases supplied by
four vendors each, respectively, during the three months ended March 31, 2020 and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zg5SqwrrnO57" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_custom_SupplierOneConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z65UES1vk0k4" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">29</ix:nonFraction></span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zkyrP7FmlPm9" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27</ix:nonFraction></span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zgtlqNsGTzW5" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_custom_SupplierFourConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% of our purchases supplied
by four vendors each, respectively, during the three months ended March 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months
ended March 31, 2020, <span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJWaOaYw1Hrj" title="Number of customers - revenue"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> customers each accounted for more than <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzqivXVzo4Og" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zxsFXqJcYeb6" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>%
of our prescription revenue for the three months ended March 31, 2020. During the three months ended March 31, 2019, <span id="xdx_909_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvuebnY3r9V1"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">five</ix:nonFraction></span>
customers each generated more than <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYlqDFn7kfh" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of our prescription revenues. Revenue generated from the five customers combined accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FiveCustomersConcentrationRiskMember_z4D7kWoziI3c" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_FiveCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83</ix:nonFraction></span>%
of our prescription revenue for the three months ended March 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, Pillpack, Inc. accounted for approximately $<span id="xdx_90F_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zK3o0Jfpg52" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,199,000</ix:nonFraction></span> of our prescription revenue,
McKesson Corporation accounted for approximately $<span id="xdx_90C_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zzWQDVF6dl7b" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,259,000</ix:nonFraction></span> of our prescription revenue, Cardinal Health accounted for
approximately $<span id="xdx_90E_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_z15vUxEeXY27" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,886,000</ix:nonFraction></span> of our prescription revenue and Pharmacy Innovation PA accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zJ6qWO7XUeI4" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,234,000</ix:nonFraction></span> of our
prescription revenue. During the three months ended March 31, 2019, PI Services accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zS9jKAOiH47h" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">967,000</ix:nonFraction></span> of our </span>prescription
revenue, AmerisourceBergen accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zv2ESvX08fr2" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">787,000</ix:nonFraction></span> of our prescription revenue, Pillpack, Inc. accounted for
approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_z1teRsXY3Nid" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">534,000</ix:nonFraction></span> of our prescription revenue, Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zk56pYPfTsmd" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">525,000</ix:nonFraction></span> of our prescription
revenue and McKesson Corporation accounted for approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zQqIFZ9wbowk" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">457,000</ix:nonFraction></span> of our prescription revenue.</p>

</ix:nonNumeric><p id="xdx_81B_zzph64VyYP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->


<!-- Field: Named-Area; Name: Contents -->
<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKjfzAFxO555" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
15 &#8211; COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities
represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease
liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased
asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use
asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct
costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is
initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the
same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease
payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured
using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments
based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications
result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period
that were not included in the initial lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a <span id="xdx_90C_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_z49Hc1Gs7cjb" title="Non-cancelable operating lease term"><ix:nonNumeric contextRef="From2013-06-302013-07-01" format="ixt-sec:durmonth" name="txmd:CapitalLeaseObligationsTerm">63</ix:nonNumeric></span>-month term. On February 18, 2015, we entered into an agreement with the same lessors to
lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_90E_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zdnTAIJYtIbe" title="Net rentable area"><ix:nonFraction name="txmd:NetRentableAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">56,212</ix:nonFraction></span> rentable square
feet, or the full premises, of which the lease on <span id="xdx_908_ecustom--RentedAreaLease_iI_usqft_c20181002_zavPAji6Zzr7" title="Rented area lease"><ix:nonFraction name="txmd:RentedAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">7,561</ix:nonFraction></span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_901_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zuk9U7TpcpOk" title="Additional area of lease occupied"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">48,651</ix:nonFraction></span> square
feet commenced in August 2019, or the full premises commencement date. The lease will expire <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_c20190801_zooqb9Fp7uQ3" title="Lessee, Operating Lease, Term of Contract"><ix:nonNumeric contextRef="AsOf2019-08-01" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract">11 years</ix:nonNumeric></span> after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term
of the lease for <span id="xdx_90B_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200331_zGKl8cgGsoKh" title="Number of options to extend lease"><ix:nonFraction name="txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">two</ix:nonFraction></span> additional consecutive periods of <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_c20200331_z7m3STSvPd17" title="Lease renewal term"><ix:nonNumeric contextRef="AsOf2020-03-31" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm">five years</ix:nonNumeric></span>. The extension option is not included in the determination of
the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods.
We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June
2019, we entered into an agreement with the same lessors to lease additional <span id="xdx_90B_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zGsNAQs5rXtf" title="Lease not yet commenced (area)"><ix:nonFraction name="txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea" contextRef="AsOf2019-06-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,536</ix:nonFraction></span> square feet of administrative office space
in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the second quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_pp0p0_zNY6Q43yVFNk" summary="xdx: Disclosure - Supplemental lease information (Details)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information at:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zxV04oRYF49a" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20191231_zmdyR94QUFKl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXsktDN2sUf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Right-of-use asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,757,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,109,154</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zMvBIFJAm8nk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,753,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,501,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zgc1gXR5vOgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,782,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,145,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20200331_zgpKv29c3Da5" style="text-align: right"><ix:nonNumeric contextRef="AsOf2020-03-31" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9
years</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zkV39ZTLEp8j" style="text-align: right"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9
years</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_zUc06LuSM8O2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>Supplemental cash flow information <br />
for the three
    months ended:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"></td><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March 31,&#160;2020</b></span></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March
                                         31, 2019</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200331_zuL23QaCMZd5" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">327,386</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeasePayments_pp0p0_c20190101__20190331_zuzqDRbG7V09" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20200331_zThhmozWlRkf" title="Right-of-use assets obtained in exchange for lease obligation" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20190101__20190331_zLBPQS6oYC3c" title="Right-of-use assets obtained in exchange for lease obligation" style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,760,171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMfhD1if9rfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>Year Ended December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20200331_zhIW313Tinf5"><b>&#160;</b></td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz43w_zCAZN4lRQIi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 44%">2020 (9 months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,239,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz43w_zpNF4VUEvJbk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,198,541</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz43w_zbebADZ5EjO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,262,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz43w_zsChrp9u3jZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,293,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz43w_z5JX4iD4rHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,326,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz43w_zEuArkid0XZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,036,931</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPz43w_z3WEFqQI4RUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,357,069</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zW2oDb4PO6sd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,821,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zidasaTE7p9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,535,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zuXTlzE5dyei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the three months ended March 31, 2020 and 2019, operating lease expense related to our real estate leases was $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20200101__20200331_zllAgsvvtDMc" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">563,764</ix:nonFraction></span> and $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20190331_zFemHXpOi1c7" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,109</ix:nonFraction></span><span style="background-color: white">,
respectively, and variable lease expense was insignificant.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Intellectual
Property Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of revenue as described in Note 3, Summary of Significant Accounting Policies<span style="background-color: white">,
to these consolidated financial statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Purchase
Commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent </span><span id="xdx_90A_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20200331_zaLFiVzssxN9" title="Significant supply commitment percentage payable" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="txmd:SignificantSupplyCommitmentPercentagePayable" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. In addition, we have a manufacturing and
supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year. As of
March 31, 2020, we have met our purchase commitments with Catalent.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Legal
Proceedings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or
future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employment
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</span></p>

</ix:nonNumeric><p id="xdx_814_zFQ38DJSyBc4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: /Named-Area; -->
<!-- Field: Set; Name: xdx; ID: xdx_01F_10_Partial -->


<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_txmd_therapeuticsmd.com_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20200331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07C_XDX_merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->



<ix:nonNumeric contextRef="From2020-01-01to2020-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zR17Y1wtVQ08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Paycheck
Protection Program Loan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act, or the CARES Act, as administered by the U.S. Small Business Administration, or the SBA. The loan in the principal
amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_uUSD_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zR5vIxPGLC1j" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,477,094</ix:nonFraction></span>, or the PPP Loan, was disbursed by Bank of America, NA, a national banking association, or BofA, pursuant
to a promissory note issued by the Company, or the Promissory Note.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The PPP
Loan matures on the two-year anniversary of the funding date and bears interest at a fixed rate of<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zE0HdnO9pnyj" title="Interest rate"> <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.00</ix:nonFraction></span>%
per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (discussed below), will
commence after the six-month anniversary of the funding date. We did not provide any collateral or guarantees for the PPP Loan,
nor did we pay any facility charge to obtain the PPP Loan. The Promissory Note provides for customary events of default,
including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material
adverse effects. We may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">All
or a portion of <span title="Description of PPP loan forgiven">the PPP Loan may be forgiven by the SBA and BofA upon application by us beginning 60 days but not later than 90
days after the funding date of the PPP Loan. Under the CARES Act, loan forgiveness is available for the sum of documented payroll
costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan.
For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $<span id="xdx_900_ecustom--IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zXo2YmzCzxuh" title="Individual employee annual compensation maximum for payroll costs under loan"><ix:nonFraction name="txmd:IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>, prorated annually.
Not more than <span id="xdx_90D_ecustom--MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zKijJPzNxrDd" title="Maximum percentage of forgiven amounts for nonpayroll costs under loan"><ix:nonFraction name="txmd:MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines,
or if salaries and wages for employees with salaries of $<span id="xdx_907_ecustom--IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zCVCWquAIq24" title="Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness"><ix:nonFraction name="txmd:IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> or less annually are reduced by more than <span id="xdx_900_ecustom--IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zyBYuvBoUsLj" title="Individual employee salary reduction specified percentage for reduction of loan forgiveness"><ix:nonFraction name="txmd:IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%.</span> Although we currently
believe that our use of the PPP Loan will meet the conditions for forgiveness of the loan, we cannot assure that the PPP Loan
will be forgiven, in whole or in part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Amendment
No. 2 to Financing Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with incurring the PPP Loan, we, together with our subsidiaries, amended the Financing Agreement to, among other things,
permit us to incur the PPP Loan and add certain affirmative covenants relating thereto.</span></p>

</ix:nonNumeric><p id="xdx_812_z6mvLj3VZ1yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_008"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">General</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our
results of operations and financial condition for the periods described. This discussion should be read together with our unaudited
consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form
10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for
the year ended December 31, 2019 filed with the Securities and Exchange Commission, or the SEC, on February 24, 2020, or our Annual
Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect
future results of operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.
Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as
well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project,
believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#8220;believes,&#8221;
&#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221;
&#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221;
and similar expressions and are based on assumptions and assessments made in light of management&#8217;s experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such
statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and
regulations of the SEC. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Important factors that could cause actual results, developments and business decisions
to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our Annual
Report, and include the following: the effects of the COVID-19 pandemic; our ability to maintain or increase sales of our approved
products; our ability to successfully commercialize IMVEXXY&#174;, BIJUVA&#174;, and ANNOVERA&#174; and to develop and commercialize
our hormone therapy drug candidates and obtain additional financing necessary therefor; our commercialization, marketing and manufacturing
capabilities and strategy for our approved products; the size of markets and the potential market opportunity for which our products
are approved and our ability to penetrate such markets; the rate and degree of market acceptance of our products; the willingness
of healthcare providers to prescribe and patients to use our products; our ability to obtain additional financing when needed;
our competitive position and the success of competing products that are or become available for the indications that we are pursuing;
our intellectual property position; whether we will be able to comply with the covenants and conditions under our term loan facility,
including the conditions to draw an additional tranche thereunder, and whether the lender will make such tranche available; whether
we will be able to comply with the covenants and conditions under the loan we received pursuant to the Paycheck Protection Program
under the Coronavirus Aid, Relief, and Economic Security Act, as administered by the U.S. Small Business Administration (SBA),
including the conditions for forgiveness of the loan; the length, cost and uncertain results of our clinical trials, the potential
of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved
products or preclude the approval of our future drug candidates; whether the U.S. Food and Drug Administration (FDA) will approve
the efficacy supplement for the lower dose of BIJUVA; our ability to protect our intellectual property, including with respect
to the Paragraph IV notice letters we received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future
clinical trials; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the
ability of our licensees to commercialize and distribute our products; the ability of our marketing contractors to market ANNOVERA;
the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product
liability lawsuits; and the influence of extensive and costly government regulation; the volatility of the trading price of our
common stock and the concentration of power in our stock ownership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;TherapeuticsMD,&#8221;
or &#8220;our company&#8221; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our
wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation,
or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">This
Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as vitaMedMD &#174;, BocaGreenMD &#174;,
IMVEXXY &#174;, BIJUVA &#174; and ANNOVERA &#174; which are protected under applicable intellectual property laws and are the property
of, or licensed to, our company. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly
Report on Form 10-Q may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in
any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor
to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade
names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement
or sponsorship of us by, these other parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD
is a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan
of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise,
and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions
range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have
a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our
women&#8217;s healthcare focus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and marketing plans to grow
our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products
has transitioned our company from predominately focused on conducting research and development to one focused on commercializing
our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts)
                                         for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
                                         activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was
                                         approved by the FDA in May 2018. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone)
                                         capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical
                                         progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe
                                         vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved
                                         by the FDA in October 2018.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         October 2019, we began a &#8220;test and learn&#8221; market introduction for our FDA-approved
                                         product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first
                                         and only patient-controlled, procedure-free, reversible prescription contraceptive option
                                         for women, which was approved by the FDA in <span style="color: #212529">August 2018
                                         and which we have licensed for commercialization in the U.S. pursuant to </span>an exclusive
                                         license agreement, or the Population Council License Agreement, with the Population Council,
                                         Inc., or the Population Council<span style="color: #212529">. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc.,
                                         or Knight, pursuant to which we granted Knight an exclusive license to commercialize
                                         IMVEXXY and BIJUVA in Canada and Israel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
                                         June 2019, we entered into an exclusive license and supply agreement, or the Theramex
                                         License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty
                                         pharmaceutical company dedicated to women&#8217;s health, to commercialize BIJUVA and
                                         IMVEXXY outside of the U.S., excluding Canada and Israel. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
common stock, par value $0.001 per share, or the Common Stock, is traded on the Nasdaq Global Select Market of The Nasdaq Stock
Market LLC, or the Nasdaq, under the symbol &#8220;TXMD.&#8221; We maintain websites at <span style="text-decoration: underline">www.therapeuticsmd.com</span> as well
as various product websites. The information contained on our websites or that can be accessed through our websites does not constitute
part of this Quarterly Report on Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Impact
of&#160;COVID-19 on our Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business has been, and we anticipate that it will continue to be, impacted by the coronavirus (COVID-19) pandemic. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as
the pandemic began to negatively affect our revenue growth. At this time, the extent of the impact of the&#160;COVID-19 pandemic on our business is highly uncertain and difficult
to predict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and marketing
infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients and prescribers.
This contingency plan is designed to be implemented in stages over the second and third quarters of 2020 as we continue to evaluate
the length of time that COVID-19 may impact our business, which is intended to allow us to conserve our financial resources during
the COVID-19 pandemic and re-scale our sales and marketing activity when conditions warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
COVID-19 contingency plan focuses on five key areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Containing
                                         costs and cutting spending.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Addressing
                                         impacts and trends for the second quarter of 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preparing
                                         for a potential longer-term impact throughout the year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leveraging
                                         vitaCare Prescription Services to continue to meet the needs of our patients and prescribers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Ensuring
                                         continued availability of our products to patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Cost
Containment and Spending Cuts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
have implemented measures to initially cut or defer more than&#160;$30 million&#160;in annual spending. This includes the deferral
of approximately&#160;$10 million&#160;in planned second quarter consumer and healthcare practitioner marketing spend for ANNOVERA
and IMVEXXY and cuts of approximately&#160;$20 million&#160;in other planned expenses for the remainder of 2020. We believe that
we have the ability to re-accelerate our planned marketing spend for ANNOVERA and IMVEXXY should market conditions improve, or
to extend or expand the cost deferrals throughout 2020. These cost cuts and reductions include permanent cost savings that have
been identified by management, as well as the interim cessation of certain spending that may be restarted in future quarters.
These cost cuts include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Negotiating
                                         lower fees or suspending services from third party vendors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Implementing
                                         a Company-wide hiring freeze;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Delaying
                                         or cancelling non-critical IT projects; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Eliminating
                                         travel, entertainment, meeting, and event expenses.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
anticipate that these savings can be extended further throughout 2020 or expanded depending on the impact of the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Employees
and Sales Force</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
sales force currently continues to function utilizing digital engagement tools and tactics and virtual detailing to remain engaged
with prescribers and distribution channels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
                                         have enhanced the ability of our sales force to support healthcare providers remotely,
                                         including the sales forces&#8217; ability to continue to provide healthcare practitioners
                                         with access to patient product samples, product marketing information, and information
                                         regarding patient affordability programs and support services.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
                                         sales force is in regular interaction with healthcare providers, including conducting
                                         &#8220;virtual&#8221; lunch and learn seminars with providers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
                                         sales force also continues product training, including sharing best practices, in advance
                                         of our anticipated future sales and marketing ramp.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Remote
Pharmacy&#160;and At-Home Delivery Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
of the date of this Quarterly Report on Form 10-Q, we continue to provide continued access to our products for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
                                         vitaCare Prescription Services patient model assists patients in obtaining easy and convenient
                                         access to their prescriptions for products at a retail pharmacy of their choice, including
                                         via home delivery retail pharmacy options. We anticipate that home delivery pharmacy
                                         options will be attractive to patients during the COVID-19 pandemic.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Through
                                         vitaCare, we have connected with more than 80% of our patients. We anticipate that vitaCare
                                         will support continued patient access to our products during the COVID-19 pandemic and
                                         will help sustain the strong refill trends for our products given vitaCare&#8217;s broad
                                         use by our patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
                                         have also engaged with independent community pharmacies and multiple third-party online
                                         pharmacies and telemedicine providers that focus on contraception or menopause to help
                                         ensure patients have real-time access to both diagnosis and treatment.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Supply
of Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We&#160;do
not anticipate a shortage of our products due to the COVID-19 pandemic as of the date of this Quarterly Report on Form
10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
                                         currently have sufficient inventory of finished product in our contracted warehouses
                                         to meet anticipated demand through at least the early part of the third quarter of this
                                         year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
                                         currently do not foresee any interruption in our contract manufacturers&#8217; abilities
                                         to continue to manufacture additional product to be used beyond the third quarter of
                                         this year. Our contract manufacturers have sufficient active pharmaceutical ingredients
                                         on hand for the continued manufacture of our products and there is currently no interruption
                                         in the supply chain for the active pharmaceutical ingredients for our products.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
                                         currently have uninterrupted wholesale and retail distribution of our products and are
                                         actively working to ensure that there continues to be an adequate supply of our products
                                         at pharmacies for sales to patients.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">While
we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our
business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but
not limited to, the duration and severity of the pandemic, the duration of &#8220;stay at home&#8221; and &#8220;social distancing&#8221;
orders, the ability of our sales force to access healthcare providers to promote our products, increases in unemployment, which
could reduce access to commercial health insurance for our patents, thus limiting payer coverage for our products, and the impact
of the pandemic on our global supply chain, all of which are uncertain and cannot be predicted. Our future results of operations
and liquidity could be materially adversely affected by delays in payments of outstanding receivable amounts beyond normal payment
terms, supply chain disruptions, uncertain demand, and the impact of any initiatives or programs that we may undertake to address
financial and operations challenges that we may face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it
is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded
with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness
of these actions remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Our
Products</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>IMVEXXY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2018, the FDA approved the 4-&#956;g and 10-&#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY
represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#956;g became available for commercial distribution
in July 2018 and both doses were commercially available in September 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">IMVEXXY
is a small, digitally inserted, softgel vaginal insert that dissolves completely. It is administered mess-free, without the need
for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that are familiar and comfortable
for patients, with no patient education required for dose application or applicators. IMVEXXY demonstrated efficacy as early as
two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone
levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies
is not known).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the FDA&#8217;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the
risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.
The FDA has also asked the sponsors of other vaginal estrogen products to participate in the observational study. In connection
with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of
this method is underway, and we do not believe that the costs will be material on an annual basis. In addition, the FDA asked
for post-approval information with respect to certain characteristics related to the product&#8217;s specifications, which we
submitted to the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>BIJUVA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical
hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS
(commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have
the same molecular structure as the hormones that are naturally produced in a woman&#8217;s body. We launched BIJUVA in April
2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">BIJUVA
offers the convenience of a single-capsule combination of two hormones (estradiol and progesterone), which may improve a user&#8217;s
compliance. The estradiol and progesterone in BIJUVA are plant-based, not animal-sourced, and contain no peanut allergens. BIJUVA
provides a sustained steady state of estradiol which reduced the frequency and severity of hot flashes in clinical studies with
no demonstrated impact on a patient&#8217;s weight or blood pressure. Additionally, through clinical trials BIJUVA has demonstrated
endometrial safety and greater than 90% amenorrhea rates, while providing no clinically meaningful changes in mammograms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
submitted a New Drug Application, or NDA, efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA in late January 2020
for review and potential approval. The NDA efficacy supplement uses existing data from our Phase 3 REPLENISH trial for BIJUVA,
for which we announced results in December 2016, together with additional information and analyses. The REPLENISH trial was the
first time that a combination of bio-identical estradiol and bio-identical progesterone used in a continuous combined daily fashion
demonstrated safety and efficacy data to support FDA-approval. We do not anticipate that the FDA will require any new clinical
trials in connection with our submission of the NDA efficacy supplement, however, there is no assurance that will be the case.
If accepted for review by the FDA, we expect that the NDA efficacy supplement will be reviewed, under current Prescription Drug
User Fee Act timeline goals, within ten months of receipt by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">With
the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method
to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this
method and validation were completed and submitted to the FDA as required in our approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
hormone therapy pharmaceutical products are characterized by safety and efficacy profiles that can be consistently manufactured
to target specifications. This provides an alternative to the non-FDA approved compounded bio-identical market. We believe that
our FDA-approved pharmaceutical products offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone
dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability
from major retail pharmacy chains rather than custom order or formulation by individual compounders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANNOVERA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA
(segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible
prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was approved by the
FDA in August 2018. In October 2019, we began a &#8220;test and learn&#8221; market introduction phase of launch for ANNOVERA
and we launched ANNOVERA commercially in March 2020. Due to the impact of the COVID-19 pandemic, we had to pause our launch
initiative and we expect to resume the ANNOVERA launch later in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
was classified by the FDA as a &#8220;new chemical entity,&#8221; or NCE, and thus has five years of regulatory exclusivity under
the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year
ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate,
a 19-nor progesterone derivative also known as Nestorone&#174;, or SA, and EE. EE is an approved active ingredient in many marketed
hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin that, based on pharmacopogical studies in
animals and <i>in vitro</i>, does not bind to the androgen or estrogen receptors and has no glucocorticoid activity at contraceptive
doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA
can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, ANNOVERA
does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for
seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted
for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active
ingredients (SA and EE). The claimed release rate of 150 &#956;g/day SA and 13/day &#956;g EE is supported by the calculated average
release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro
release.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of
venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the
FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided
that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against
royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational
nature of the study, we do not believe that the costs of the study will be material on an annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that ANNOVERA will compete across all the contraception options for women with focus on those women seeking a long-lasting
option without a procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
patients, ANNOVERA provides a single long-lasting reversible birth control product that does not require a procedure at the doctor&#8217;s
office for insertion or removal, empowering women to be in complete control of their fertility and menstruation with a 21/7 regimen.
We believe that ANNOVERA is a unique alternative for women who have previously chosen other forms of birth control. These include
nulliparous women (or women who have never given birth), women who are considering an IUD but would rather not have a procedure,
women who are between pregnancies but desire protection without a long-term commitment, and women who are not satisfied with oral
options due to the daily usage or potential side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that the strong initial commercial net revenue per unit of ANNOVERA and rapid commercial insurance adoption provide us
with an opportunity to deploy additional financial resources to maximize ANNOVERA&#8217;s consumer-focused commercialization strategy
and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when a generic equivalent
has not been established. As part of this strategy, we are pursuing distribution opportunities for ANNOVERA with multiple direct-to-consumer
contraceptive platforms that are both low cost to TherapeuticsMD and offer an attractive return to the platforms. However, as
a result of the COVID-19 pandemic, we have deferred a significant portion of our planned 2020 marketing spend for ANNOVERA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Commercialization
Model </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are commercializing the products in our portfolio through a common model focused on the belief that providing good experiences
for both health care practitioners, or HCPs, and patients will drive profitability for TherapeuticsMD. Given that our portfolio
focus is exclusively in women&#8217;s health, we believe that each new product launch will allow us to further leverage our existing
infrastructure and build out our reputation as the premier women&#8217;s health organization in the U.S. Below is more detail
on our commercialization model:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>HCP
Education</b> - Initially, we focus on the high writing and high potential HCPs in each territory to gain a full understanding
of their prescribing behavior and practices. Our focus is on driving initial prescriptions of these writers for each new product
launch and utilizing the time to also pull through on our portfolio of existing products. Once regular writing is established
with the initial group of HCPs, we expand our reach to a larger set of HCPs writing in the category. We educate HCPs on our products
primarily with our field sales organization. We have defined a sales force targeting approximately 200 territories, which includes
the most significant part of the addressable markets across our product portfolio. We are deploying a hybrid sales model that
combines an internal sales leadership team with a fully dedicated contract sales force to call on our target HCPs. As of March
31, 2020, at least 19,500 HCPs had written at least one prescription of IMVEXXY and at least 5,900 HCPs had written at least one
prescription of BIJUVA, the majority of which are also IMVEXXY writers demonstrating the value of portfolio and focus. In addition,
as of March 31, 2020, at least 2,000 HCPs had written at least one prescription of ANNOVERA. In addition to our sales organization,
we leverage non-personal promotion (multi-channel advertising) to targets and non-targets that drive awareness, education, and
action. These efforts allow for pull through of the sales organization efforts and identification of new targets that have interest
in writing prescriptions for one or more of our products. We believe this will drive increased prescribing for our products and
lift the overall writing universe and our products top of mind in the HCP community.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>BIO-IGNITE
</b>- In addition to our sales organization calling on HCPs, we have a Key Account Management, or KAM, team to support our BIO-IGNITE
pharmacy partners and continue to build our internal capabilities to support both organizations, including compliance professionals
and programs and key data support systems that provide real-time data for the sales force and KAMs. Our KAMs have national coverage
and target over 1,900 community pharmacies that have a focus on compounded bio-identical hormones and the over 2,000 additional
HCPs that are affiliated with these pharmacies. As of March 31, 2020, there were over 220 BIO-IGNITE compounding pharmacies that
were dispensing BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Payer
Access</b> - With the ever-changing payer environment, it is critical to maximize breadth of coverage as quickly as possible to
not inhibit patient access to product. We do this while working to negotiate the best possible contracts for us. Many commercial
payers employ &#8220;new-to-market blocks&#8221; for newly launched products until the payers have the opportunity to make a coverage
decision based upon their internal review of the product. When a product is not covered, the patient is responsible to pay the
full price for the medication, which can significantly limit utilization of the product. As we seek to increase the number of
lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage. Currently, both IMVEXXY and
BIJUVA are broadly available in major pharmacy chains in the U.S., as well as with our BIO-IGNITE partners, via our third-party
logistics and our distribution partners. As of March 31, 2020, we have obtained coverage for the majority of commercial payers
for both products and continue to seek unrestricted coverage from the remaining commercial insurance plans that we have not yet
contracted with to provide affordable access for patients. For IMVEXXY, we achieved unrestricted coverage with the top ten commercial
payers of VVA products by commercial payer lives and we continue to sign new agreements with other payers to cover IMVEXXY. In
addition, as of March 31, 2020, two of the top six (or three of the top eight) Medicare Part D payers of VVA products were adjudicating
IMVEXXY, with additional decisions for other Medicare Part D payers expected during the second half of 2020. For BIJUVA, through
March 31, 2020, we have achieved unrestricted coverage with seven of the top ten commercial payers of VMS products by commercial
payer lives and we continue to sign new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the
VMS market, as of March 31, 2020, two of the top six Medicare Part D payers of VMS products were adjudicating BIJUVA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
ANNOVERA, we believe that its unique characteristics will assist us in pursuing favorable commercial payer coverage, including
only one pharmacy fill fee per year and no office visit or procedure fees. We have made substantial progress in achieving unrestricted
access to ANNOVERA through commercial payers, including having achieved adjudication with five of the top ten commercial payers
by commercial payer lives as of March 31, 2020, and we continue to pursue discussions with several of the country&#8217;s largest
commercial insurers to further expand coverage. As of March 31, 2020, approximately 64% of the commercial payer market covered
ANNOVERA with unrestricted access under pharmacy benefits and approximately 76% covered ANNOVERA with step or prior authorization
access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2020, we entered into an agreement with Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the
public health system, to market ANNOVERA in the U.S. public health sector. As part of the Population Council License Agreement,
we have agreed to provide significantly reduced pricing to federally designated Title X family planning clinics serving underrepresented
women. We also have agreements to market ANNOVERA to the U.S. Department of Defense, the U.S. Veteran&#8217;s Administration, and in
Puerto Rico.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply
</b>- We want to ensure our products are available in all classes of trade and delivery systems. We offer our products through
traditional chain wholesalers (Cardinal, McKesson and AmerisourceBergen) and independent retail pharmacies, community compounding
pharmacies with our BIO-IGNITE program, and mail order. We continue to develop unique opportunities to sell direct to pharmacies
to streamline distribution and better control costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Patient
Affordability Programs</b> - We have affordability and adherence programs in place for patients so that we can support appropriate
use of our products by patients. Our co-pay assistance programs allow all patients to access our products at a reasonable cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
We continue to support our patient education and affordability program that allows all eligible patients who enroll to receive
IMVEXXY and BIJUVA at a reasonable cost. When a product is not covered by a patient&#8217;s commercial insurance, the patient
is responsible to pay the full price for the medication, which can significantly limit a patient&#8217;s ability to pay and subsequent
utilization of the product. Starting October 1, 2019, enrolled patients pay as little as $35 for a prescription of IMVEXXY with
commercial insurance coverage and pay as little as $50 for a prescription of IMVEXXY without commercial insurance coverage. For
ANNOVERA, for commercially insured patients, we offer patients assistance for as low as $60 for an annual prescription. Many patients
will not need a co-pay assistance program for ANNOVERA given the requirements of the ACA at the federal level and similar laws
at the state level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;
We continue to dialogue with the FDA regarding the potential inclusion of ANNOVERA as a new class of contraception for women in
the FDA&#8217;s Birth Control Guide, which would require private health plans to cover ANNOVERA with no patient out-of-pocket
costs as part of the ACA. While we are optimistic about our chances to secure a new contraception class for ANNOVERA, there is
no assurance that the FDA will make such a determination and it is possible that other FDA-approved products could also be included
in such a new class. The FDA may also find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share
with NuvaRing and its generic equivalents, and potentially others. Eight states require insurance coverage of prescription contraception
with co-pay regardless of inclusion in the FDA&#8217;s Birth Control Guide and 11 states, plus Washington D.C., require coverage
of prescription contraception with no co-pay regardless of inclusion in the FDA&#8217;s Birth Control Guide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Patient
Adherence</b> - Establishing compliance and adherence programs that make getting on a prescription medication and obtaining prescribed
refills easy and convenient for the patient and HCPs is a critical lever in our commercial model. Our focus is on minimizing complications
in patients filling their first prescription and engaging with them throughout the life of their treatment to ensure patients
stay on and use therapy for the appropriate length of time. We have delivered effective patient engagement programs for both our
prescription prenatal line and for IMVEXXY with average adherence rates above the averages in their respective categories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consumer
Communication</b> - Another critical level in the commercial model is consumer communication. Our initial focus is on those patients
who are already predisposed to seek treatment, such as those patients new to therapy, and those patients dissatisfied with their
current therapy. Next, we are focused on expanding the market by energizing patients who are experiencing bothersome symptoms
but who have not been motived to seek treatment. Methods of communication include online and offline media and span branded and
unbranded communication to ensure we drive action from awareness of symptoms to desire to speak to an HCP to acquire a prescription.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>License
Agreements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with the Population Council </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20 million within
30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the
third quarter of 2019, and we paid the Population Council a second milestone payment of $20 million as a result of the commercial
batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales
of ANNOVERA, as detailed below. We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA.
We are required to pay the Population Council additional milestone payments of $40 million upon cumulative net sales of ANNOVERA
in the U.S. by us and our affiliates and permitted sublicensees of each of $200 million, $400 million and $1.0 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net
sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
<tr style="vertical-align: top">
    <td style="width: 78%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Annual
    Net Sales</span></b></span></td>
    <td style="width: 12%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Royalty
    Rate</span></b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Less than or equal
    to $50.0 million</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">5%</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Greater than $50.0
    million and less than or equal to $150.0 million</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10%</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Greater than $150.0
    million</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">15%</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first
arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter
will be reduced to 20% of the initial rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by
the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required
by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval
study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population
Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year
vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Unless
earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the
last-to-expire of the Population Council&#8217;s U.S. patents that are licensed to us, or the date following such expiration
that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA
in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events
and by us on 180 days&#8217; prior notice to the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights
for two other investigational vaginal contraceptive systems in development by the Population Council.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Knight </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted
Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License
Agreement, Knight will pay us a milestone fee upon the first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales
milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based
on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. In October 2019 and November 2019, Knight&#8217;s
New Drug Submissions for Joyesta (IMVEXXY) and BIJUVA, respectively, were accepted for review by Health Canada. Knight will be
responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate
the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required
for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may
terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement
for any material breach by the other party that is not cured within certain specified time periods or if the other party files
for bankruptcy or other related matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
Agreement with Theramex </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, we entered into a licensing and supply agreement, or the Theramex License Agreement, with Theramex pursuant to which
we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except
for Canada and Israel, or the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an
upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone
payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each
of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be
paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory
ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales
of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or
registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within
certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such
regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges
our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not
cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may
sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant
to the terms of the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and IMVEXXY to Theramex.
We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Theramex
License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, we had 30 issued foreign patents and 31 issued domestic or, U.S., patents, which included 12 domestic utility
patents that relate to BIJUVA, three domestic patents that relate to estradiol and progesterone product candidates, eight domestic
patents that relate to IMVEXXY, which establish an important intellectual property foundation for IMVEXXY, one domestic utility
patent that relates to a pipeline transdermal patch technology, one domestic utility patent that relates to our topical-cream
candidates, two domestic patents that relate to formulations containing progesterone, one domestic utility patent that relates
to our OPERA&#174; information technology platform that we wrote off in the second quarter of 2019, and three domestic utility
patents that relate to TX-009HR, our progesterone and estradiol drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A
significant portion of our historical operating expenses have been incurred in research and development activities. Research and
development expenses relate primarily to the discovery and development of our drug candidates. Our research and development expenses
consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants that conduct
our clinical and preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based
compensation; the cost of developing our chemistry, manufacturing, and controls capabilities, and costs associated with other
research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with
respect to drug candidates that have not received Investigational New Drug Application approval from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table indicates our research and development expense by project for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black thin solid; text-align: center"><b>2020</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black thin solid; text-align: center"><b>2019</b></td><td><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0; width: 24%">TX 001-HR (BIJUVA)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">587</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">1,510</td><td style="text-align: left; width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0">TX 004-HR (IMVEXXY)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">765</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">874</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0">Other research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">1,926</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">3,169</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.25pt; padding-left: 0">Total</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">3,269</td><td style="padding-bottom: 2.25pt; text-align: left">&#160;</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">6,318</td><td style="padding-bottom: 2.25pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenditures have been reduced as we refocus our resources towards the commercialization of our approved
pharmaceutical products. We will continue to deploy limited resources as we develop our drug pipeline, continue stability testing and
validation on our pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work
with regulatory authorities on existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of clinical trials may vary significantly over the life of a project owing to a variety of factors. We base our expenses
related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research
and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory
testing, regulatory submission and response work. For a discussion of the nature of efforts, steps and costs necessary to complete
these projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Results
of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Three
months ended March 31, 2020 compared with three months ended March 31, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1px solid; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0; width: 61%; text-indent: 0">Revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">12,251</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,304</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0; text-indent: 0">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">763</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,952</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">60,458</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">41,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">19,169</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: 0">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50,922</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(38,105</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,817</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">(5,927</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">(1,401</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">(4,526</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.25pt; padding-left: 0; text-indent: 0">Net loss</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(56,849</td><td style="padding-bottom: 2.25pt; text-align: left">)</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(39,506</td><td style="padding-bottom: 2.25pt; text-align: left">)</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">(17,343</td><td style="padding-bottom: 2.25pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Revenues
and Cost of Goods Sold</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. We launched
IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third quarter
of 2019 and although we commercially launched ANNOVERA in early March  2020, we subsequently paused the launch due to the COVID-19
pandemic. Revenue for the three months ended March 31, 2020 increased approximately $8,304,000, or 210%, to approximately $12,251,000,
compared with approximately $3,947,000 for the three months ended March 31, 2019. Revenue increased primarily due to continued
ramping of sales of IMMVEXXY, sales of BIJUVA, and pre-launch sales of ANNOVERA during the three months ended March 31,
2020 as compared to the prior year period. Our revenue in the prior year period only consisted of sales of IMVEXXY and our prenatal
vitamins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
of IMMVEXXY increased approximately $4,382,000 as compared to the prior period, which was primarily due to a higher number of
units sold and increased net revenue per unit. Revenue for the three months ended March 31, 2020 also included sales of
BIJUVA of approximately $1,111,000, which was commercially launched in the second quarter of 2019, and sales of ANNOVERA of
approximately $2,273,000, which were affected by the recent COVID-19 pandemic. In addition, during the three months ended
March 31, 2020, our prenatal vitamin sales increased approximately $538,000 due to increased net revenue per unit as compared
to the prior year period, partially offset by a decreased number of units sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the launches of IMVEXXY and BIJUVA we introduced co-pay assistance programs which allow eligible enrolled patients to access the
products at a reasonable cost regardless of insurance coverage. We expect that our product revenue will improve in the long term
as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA, and ANNOVERA
prescriptions at pharmacies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of goods sold increased approximately $1,952,000, or 256%, to approximately $2,715,000 for the three months ended March 31, 2020,
compared with approximately $763,000 for the three months ended March 31, 2019, most of which is attributable to the 210% increase
in revenue. A portion of the increase is due to royalty fees of approximately $114,000 and the amortization of our license fee
of approximately $746,000 related to ANNOVERA. Our gross margin related to prescription products was approximately 78% and 81%
for the three-month periods ended March 31, 2020 and 2019, respectively. The change in our gross margin is primarily related to
the change in product mix between the two periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Our
operating costs have increased substantially as we continue to support the launch of our new pharmaceutical products in the
market. BIJUVA was launched in the second quarter of 2019. W</span><span style="font: 10pt Times New Roman, Times, Serif">e
commercially launched ANNOVERA in early March 2020, which was subsequently paused due to the outbreak of the COVID-19
pandemic. During the three months ended March 31, 2019, we were primarily focused on growing sales of IMVEXXY and prenatal
vitamins. <span style="color: windowtext">Our principal operating costs include the following items as a percentage of total
operating expenses: </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: justify; padding-left: 0">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">52.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">41.2</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0">Human resources related costs, including salaries, benefits and taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.9</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.5</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Operating
expenses increased by approximately $19,169,000, or 46%, to approximately $60,458,000 for the three months ended March 31, 2020,
from approximately $41,289,000 for the three months ended March 31, 2019 as a result of the following items:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>Change</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="10" style="border-bottom: Black 1px solid; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0; width: 61%">Sales and marketing, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">31,530</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,518</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0">Human resources related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,122</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,049</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">696</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0">Other operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">6,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">4,316</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1px solid; text-align: left">&#160;</td><td style="border-bottom: Black 1px solid; text-align: right">1,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.25pt; padding-left: 0">Total operating expenses</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">60,458</td><td style="padding-bottom: 2.25pt; text-align: left">&#160;</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">41,289</td><td style="padding-bottom: 2.25pt; text-align: left">&#160;</td><td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; text-align: right">19,169</td><td style="padding-bottom: 2.25pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing costs, excluding human resources costs, for the three months ended March 31, 2020 increased by approximately
$14,518,000, or 85%, to approximately $31,530,000, compared with approximately $17,012,000 for the three months ended March
31, 2019. This increase was primarily due to higher expenses associated with sales and marketing efforts to support the
significant initiatives related to the launch of ANNOVERA in March 2020, which was subsequently paused as a result of the
outbreak of the COVID-19 pandemic, as well as continuing to support the commercialization of BIJUVA and IMVEXXY. The sales
and marketing increase includes a change of approximately $9,900,000 related to advertising expenses related primarily to the
preparation of the launch of ANNOVERA and increased spend on consumer media to support growth of sales for IMVEXXY and
BIJUVA, an increase of approximately $1,700,000 in consulting projects including costs for outsourced sales personnel and
their related expenses, and an increase of approximately $1,200,000 in incentives related to increased sales of our products.
The sales and marketing expenses also increased due to higher costs related to product samples, physician education and
training expenses related to product commercialization. As noted in the COVID-19 discussion above, we have implemented
measures to cut or defer spending, including sales and marketing costs, as a result of the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Human
resources related costs, including salaries, benefits and taxes, for the three months ended March 31, 2020 increased by approximately
$5,122,000, or 46%, to approximately $16,230,000, compared with approximately $11,108,000 for the three months ended March 31,
2019, primarily as a result of an increase in personnel costs in sales, marketing and regulatory areas to support the commercialization
of our pharmaceutical products in 2020 as compared to 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
research and development costs for the three months ended March 31, 2020 decreased by approximately $3,049,000, or 48%, to
approximately $3,269,000, compared with approximately $6,318,000 for the three months ended March 31, 2019. Research and
development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages,
non-cash compensation, and benefits of personnel involved in research and development activities. Research and development
expenditures have been reduced as we refocus our resources towards the commercialization of our approved pharmaceutical
products. We continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation
on our pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory
authorities on existing submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in February 2013, we have incurred approximately $131,622,000
                                         in research and development costs with respect to BIJUVA.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
                                         the project&#8217;s inception in August 2014, we have incurred approximately $48,642,000
                                         in research and development costs with respect to IMVEXXY.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business
&#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Professional
fees and consulting costs for the three months ended March 31, 2020 increased by approximately $696,000, or 27%, to approximately
$3,231,000, compared with approximately $2,535,000 for the three months ended March 31, 2019, primarily as a result of increased
legal and other professional fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
operating expense for the three months ended March 31, 2020 increased by approximately $1,882,000, or 44%, to approximately $6,198,000,
compared with approximately $4,316,000 for the three months ended March 31, 2019, as a result of increased information technology,
rent and utilities expense, dues and subscriptions, insurance and other office expenses primarily to support commercialization
of our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
a result of the foregoing, our operating loss increased approximately $12,817,000, or 34%, to approximately $50,922,000 for the
three months ended March 31, 2020, compared with approximately $38,105,000 for the three months ended March 31, 2019, primarily
as a result of an increase in total operating expenses to support commercialization and launch efforts related to our pharmaceutical
products, partially offset by increased total revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA,
and ANNOVERA, although there is no assurance that our commercialization of IMVEXXY, BIJUVA, and ANNOVERA will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Other
expense, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
<span style="color: windowtext">expense, net increased by approximately $4,526,000, or 323%, to an expense of approximately $5,927,000
for the three months ended March 31, 2020, compared with an expense of approximately $1,401,000 for the three months ended March
31, 2019, primarily as a result of increased interest expense related to our Financing Agreement.&#160;For more information regarding
our Financing Agreement, see &#8220;Liquidity and Capital Resources&#8221; below.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Net
Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because of the net effects of the foregoing, net loss increased approximately $17,343,000, or 44%, to
approximately $56,849,000 for the three months ended March 31, 2020, compared with approximately $39,506,000 for the three months
ended March 31, 2019. Net loss per share of common stock, basic and diluted, was ($0.21) and ($0.16) for the three months ended
March 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Liquidity
and Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities.
For the three-year period ending December 31, 2019, we received approximately $236,000,000 in net proceeds from the issuance of
shares of our common stock. As of March 31, 2020, we had cash totaling approximately $170,098,000. However, changing circumstances
may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently
expected because of circumstances beyond our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts,
chargebacks and payment discounts by the average daily net product revenues during the quarter. We also disclose gross DSO, which
includes the calculation of gross accounts receivable divided by the average daily gross product revenues to distributors during
the quarter. For the three months ended March 31, 2020, our gross DSO was 52 days compared to 55 days for the three months ended
December 31, 2019, and our net DSO was 153 days for the three months ended March 31, 2020 compared to 141 days for the three months
ended December 31, 2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer
payment terms associated with the launches of IMVEXXY, BIJUVA and ANNOVERA and changes in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending, Inc.,
as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors, which provides us with a $300,000,000 first lien secured term loan credit facility,
or the Facility. The Facility provides for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into
the Financing Agreement; (ii) $50,000,000 was drawn on February 18, 2020; and (iii) $50,000,000 will be available to us in the
Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the delivery of our financial statements
for the fiscal quarter ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to. Borrowings
under the Facility accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime
rate plus 6.75%, subject to a prime rate floor of 5.20% as selected by us. Interest on amounts borrowed under the Facility is
payable quarterly. The outstanding principal amount of the Facility is payable in four equal quarterly installments beginning
on June 30, 2023, with the Facility maturing on March 31, 2024. A portion of the initial tranche of borrowing under the Facility
in the amount of approximately $81,661,000 was used to repay all amounts outstanding under our prior financing agreement with
MidCap Financial Trust, or the MidCap Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
there is uncertainty related to the anticipated impact of the COVID-19 pandemic on our future results, we believe that our current
cash reserves and the recent steps we have taken to reduce costs will help us to manage our business through the pandemic.&#160;We
have reviewed numerous potential scenarios in connection with the impact of&#160;COVID-19 on our business and, based on our analysis,
we believe our existing cash reserves, our currently anticipated operating cash flows, and availability under the Facility, if
we are able to access such funds, will be sufficient to meet our cash needs arising in the ordinary course of business for the
next twelve months from the date of this Quarterly Report on Form 10-Q.&#160;However, if the successful commercialization of IMVEXXY,
BIJUVA, or ANNOVERA is delayed, or the impact of the COVID-19 pandemic is worse than we anticipate, our existing cash reserves
and availability under the Facility, if we are able to access such funds, may be insufficient to satisfy our liquidity requirements
until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA and we may not be able to access funds under the
Facility. If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing, and
other commercialization efforts and we may seek to sell additional equity or debt securities. Our ability to sell equity securities
will be limited by the authorized shares that we have available to issue. Our ability to sell debt securities or obtain additional
debt financing is restricted pursuant to the Financing Agreement. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, to the extent permitted under the Financing Agreement, the ownership interests of our
existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that
adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances,
or licensing arrangements with third parties, certain of which are restricted under the Financing Agreement, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs, or proposed products, if permitted under the Financing
Agreement. Additionally, we may have to grant licenses on terms that may not be favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive products
and product candidates. The following table sets forth the primary sources and uses of cash for each of the periods set forth
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary
of (Uses) and Sources of Cash</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>Three Months Ended <br />March 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1px solid; text-align: center"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1px solid; text-align: center"><b>(000s)</b></td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0; width: 74%; text-indent: 0">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 10%">(39,111</td><td style="text-align: left; width: 1%">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(38,163</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0; text-indent: 0">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(443</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(666</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0; padding-left: 0">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
principal use of cash in operating activities for the three months ended March 31, 2020 was to fund our current expenses primarily
related to supporting commercialization activities for IMVEXXY, BIJUVA, and ANNOVERA, sales, marketing, scale-up and manufacturing
activities and clinical development, adjusted for non-cash items. The increase of approximately $948,000 in cash used in operating
activities for the three months ended March 31, 2020 compared with the comparable period in the prior year was due primarily to
an increase in our net loss coupled with changes in the components of working capital which were primarily due to the launch and
commercialization of our pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Investing
activities include costs related to patents and fixed assets. Investing activities for the three months ended March 31, 2020 decreased
by $223,000 primarily due to lower amounts spent on fixed assets during the three months ended March 31, 2020 as compared to the
three months ended March 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Financing
activities currently represent the principal source of our cash flow. Our financing activities for the three months ended March
31, 2020 provided net cash of approximately $48,822,000 which consisted of the funding from our Financing Agreement of approximately
$50,000,000 and the exercise of options to purchase common stock of approximately $72,000, partially offset by the payment of
deferred financing fees of approximately $1,250,000. Our financing activities for the three months ended March 31, 2019 provided
net cash of approximately $100,000, which was related to the exercise of stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>New
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020 and the adoption did not have a material effect
on our disclosures for the three months ended March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we&#160;adopted&#160;ASU&#160;2016-13&#160;under a modified retrospective approach for all financial assets measured
at amortized cost. There was no adjustment recorded for the cumulative effect of adopting&#160;ASU 2016-13. The adoption expanded
disclosures about our credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_009"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest
rates. To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment
securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt
securities and commercial paper, all with various maturity dates. Due to the low risk profile of our investments, an immediate
100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Amounts
borrowed under the Financing Agreement will accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of
2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering the total outstanding principal balance
under the Financing Agreement of $250,000,000 at March 31, 2020, a 1.0% change in interest rates would result in an impact to
income before income taxes of $2,500,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_010"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Disclosure
Controls and Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within
the time period specified in the SEC's rules and forms and is accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate, in order to allow timely decisions in connection with required
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Evaluation
of Disclosure Controls and Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the
period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on
Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we
file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in
the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented
or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration
of the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Changes
in Internal Controls</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, there were no changes in our internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_011"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_012"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our business or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_013"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Except
as set forth below, there have been no material changes with respect to those risk factors previously disclosed in Item 1A &#8220;Risk
Factors&#8221; in Part I of our Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Our
financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing
COVID-19 (coronavirus) pandemic.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
outbreak of the novel COVID-19 (coronavirus) has evolved into a global pandemic. COVID-19 has spread to many regions of the world,
including the United States and Europe. The full extent to COVID-19 impacts our business and operating results will depend on
future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning
COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">While
we have developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and
marketing infrastructure, protect our balance sheet during this period of market disruption and meet the needs of our patients
and prescribers, including cost-containment and spending cuts in the second quarter of 2020 that can be extended through the rest
of the year depending on the evolution of COVID-19, we have suspended our previously announced 2020 financial guidance due to
the unknown impact of COVID-19 on our business and the rapidly evolving nature of the pandemic. As a result of COVID-19, we will,
among other things, (i) defer approximately $10 million in consumer and healthcare practitioner marketing spending for ANNOVERA
and IMVEXXY, (ii) make cuts of approximately $20 million in other planned expenses for the year, (iii) negotiate lower fees and/or
suspend services from non-critical third party vendors, (iv) implement a hiring freeze, (v) delay or cancel any non-critical information
technology projects and (vi) eliminate travel, entertainment, meeting and event expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we currently continue to have uninterrupted wholesale and retail distribution of our products and we do not anticipate a shortage
of our products due to COVID-19 at this time, disruptions may occur for our customers or suppliers that may materially affect
our ability to obtain supplies or other components for our products, manufacture additional products or deliver inventory in a
timely manner. This would result in lost sales, additional costs, or penalties, or damage to our reputation. In addition, due
to closures and restrictions on travel, our sales force is currently functioning largely utilizing digital engagement tools and
tactics and virtual detailing, which may be less effective than our ordinary course sales and marketing programs. We may also
require an increased level of working capital if we experience extended billing and collection cycles as a result of displaced
employees at our company, payers, revenue cycle management contractors, or otherwise. We may also experience other unknown impacts
from COVID-19 that cannot be predicted. Accordingly, disruptions to our business as a result of COVID-19 could result in a material
adverse effect on our business, results of operations, financial condition and prospects in the near-term and beyond 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_014"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; padding-right: 5.4pt; padding-left: 0"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 65%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="border-bottom: Black 0.25pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><a href="ex31-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">May
    6, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><a href="ex31-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">May
    6, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><a href="ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">32.1**</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">May
    6, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Section 1350 Certification of Chief Executive Officer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><a href="ex32-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">32.2**</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">May
    6, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Section 1350 Certification of Chief Financial Officer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded
    within the Inline XBRL document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File (formatted as Inline XBRL and Contained in Exhibit 101)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 0; margin-bottom: 0"><div style="border-top: Black 1pt solid; margin-right: auto; font-size: 1pt; width: 20%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">**
Furnished herewith.</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">DATE:
May 6, 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC.</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert G. Finizio</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">/<i>s/ Daniel A. Cartwright</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_033120.htm">TherapeuticsMD,Inc. 10-Q</A><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert G. Finizio, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
    in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
    13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions): </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert G. Finizio</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    G. Finizio</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Executive Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Executive Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_033120.htm">TherapeuticsMD,Inc. 10-Q</A><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Daniel A. Cartwright, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
    in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
    13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions): </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    6, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    A. Cartwright</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Financial Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Financial and Accounting Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_033120.htm">TherapeuticsMD,Inc. 10-Q</A><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the quarterly report of TherapeuticsMD, Inc. (the &quot;Company&quot;) on Form 10-Q for the quarterly period ended
March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), I, Robert G.
Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 46pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 45.6pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 46pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 45.6pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and result of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 6, 2020</FONT></TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Robert G. Finizio</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_033120.htm">TherapeuticsMD,Inc. 10-Q</A><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the quarterly report of TherapeuticsMD, Inc. (the &quot;Company&quot;) on Form 10-Q for the quarterly period ended
March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &quot;Report&quot;), I, Daniel A.
Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &sect; 1350,
as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 46pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 45.6pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
                                         Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 46pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 45.6pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         information contained in the Report fairly presents, in all material respects, the financial
                                         condition and result of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 6, 2020</FONT></TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 14; Value: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>txmd-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSa+L6bP9w5dzqelBtm96HclazygrKIHRCS8oaMImAesA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20200331" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20200331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" id="ConsolidatedStatementsOfStockholdersDeficitEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1Company" id="Note1Company">
	  <link:definition>00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" id="Note3SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4Inventory" id="Note4Inventory">
	  <link:definition>00000010 - Disclosure - NOTE 4 &#8211; INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" id="Note5OtherCurrentAssets">
	  <link:definition>00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" id="Note6FixedAssetsNet">
	  <link:definition>00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" id="Note7IntangibleAssetsNet">
	  <link:definition>00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" id="Note8OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9Debt" id="Note9Debt">
	  <link:definition>00000015 - Disclosure - NOTE 9 &#8211; DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" id="Note10NetLossPerShare">
	  <link:definition>00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" id="Note11StockholdersEquity">
	  <link:definition>00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" id="Note12IncomeTaxes">
	  <link:definition>00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" id="Note13RelatedParties">
	  <link:definition>00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" id="Note14BusinessConcentrations">
	  <link:definition>00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" id="Note15CommitmentsAndContingencies">
	  <link:definition>00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" id="Note16SubsequentEvents">
	  <link:definition>00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" id="Note3SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" id="Note3SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" id="Note4InventoryTables">
	  <link:definition>00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" id="Note5OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" id="Note6FixedAssetsNetTables">
	  <link:definition>00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" id="Note7IntangibleAssetsNetTables">
	  <link:definition>00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" id="Note8OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtTables" id="Note9DebtTables">
	  <link:definition>00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" id="Note10NetLossPerShareTables">
	  <link:definition>00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" id="Note11StockholdersEquityTables">
	  <link:definition>00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" id="Note15CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" id="Note1CompanyDetailsNarrative">
	  <link:definition>00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" id="FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails">
	  <link:definition>00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" id="InventoryConsistsOfFollowingDetails">
	  <link:definition>00000037 - Disclosure - Inventory consists of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" id="OtherCurrentAssetsConsistOfFollowingDetails">
	  <link:definition>00000038 - Disclosure - Other current assets consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" id="FixedAssetsNetConsistOfFollowingDetails">
	  <link:definition>00000039 - Disclosure - Fixed assets, net consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" id="Note6FixedAssetsNetDetailsNarrative">
	  <link:definition>00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" id="FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details">
	  <link:definition>00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" id="EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails">
	  <link:definition>00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" id="Note7IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" id="OtherCurrentLiabilitiesConsistOfFollowingDetails">
	  <link:definition>00000044 - Disclosure - Other current liabilities consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" id="AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails">
	  <link:definition>00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" id="Note9DebtDetailsNarrative">
	  <link:definition>00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
	  <link:definition>00000047 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" id="Note10NetLossPerShareDetailsNarrative">
	  <link:definition>00000048 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" id="ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails">
	  <link:definition>00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" id="SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails">
	  <link:definition>00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" id="RestrictedStockAndPerformanceStockAwardsDetails">
	  <link:definition>00000051 - Disclosure - Restricted stock and performance stock awards (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" id="Note11StockholdersEquityDetailsNarrative">
	  <link:definition>00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" id="Note13RelatedPartiesDetailsNarrative">
	  <link:definition>00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" id="Note14BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000054 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" id="SupplementalLeaseInformationDetails">
	  <link:definition>00000055 - Disclosure - Supplemental lease information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" id="FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails">
	  <link:definition>00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" id="Note15CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" id="Note16SubsequentEventsDetailsNarrative">
	  <link:definition>00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="txmd_VitaminsAndImvexxyMember" name="VitaminsAndImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaAndAnnoveraMember" name="BijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionVitaminsMember" name="PrescriptionVitaminsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyMember" name="ImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaMember" name="BijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnoveraMember" name="AnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreement1Member" name="CouncilLicenseAgreement1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep1Member" name="CouncilLicenseAgreementStep1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep2Member" name="CouncilLicenseAgreementStep2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep3Member" name="CouncilLicenseAgreementStep3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsMember" name="DomesticUSPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsMember" name="ForeignPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsBijuvaMember" name="DomesticPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsBijuvaMember" name="ForeignPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsNonApprovedBijuvaMember" name="DomesticPatentsNonApprovedBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsImvexxyMember" name="DomesticUSPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSUtilityPatentsImvexxyMember" name="DomesticUSUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSDesignPatentsImvexxyMember" name="DomesticUSDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsImvexxyMember" name="ForeignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentsImvexxyMember" name="ForeignUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignDesignPatentsImvexxyMember" name="ForeignDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" name="DomesticUtilityPatentTopicalCreamCandidatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTransdermalPatchMember" name="DomesticUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentTransdermalPatchMember" name="ForeignUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTx009HRMember" name="DomesticUtilityPatentTx009HRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsProgesteroneFormulationsMember" name="DomesticPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsProgesteroneFormulationsMember" name="ForeignPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentOperaMember" name="DomesticUtilityPatentOperaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementMember" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheThreeMember" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyBijuvaAndAnnoveraMember" name="ImvexxyBijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MidCapAgreementMember" name="MidCapAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsCashlessExerciseMember" name="WarrantsCashlessExerciseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Plan2019Member" name="Plan2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NewSharesMember" name="NewSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierOneConcentrationRiskMember" name="SupplierOneConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierTwoConcentrationRiskMember" name="SupplierTwoConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierThreeConcentrationRiskMember" name="SupplierThreeConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierFourConcentrationRiskMember" name="SupplierFourConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FourCustomersConcentrationRiskMember" name="FourCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FiveCustomersConcentrationRiskMember" name="FiveCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPillPackRiskMember" name="CustomerConcentrationPillPackRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationMcKessonCorporationRiskMember" name="CustomerConcentrationMcKessonCorporationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationCardinalHealthRiskMember" name="CustomerConcentrationCardinalHealthRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" name="CustomerConcentrationPharmacyInnovationsPaRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPIServicesRiskMember" name="CustomerConcentrationPIServicesRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationAmerisourceBergenRiskMember" name="CustomerConcentrationAmerisourceBergenRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseRights" name="LicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" name="LicenseAgreementWithPopulationCouncilPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentUponFDAApproval" name="MilestonePaymentUponFDAApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetSalesAmountPerStepbasedRoyalty" name="NetSalesAmountPerStepbasedRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyPercent" name="RoyaltyPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturing" name="PrepaidManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedRebates" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtTrancheAxis" name="DebtTrancheAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_DebtTrancheDomain" name="DebtTrancheDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiborFloorRate" name="LiborFloorRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrimeRateFloor" name="PrimeRateFloor" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfInstallmentPayments" name="NumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" name="PrepaymentFeeForFirstTwoYearsFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeThirdYearFundingPercent" name="PrepaymentFeeThirdYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFourthYearFundingPercent" name="PrepaymentFeeFourthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFifthYearFundingPercent" name="PrepaymentFeeFifthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FacilityFeePaidPercent" name="FacilityFeePaidPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" name="MinimumCashBalanceRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfTranchesUnderTermLoanFacility" name="NumberOfTranchesUnderTermLoanFacility" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentOfDebtWithNewCreditFacility" name="RepaymentOfDebtWithNewCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentFeePercentage" name="RepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" name="NumberOfStockIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetRentableAreaLease" name="NetRentableAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RentedAreaLease" name="RentedAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalAreaOfLeaseOccupied" name="AdditionalAreaOfLeaseOccupied" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" name="LesseeOperatingLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" name="LesseeOperatingLeaseLeaseNotYetCommencedArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SignificantSupplyCommitmentPercentagePayable" name="SignificantSupplyCommitmentPercentagePayable" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" name="IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" name="MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" name="IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" name="IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsTopicalCreamMember" name="DomesticUSPatentsTopicalCreamMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentDLimoneneMember" name="DomesticUtilityPatentDLimoneneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SubscriptionAgreementKnightMember" name="SubscriptionAgreementKnightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RegulatoryMilestoneAdditionalPayment" name="RegulatoryMilestoneAdditionalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesMilestonePaymentsInTranches" name="SalesMilestonePaymentsInTranches" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CreditAgreementMember" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersConcentrationRiskMember" name="ThreeCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PlanAwardsNumberOfNewShares" name="PlanAwardsNumberOfNewShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementGoldmanSachsMember" name="UnderwritingAgreementGoldmanSachsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PeriodExercisableUnderwritersOption" name="PeriodExercisableUnderwritersOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritersOptionGrantedInPeriodShares" name="UnderwritersOptionGrantedInPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheOneMember" name="TrancheOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RevenueRequirementToDrawOnTermLoan" name="RevenueRequirementToDrawOnTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoThreeMember" name="TrancheTwoThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" name="LesseeFinanceLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercised" name="NumberOfStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaymentsToAcquireIntellectualPropertyLicense" name="PaymentsToAcquireIntellectualPropertyLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfVendors" name="NumberOfVendors" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementTheramexMember" name="LicenseAgreementTheramexMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualNetSalesMilestone" name="AnnualNetSalesMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedIntellectualLicenseFee" name="AccruedIntellectualLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CashUpfrontPaymentReceived" name="CashUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementJPMorganChaseMember" name="UnderwritingAgreementJPMorganChaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ProceedsFromIssuancePublicOffering" name="ProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWarrantRollForwardTableTextBlock" name="ScheduleOfWarrantRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtcProductsMember" name="OtcProductsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingVestedAndExercisable" name="WarrantsOutstandingVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsUnvestedWeightedAverageExercisePrice" name="WarrantsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceOtherThanOptions" name="WeightedAverageExercisePriceOtherThanOptions" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsDomestic" name="NumberOfIssuedPatentsDomestic" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsForeign" name="NumberOfIssuedPatentsForeign" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriod20YearsMember" name="ExpirationPeriod20YearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriodIndefiniteMember" name="ExpirationPeriodIndefiniteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NolCarryForwardPeriod" name="NolCarryForwardPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CatalentMember" name="CatalentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_QuarterlyRoyaltyPaymentsPercentage" name="QuarterlyRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" name="RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalLeasedSpaceMember" name="AdditionalLeasedSpaceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer" name="MinimumAnnualSpendingAmountPlannedToCutOrDefer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend" name="PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PlannedCutsOfOtherExpenses" name="PlannedCutsOfOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>txmd-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200331.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200331.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20200331.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200331.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200331.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200331.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200331.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200331.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200331.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20200331.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200331.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200331.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200331.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20200331.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:href="txmd-20200331.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200331.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200331.xsd#AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200331.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:href="txmd-20200331.xsd#ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:href="txmd-20200331.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:href="txmd-20200331.xsd#RestrictedStockAndPerformanceStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200331.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200331.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_txmdLicenseRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000047 - Disclosure - NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:title="00000048 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:title="00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:title="00000051 - Disclosure - Restricted stock and performance stock awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>txmd-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200331.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200331.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20200331.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200331.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200331.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200331.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200331.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200331.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200331.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20200331.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200331.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200331.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200331.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20200331.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:href="txmd-20200331.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200331.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200331.xsd#AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200331.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:href="txmd-20200331.xsd#ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:href="txmd-20200331.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:href="txmd-20200331.xsd#RestrictedStockAndPerformanceStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200331.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200331.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdRoyaltyPercent_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_160" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_220" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage_200" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_200" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_200" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_200" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_200" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_200" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_200" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000047 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:title="00000048 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:title="00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:title="00000051 - Disclosure - Restricted stock and performance stock awards (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NewSharesMember" xlink:label="loc_txmdNewSharesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNewSharesMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_250" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_250" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_250" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation_250" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_250" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_250" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_250" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_250" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_250" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_250" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_250" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_250" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_250" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierFourConcentrationRiskMember" xlink:label="loc_txmdSupplierFourConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierFourConcentrationRiskMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FiveCustomersConcentrationRiskMember" xlink:label="loc_txmdFiveCustomersConcentrationRiskMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFiveCustomersConcentrationRiskMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="loc_txmdCustomerConcentrationPIServicesRiskMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesRiskMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues_220" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="loc_txmdPaycheckProtectionProgramLoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_txmdPaycheckProtectionProgramLoanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:label="loc_txmdIndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:label="loc_txmdMaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="loc_txmdIndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="loc_txmdIndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_30" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>txmd-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="txmd_VitaminsAndImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaminsAndImvexxyMember_lbl" xml:lang="en-US">Vitamins and IMVEXXY [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="txmd_BijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaAndAnnoveraMember_lbl" xml:lang="en-US">BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrescriptionVitaminsMember" xlink:label="txmd_PrescriptionVitaminsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionVitaminsMember_lbl" xml:lang="en-US">Prescription Vitamins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyMember" xlink:label="txmd_ImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyMember_lbl" xml:lang="en-US">Imvexxy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaMember" xlink:label="txmd_BijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaMember_lbl" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnoveraMember" xlink:label="txmd_AnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoveraMember_lbl" xml:lang="en-US">ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="txmd_CouncilLicenseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreement1Member_lbl" xml:lang="en-US">Council License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="txmd_CouncilLicenseAgreementStep1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep1Member_lbl" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="txmd_CouncilLicenseAgreementStep2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep2Member_lbl" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="txmd_CouncilLicenseAgreementStep3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep3Member_lbl" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsMember" xlink:label="txmd_DomesticUSPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsMember_lbl" xml:lang="en-US">Domestic US Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsMember" xlink:label="txmd_ForeignPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsMember_lbl" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="txmd_DomesticPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsBijuvaMember_lbl" xml:lang="en-US">Domestic Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="txmd_ForeignPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsBijuvaMember_lbl" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xml:lang="en-US">Domestic Patents NonApproved BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="txmd_DomesticUSPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="txmd_ForeignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="txmd_ForeignDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_lbl" xml:lang="en-US">Domestic Utility Patent Topical Cream Candidates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="txmd_DomesticUtilityPatentTx009HRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_lbl" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="txmd_DomesticUtilityPatentOperaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentOperaMember_lbl" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="txmd_FinancingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementMember_lbl" xml:lang="en-US">Financing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheAxis" xlink:label="txmd_DebtTrancheAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtTrancheAxis_lbl" xml:lang="en-US">Debt Tranche [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheTwoMember" xlink:label="txmd_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheThreeMember" xlink:label="txmd_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheThreeMember_lbl" xml:lang="en-US">Tranche 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MidCapAgreementMember" xlink:label="txmd_MidCapAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MidCapAgreementMember_lbl" xml:lang="en-US">Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsMember" xlink:label="txmd_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsMember_lbl" xml:lang="en-US">Warrants Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="txmd_WarrantsCashlessExerciseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsCashlessExerciseMember_lbl" xml:lang="en-US">Warrants - Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_Plan2019Member" xlink:label="txmd_Plan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Plan2019Member_lbl" xml:lang="en-US">Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NewSharesMember" xlink:label="txmd_NewSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NewSharesMember" xlink:to="txmd_NewSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NewSharesMember_lbl" xml:lang="en-US">New Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US">Affiliated Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="txmd_SupplierOneConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierOneConcentrationRiskMember" xlink:to="txmd_SupplierOneConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierOneConcentrationRiskMember_lbl" xml:lang="en-US">Supplier One Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="txmd_SupplierTwoConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierTwoConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="txmd_SupplierThreeConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierThreeConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 3</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierFourConcentrationRiskMember" xlink:label="txmd_SupplierFourConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierFourConcentrationRiskMember" xlink:to="txmd_SupplierFourConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierFourConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Four Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="txmd_FourCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FourCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FiveCustomersConcentrationRiskMember" xlink:label="txmd_FiveCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FiveCustomersConcentrationRiskMember" xlink:to="txmd_FiveCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FiveCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Five Customers Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="txmd_CustomerConcentrationPillPackRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_lbl" xml:lang="en-US">PillPack - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xml:lang="en-US">Cardinal Health - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:to="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_lbl" xml:lang="en-US">Pharmacy Innovations PA - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesRiskMember" xlink:to="txmd_CustomerConcentrationPIServicesRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember_lbl" xml:lang="en-US">PI Services - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xml:lang="en-US">AmerisourceBergen - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="txmd_PaycheckProtectionProgramLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaycheckProtectionProgramLoanMember" xlink:to="txmd_PaycheckProtectionProgramLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Paycheck Protection Program Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $781,419 and $904,040, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseRights" xlink:label="txmd_LicenseRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRights_lbl" xml:lang="en-US">License rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">&#160;LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 15</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' (Deficit) Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized: 271,677,742 and 271,177,076 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Product revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of shares from release of restricted stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="txmd_NoncashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">(Recovery of) provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NOTE 1 &#8211; THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 4 &#8211; INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">NOTE 5 &#8211; OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 6 &#8211; FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 7 &#8211; INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">NOTE 9 &#8211; DEBT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NOTE 10 &#8211; NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 12 &#8211; INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 13 &#8211; RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">NOTE 16 &#8211; SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_lbl" xml:lang="en-US">License Agreement with the Population Council</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">The following table provides information about disaggregated revenue by product mix</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Other current assets consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets, net consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and 2019 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Restricted stock and performance stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfSubsidiaries" xlink:label="txmd_NumberOfSubsidiaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products following product expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="txmd_MilestonePaymentUponFDAApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentUponFDAApproval_lbl" xml:lang="en-US">Milestone payment upon FDA Approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">License rights acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xml:lang="en-US">Net sales amount per step-based royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RoyaltyPercent" xlink:label="txmd_RoyaltyPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPercent_lbl" xml:lang="en-US">Royalty (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xml:lang="en-US">Maximum costs and expenses for post approval</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing fees on undrawn tranches (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidManufacturing" xlink:label="txmd_PrepaidManufacturing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturing_lbl" xml:lang="en-US">Prepaid manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="us-gaap_IndefiniteLivedTrademarks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTrademarks" xlink:to="us-gaap_IndefiniteLivedTrademarks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTrademarks_lbl" xml:lang="en-US">Indefinite-Lived Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (9 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Accrued wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="txmd_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedRebates" xlink:label="txmd_AccruedRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedRebates_lbl" xml:lang="en-US">Accrued rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt discount and financing fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">TOTAL LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Total revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LiborFloorRate" xlink:label="txmd_LiborFloorRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiborFloorRate_lbl" xml:lang="en-US">LIBOR floor rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrimeRateFloor" xlink:label="txmd_PrimeRateFloor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrimeRateFloor_lbl" xml:lang="en-US">Prime rate floor</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfInstallmentPayments" xlink:label="txmd_NumberOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfInstallmentPayments_lbl" xml:lang="en-US">Number of quarterly principal installment payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xml:lang="en-US">Prepayment fee for first two years funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee third year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fourth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fifth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FacilityFeePaidPercent" xlink:label="txmd_FacilityFeePaidPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FacilityFeePaidPercent_lbl" xml:lang="en-US">Facility fee paid (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xml:lang="en-US">Number of tranches under term loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xml:lang="en-US">Repayment of debt with new credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeePercentage" xlink:label="txmd_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentFeePercentage" xlink:label="txmd_RepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentFeePercentage_lbl" xml:lang="en-US">Repayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares under options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares under options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares under options, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares under options, cancelled forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, cancelled forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under options, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares under options, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested/released</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, vested/released</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Number of stock issued in cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xml:lang="en-US">Range - exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Amount billed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCustomers" xlink:label="txmd_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers - revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short-term operating lease liability (included in Other current liabilities)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (9 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NetRentableAreaLease" xlink:label="txmd_NetRentableAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetRentableAreaLease_lbl" xml:lang="en-US">Net rentable area</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RentedAreaLease" xlink:label="txmd_RentedAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RentedAreaLease_lbl" xml:lang="en-US">Rented area lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="txmd_AdditionalAreaOfLeaseOccupied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_lbl" xml:lang="en-US">Additional area of lease occupied</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_lbl" xml:lang="en-US">Number of options to extend lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xml:lang="en-US">Lease not yet commenced (area)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xml:lang="en-US">Significant supply commitment percentage payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:label="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:to="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_lbl" xml:lang="en-US">Individual employee annual compensation maximum for payroll costs under loan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:label="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:to="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_lbl" xml:lang="en-US">Maximum percentage of forgiven amounts for nonpayroll costs under loan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:to="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_lbl" xml:lang="en-US">Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:to="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_lbl" xml:lang="en-US">Individual employee salary reduction specified percentage for reduction of loan forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyMember_doc" xml:lang="en-US">Information about ImvexxyTm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsMember_doc" xml:lang="en-US">Domestic US Patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsMember_doc" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsBijuvaMember_doc" xml:lang="en-US">Domestic Patents Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsBijuvaMember_doc" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xml:lang="en-US">Domestic Patents NonApproved Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsTopicalCreamMember" xlink:to="txmd_DomesticUSPatentsTopicalCreamMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember_doc" xml:lang="en-US">Domestic US Patents Topical Cream</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentDLimoneneMember" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentDLimoneneMember" xlink:to="txmd_DomesticUtilityPatentDLimoneneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember_doc" xml:lang="en-US">Domestic Utility Patent DLimonene</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentOperaMember_doc" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_doc" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreement1Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoveraMember_doc" xml:lang="en-US">The drug name.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep1Member_doc" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPercent_doc" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep2Member_doc" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep3Member_doc" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="txmd_SubscriptionAgreementKnightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubscriptionAgreementKnightMember_doc" xml:lang="en-US">Subscription Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_doc" xml:lang="en-US">Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="txmd_SalesMilestonePaymentsInTranches" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesMilestonePaymentsInTranches_doc" xml:lang="en-US">Amount of sales milestone payments per licensing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedRebates_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CreditAgreementMember" xlink:label="txmd_CreditAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CreditAgreementMember" xlink:to="txmd_CreditAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CreditAgreementMember_doc" xml:lang="en-US">CreditAgreementMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementMember_doc" xml:lang="en-US">Represents member of financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierTwoConcentrationRiskMember_doc" xml:lang="en-US">Supplier Two Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierThreeConcentrationRiskMember_doc" xml:lang="en-US">Supplier Three Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="txmd_ThreeCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_doc" xml:lang="en-US">Three Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FourCustomersConcentrationRiskMember_doc" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_doc" xml:lang="en-US">Major customers in concentration of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xml:lang="en-US">Custome rConcentration AmerisourceBergen Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xml:lang="en-US">Customer Concentration Cardinal Health Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetRentableAreaLease_doc" xml:lang="en-US">Net rentable area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RentedAreaLease_doc" xml:lang="en-US">Rented area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xml:lang="en-US">Future rented area to be occupied for administrative office space as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsMember_doc" xml:lang="en-US">Warrants Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="txmd_PlanAwardsNumberOfNewShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlanAwardsNumberOfNewShares" xlink:to="txmd_PlanAwardsNumberOfNewShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PlanAwardsNumberOfNewShares_doc" xml:lang="en-US">Number of new shares authorized for stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Plan2019Member_doc" xml:lang="en-US">New 2019 Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesRiskMember" xlink:to="txmd_CustomerConcentrationPIServicesRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember_doc" xml:lang="en-US">PI Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_doc" xml:lang="en-US">Additional rented area occupied under the lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xml:lang="en-US">Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xml:lang="en-US">Underwriter Agrrement GoldmanSachs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="txmd_PeriodExercisableUnderwritersOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PeriodExercisableUnderwritersOption_doc" xml:lang="en-US">The period the option is exercisable per agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xml:lang="en-US">The number of shares available to be purchased per underwriter's option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheAxis_doc" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheOneMember" xlink:label="txmd_TrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheOneMember" xlink:to="txmd_TrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheOneMember_doc" xml:lang="en-US">Tranche of the Credit Facility Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three as defined in financing agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RevenueRequirementToDrawOnTermLoan" xlink:to="txmd_RevenueRequirementToDrawOnTermLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan_doc" xml:lang="en-US">The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiborFloorRate_doc" xml:lang="en-US">Represents libor floor rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FacilityFeePaidPercent_doc" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheTwoThreeMember" xlink:label="txmd_TrancheTwoThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoThreeMember" xlink:to="txmd_TrancheTwoThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoThreeMember_doc" xml:lang="en-US">Tranche Two Three Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentFeePercentage_doc" xml:lang="en-US">The repayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MidCapAgreementMember_doc" xml:lang="en-US">Represents member of Mid Cap agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentUponFDAApproval_doc" xml:lang="en-US">The amount of milestone payments upon FDA approval.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xml:lang="en-US">The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaMember_doc" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheDomain" xlink:label="txmd_DebtTrancheDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheDomain" xlink:to="txmd_DebtTrancheDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheDomain_doc" xml:lang="en-US">DebtTrancheDomain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRights_doc" xml:lang="en-US">The amount of license rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NoncashOperatingLeaseExpense_doc" xml:lang="en-US">Amount of expense related to operating lease costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfInstallmentPayments_doc" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="txmd_NumberOfStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionVitaminsMember_doc" xml:lang="en-US">Information about Prescription Vitamins.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xml:lang="en-US">The cash outlow for payments to acquir intellectual property license.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfVendors" xlink:label="txmd_NumberOfVendors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfVendors_doc" xml:lang="en-US">Number of vendors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="txmd_LicenseAgreementTheramexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementTheramexMember_doc" xml:lang="en-US">License Agreement Theramex</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnualNetSalesMilestone" xlink:label="txmd_AnnualNetSalesMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualNetSalesMilestone_doc" xml:lang="en-US">Annual net sale milestones in the Territory per license agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedIntellectualLicenseFee" xlink:label="txmd_AccruedIntellectualLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedIntellectualLicenseFee" xlink:to="txmd_AccruedIntellectualLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedIntellectualLicenseFee_doc" xml:lang="en-US">Amount of expenses incurred but not yet paid for intellectual license fee, due within one year or the normal operating cycle, if longer.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="txmd_CashUpfrontPaymentReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CashUpfrontPaymentReceived_doc" xml:lang="en-US">The cash inflow from license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeePercentage_doc" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSubsidiaries_doc" xml:lang="en-US">Number of subsidiaries for period reported.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xml:lang="en-US">Underwriting Agreement JP Morgan Chase Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="txmd_ProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromIssuancePublicOffering_doc" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital by public offering.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_OtcProductsMember" xlink:label="txmd_OtcProductsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtcProductsMember" xlink:to="txmd_OtcProductsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OtcProductsMember_doc" xml:lang="en-US">OTC Products</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturing_doc" xml:lang="en-US">Prepaid manufacturing costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders could have acquired the underlying shares with respect to warrants that expired.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsOutstandingVestedAndExercisable" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingVestedAndExercisable" xlink:to="txmd_WarrantsOutstandingVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable_doc" xml:lang="en-US">Weighted-average exercise price, at which warrant holders can acquire shares reserved for issuance, for fully vested and exercisable warrants outstanding.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:to="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xml:lang="en-US">Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerBMember" xlink:label="txmd_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerBMember" xlink:to="txmd_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerBMember_doc" xml:lang="en-US">Customer B</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerCMember" xlink:label="txmd_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerCMember" xlink:to="txmd_CustomerCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerCMember_doc" xml:lang="en-US">Customer C</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerDMember" xlink:label="txmd_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerDMember" xlink:to="txmd_CustomerDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerDMember_doc" xml:lang="en-US">Customer D</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerAMember" xlink:label="txmd_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerAMember" xlink:to="txmd_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerAMember_doc" xml:lang="en-US">Customer A</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="txmd_NumberOfIssuedPatentsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsDomestic" xlink:to="txmd_NumberOfIssuedPatentsDomestic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsDomestic_doc" xml:lang="en-US">Number of issued patents domestic.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="txmd_NumberOfIssuedPatentsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsForeign" xlink:to="txmd_NumberOfIssuedPatentsForeign_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsForeign_doc" xml:lang="en-US">Number of issued patents foreign.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaminsAndImvexxyMember_doc" xml:lang="en-US">Vitamins and IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaAndAnnoveraMember_doc" xml:lang="en-US">BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="txmd_ExpirationPeriod20YearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriod20YearsMember_doc" xml:lang="en-US">Expiration Period 20 Years</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="txmd_ExpirationPeriodIndefiniteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriodIndefiniteMember_doc" xml:lang="en-US">Expiration Period Indefinite</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLossCarryforwardsExpirationYear" xlink:to="txmd_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Expiration year of operating loss carryforward.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NolCarryForwardPeriod" xlink:label="txmd_NolCarryForwardPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NolCarryForwardPeriod" xlink:to="txmd_NolCarryForwardPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NolCarryForwardPeriod_doc" xml:lang="en-US">Expiration period of operating loss carryforward included in operating loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:to="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xml:lang="en-US">Pharmacy Innovations PA - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsCashlessExerciseMember_doc" xml:lang="en-US">Warrants - Cashless Exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xml:lang="en-US">The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CatalentMember" xlink:label="txmd_CatalentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CatalentMember_doc" xml:lang="en-US">Catalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:to="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xml:lang="en-US">The percentage of quarterly royalty payments on net sales which the company is entitled to receive.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:label="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:to="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_doc" xml:lang="en-US">The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock with respect to warrants that were exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AdditionalLeasedSpaceMember" xlink:label="txmd_AdditionalLeasedSpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalLeasedSpaceMember" xlink:to="txmd_AdditionalLeasedSpaceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalLeasedSpaceMember_doc" xml:lang="en-US">Additional Leased Space</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:to="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock_doc" xml:lang="en-US">License Agreement With Population Council</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaycheckProtectionProgramLoanMember" xlink:to="txmd_PaycheckProtectionProgramLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaycheckProtectionProgramLoanMember_doc" xml:lang="en-US">Paycheck Protection Program Loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:to="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_doc" xml:lang="en-US">Individual employee annual compensation maximum for payroll costs under loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:to="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_doc" xml:lang="en-US">Maximum percentage of forgiven amounts for nonpayroll costs under loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:to="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_doc" xml:lang="en-US">Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:to="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_doc" xml:lang="en-US">Individual employee salary reduction specified percentage for reduction of loan forgiveness.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer" xlink:label="txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer" xlink:to="txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumAnnualSpendingAmountPlannedToCutOrDefer_doc" xml:lang="en-US">Minimum annual spending amount planned to cut or defer.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend" xlink:label="txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend" xlink:to="txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PlannedDeferralOfConsumerAndHealthcarePractitionerMarketingSpend_doc" xml:lang="en-US">Planned deferral of consumer and healthcare practitioner marketing spend.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PlannedCutsOfOtherExpenses" xlink:label="txmd_PlannedCutsOfOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlannedCutsOfOtherExpenses" xlink:to="txmd_PlannedCutsOfOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PlannedCutsOfOtherExpenses_doc" xml:lang="en-US">Planned cuts of other expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:to="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTopicalCreamCandidatesMember_doc" xml:lang="en-US">Domestic Utility Patent Topical Cream Candidates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FiveCustomersConcentrationRiskMember" xlink:to="txmd_FiveCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FiveCustomersConcentrationRiskMember_doc" xml:lang="en-US">Five Customers Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrimeRateFloor" xlink:to="txmd_PrimeRateFloor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrimeRateFloor_doc" xml:lang="en-US">Prime rate floor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NewSharesMember" xlink:to="txmd_NewSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NewSharesMember_doc" xml:lang="en-US">New shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>txmd-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20200331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20200331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20200331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20200331.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20200331.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20200331.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20200331.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20200331.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20200331.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20200331.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20200331.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20200331.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20200331.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20200331.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20200331.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20200331.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20200331.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:href="txmd-20200331.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20200331.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:href="txmd-20200331.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20200331.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20200331.xsd#Note7IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20200331.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20200331.xsd#AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20200331.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20200331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:href="txmd-20200331.xsd#Note10NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:href="txmd-20200331.xsd#ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:href="txmd-20200331.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:href="txmd-20200331.xsd#RestrictedStockAndPerformanceStockAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20200331.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20200331.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20200331.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20200331.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20200331.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdLicenseRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLongTermDebtNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; (DEFICIT) EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNet" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:label="loc_txmdLicenseAgreementWithPopulationCouncilPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_txmdLicenseAgreementWithPopulationCouncilPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfSubsidiaries" xlink:label="loc_txmdNumberOfSubsidiaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_txmdNumberOfSubsidiaries" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000036 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdRoyaltyPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTopicalCreamCandidatesMember" xlink:label="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTopicalCreamCandidatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmdPrimeRateFloor" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrimeRateFloor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000047 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative" xlink:title="00000048 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails" xlink:title="00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails" xlink:title="00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails" xlink:title="00000051 - Disclosure - Restricted stock and performance stock awards (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NewSharesMember" xlink:label="loc_txmdNewSharesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNewSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000053 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000054 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierOneConcentrationRiskMember" xlink:label="loc_txmdSupplierOneConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierOneConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SupplierFourConcentrationRiskMember" xlink:label="loc_txmdSupplierFourConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierFourConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_FiveCustomersConcentrationRiskMember" xlink:label="loc_txmdFiveCustomersConcentrationRiskMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFiveCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="loc_txmdCustomerConcentrationPIServicesRiskMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000055 - Disclosure - Supplemental lease information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000057 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdNetRentableAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdRentedAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdLesseeOperatingLeaseExistenceOfOptionToExtendNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_PaycheckProtectionProgramLoanMember" xlink:label="loc_txmdPaycheckProtectionProgramLoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_txmdPaycheckProtectionProgramLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:label="loc_txmdIndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:label="loc_txmdMaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdMaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="loc_txmdIndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20200331.xsd#txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:label="loc_txmdIndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdIndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810329008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">NOTE 13 &#8211; RELATED PARTIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrEhlWxw6pSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
13 &#8211; RELATED PARTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended March 31, 2020 and 2019, we were billed by Catalent approximately
$</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z3oFfM9nGANh" title="Amount billed">1,303,000</span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zpJg8liN9Tx8" title="Amount billed">1,397,000</span><span style="background-color: white">,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of March 31, 2020 and December 31, 2019, there were amounts due to Catalent of approximately $</span><span id="xdx_90C_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zQme2UgDxVZj" title="Amounts due to related party">755,000</span> <span style="background-color: white">and
$</span><span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zE9PfebzlMbc" title="Amounts due to related party">35,000</span><span style="background-color: white">, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806521792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">NOTE 9 &#8211; DEBT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z82LLu6cLDFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
9 &#8211; <span>DEBT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending, Inc.,
as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors, which provides us with a $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zWPkSvsXL9h1" title="Line of Credit Facility, Maximum Borrowing Capacity">300,000,000</span> first lien secured term loan credit facility,
or the Facility. The Facility provides for availability to us in three tranches: (i) $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3Ll7wDx1wG4" title="Line of Credit Facility, Maximum Borrowing Capacity">200,000,000</span> was drawn upon entering into
the Financing Agreement; (ii) $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zYsC9VY9MIPl" title="Line of Credit Facility, Maximum Borrowing Capacity">50,000,000</span> will be available to us in the Administrative Agent&#8217;s sole and absolute discretion
either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such
earlier date as the Administrative Agent shall have consented to; and (iii) $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pp0p0_uUSD_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zoLD73qIGCig" title="Proceeds from Financing Agreement">50,000,000</span> was drawn on February 18, 2020 following
our achievement of more than $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zGtCJgVwZ2W3" title="Total revenue, net">11,000,000</span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings
under the Facility accrue interest at either (i) <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zN0gfsr3sTQj" title="Debt Instrument, Description of Variable Rate Basis">3-month LIBOR</span> plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKMLQ3reYHj" title="Debt Instrument, Basis Spread on Variable Rate">7.75</span>%, subject to a LIBOR floor of <span id="xdx_90D_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zzvzcptvKy61" title="LIBOR floor rate">2.70</span>% or (ii) the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zDSXBczIiu9c" title="Debt Instrument, Description of Variable Rate Basis">prime
rate</span> plus<span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVaCXkW2EqNg" title="Debt Instrument, Basis Spread on Variable Rate"> 6.75</span>%, subject to a prime rate floor of <span id="xdx_909_ecustom--PrimeRateFloor_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zFKwSneXwckf" title="Prime rate floor">5.2</span>% as selected by us. Interest on amounts borrowed under the Facility is payable
quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_pp0p0_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zrSUU2CqKBI8" title="Number of quarterly principal installment payments">four</span> equal quarterly installments beginning on June
30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or
in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) <span id="xdx_904_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKBjGlANUAa" title="Prepayment fee for first two years funding (percent)">30.0</span>% for the first two years following
the initial funding date of the applicable borrowing, (ii) <span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zL5GMcTY54E8" title="Prepayment fee third year funding (percent)">5.0</span>% for the third year following the initial funding date of the applicable
borrowing, (iii) <span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zpxVfOTjgUh7" title="Prepayment fee fourth year funding (percent)">3.0</span>% for the fourth year following the initial funding date of the applicable borrowing and (iv) <span id="xdx_900_ecustom--PrepaymentFeeFifthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zD71f1AmJPW2" title="Prepayment fee fifth year funding (percent)">1.0</span>% for the
fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the
initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to <span id="xdx_909_ecustom--FacilityFeePaidPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJW687VTUUul" title="Facility fee paid (percent)">2.5</span>% of the initial amount
borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are
also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses.
The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary
for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of
$<span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo4Eg4yeOU1f" title="Minimum cash balance requirement under credit agreement">60,000,000</span>, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY,
BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes
other representations, warranties, indemnities and events of default that are customary for financings of this type, including
an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable
and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries
under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority
perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under
the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zDTdjYS5Aboj" title="Line of Credit Facility, Maximum Borrowing Capacity">200,000,000</span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_907_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pp0p0_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3NpDGkghri8" title="Number of tranches under term loan facility">three</span> separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i) <span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zADPCpIJOxxl" title="Debt Instrument, Description of Variable Rate Basis">one-month LIBOR</span> (subject to a LIBOR floor of <span id="xdx_90B_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zAGkdJaSJU29" title="LIBOR floor rate">1.50</span>%) plus (ii)
<span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZ5k1Fi7hZSl" title="Debt Instrument, Basis Spread on Variable Rate">7.75</span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $<span id="xdx_90F_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0p0_uUSD_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zAoKWmSzHmFf" title="Repayment of debt with new credit facility">81,661,000</span> was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of <span id="xdx_90B_ecustom--PrepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zvRGWtRwnkAk" title="Prepayment fee percentage">4</span>%, a repayment fee of <span id="xdx_909_ecustom--RepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zi6WrZzuK6E1" title="Repayment fee percentage">4</span>% and other fees and expenses payable to the lenders under the Credit Agreement. As
a result of the termination of the Credit Agreement, we recorded $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_uUSD_c20190101__20190331_zNzeyMeQDmKg" title="Loss on extinguishment of debt::XDX::-10057632"><span style="-sec-ix-hidden: xdx2ixbrl0891">10,057,632</span></span> in loss on extinguishment of debt in the second quarter
of 2019. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the three
months ended March 31, 2019 related to the Credit Agreement was $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zlpbCVvShyTg" title="Interest Expense, Debt">1,969,872</span>. During the three months ended March 31, 2019, we amortized
$<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zNXj11pAtXag" title="Amortization of deferred financing costs">120,146</span> of debt issuance costs as interest expense in the accompanying unaudited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">As
of March 31, 2020, we had $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z66dY4kGWlYg" title="Long-term Debt, Gross">250,000,000</span>
in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
consolidated financial statements. We incurred $<span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zpSNKaTaHGF1" title="Deferred financing fees">7,902,270</span>
in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing
Agreement have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to
the two tranches of borrowings that we received of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_uUSD_c20200331_zicw1GXgnUYf" title="Debt Instrument, Unamortized Discount">7,626,891</span>
have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with an unfunded tranche are deferred as assets until such tranche has been drawn. As of March 31,
2020, deferred financing fees related to the unfunded tranche of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20200331__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zI6pEfqmQys1">50,000,000</span>
were included in other current assets in the accompanying consolidated financial statements. During the three months ended
March 31, 2020, we amortized $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20200101__20200331__custom--DebtTrancheAxis__custom--TrancheTwoMember_zc8F2LSPivWk" title="Amortization of deferred financing costs">319,408</span> <span style="background-color: white">of
deferred financing fees related to the two tranches that have been received as interest expense in the accompanying
consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in
arrears. Interest expense for the three months ended March 31, 2020 was $<span id="xdx_90D_eus-gaap--InterestExpenseBorrowings_pp0p0_uUSD_c20200101__20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zdWYXM1Y1Ql6" title="Interest Expense, Borrowings">5,942,639</span>.
The overall effective interest rate under the Financing Agreement was approximately </span><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20200331_zZxV3QA7ITL6" title="Debt Instrument, Interest Rate, Effective Percentage">11</span><span style="background-color: white">%
as of March 31, 2020</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zuYWva5GXJfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020 and December 31, 2019, <span>the carrying value of our debt consisted</span> of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zdBxYTuLbYf1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49C_20191231_zpRZ2jcdfYq8" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zapwzyTEff58" style="width: 12%; text-align: right" title="Long-term Debt, Gross">250,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zYDRx6oDWyG3" style="width: 12%; text-align: right" title="Long-term Debt, Gross">200,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_uUSD_zA0yZPzpbaal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,571,329</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,365,357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_uUSD_zFY2FfjOmEPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">243,428,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">194,634,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zIY9DzQZVFSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810329008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">NOTE 5 &#8211; OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zDZvXy7VLrS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
5 &#8211; <span>OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zdpQqp1SYAR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_z315oeVj3xmd" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_494_20191231_zvT6CFgvEhGl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_404_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_uUSD_maPEAOAzkyn_zs1RarO2Qbud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">553,789</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFinanceCostsCurrentNet_iI_uUSD_maPEAOAzkyn_z0bbbNByTM9i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_uUSD_maPEAOAzkyn_zSzus1ZnjEr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,064,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--PrepaidManufacturing_iI_uUSD_maPEAOAzkyn_zxx7GgLpXD74" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">955,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_uUSD_maPEAOAzkyn_z7QgK5iLgiA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,769,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_uUSD_mtPEAOAzkyn_zn3jtKbW7UZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,618,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A5_zyRjQ5Y3nUai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806432192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and 2019 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmiZZrXoInTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and
2019 are set forth in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKT3HpcC3Ctk" style="width: 12%; text-align: right" title="Weighted average grant date fair value">0.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKCm4GBhbZ64" style="width: 12%; text-align: right" title="Weighted average grant date fair value">3.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAoURtu9Slh2" style="font: 10pt Times New Roman, Times, Serif">1.32</span><span style="font: 10pt Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrhE696UcnGe">1.68</span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zclHBCYrH4Y8" style="text-align: right" title="Risk-free interest rate">2.54</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKbbd5VICeke" title="Volatility - minimum">63.53</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyNJb5gWKHf9" title="Volatility - maximum">65.72</span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zp37dwdC0gd" style="text-align: right" title="Volatility">61.85</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zBqThQyn9EH2" title="Term">6</span>-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zI3qCxPIUrU9" title="Term">6.7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm4RzCP1iPK" style="text-align: right" title="Term">6.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRCbPvXZsR1g" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z97xFrXVFlxg" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCouQC6ZD5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual <br/>Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF74Vd7stZY6" style="width: 11%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg5erwQ0O0H1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlNh1WMeN8Tk" style="width: 11%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nHUxpATmu4" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIrW2Q4UU0yl" style="text-align: right" title="Number of shares under options, granted">636,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKkPU4yQi8b" style="text-align: right" title="Weighted average exercise price, granted">1.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPDM0gLWg4I4" style="text-align: right" title="Number of shares under options, exercised">(350,666</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEkpJ98J88v9" style="text-align: right" title="Weighted average exercise price, exercised">0.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKMQTcpYeBii" style="text-align: right" title="Aggregate intrinsic value, exercised">725,199</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9eD9aqL6MO8" style="text-align: right" title="Number of shares under options, expired">(50,472</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gOKEtgi3Al" style="text-align: right" title="Weighted average exercise price, expired">0.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyA0VXRGp0Xc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(110,375</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HEMrytqGP7" style="text-align: right" title="Weighted average exercise price, cancelled forfeited">4.48</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR85TrJIPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">25,155,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35NKobVHVH5" style="text-align: right" title="Weighted average exercise price, ending">4.65</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvu9zkcQx5pg" style="text-align: right" title="Weighted average remaining contractual life">5.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjmPJFz78dti" style="text-align: right" title="Aggregate intrinsic value, ending">787,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTP5Y15iGVAc" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,258,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7MNd8qOHPMd" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ye87I9gl87" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_uUSD_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zucj29CP0SH6" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">787,178</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHbMwgnL9hrg" style="text-align: right" title="Number of shares under options, unvested ending">5,896,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKAsY49mCuXg" style="text-align: right" title="Weighted average exercise price, unvested ending">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3rZDaT0F483" style="text-align: right" title="Weighted average remaining contractual life, unvested">9.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Restricted stock and performance stock awards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8Mso4923Ztl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock and performance stock awards (Details)">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Restricted
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Performance
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfs80wXB0Y6" style="width: 12%; text-align: right" title="Number of shares, beginning">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1gikQdahEX7" style="text-align: right" title="Weighted average grant date fair value, beginning">3.56</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right" title="Number of shares, beginning">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average grant date fair value, beginning">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDPV5o0aOG94" style="text-align: right" title="Number of shares, granted">3,384,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgCPBNvZ4a9i" style="text-align: right" title="Weighted average grant date fair value, granted">1.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8L3oT6dXQG6" style="text-align: right" title="Number of shares, granted">2,384,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhdvXun1r73j" style="text-align: right" title="Weighted average grant date fair value, granted">1.07</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Vested/Released</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsSLdiyKRYI7" style="text-align: right" title="Number of shares, vested/released">(150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znw5y3XsKQba" style="text-align: right" title="Weighted average grant date fair value, vested/released">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1kzQucs7e08" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">4,474,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKxgxHQZES9d" style="text-align: right" title="Weighted average grant date fair value, ending">2.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zCUDguZmo065" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">2,384,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5SxZglFc9d2" style="text-align: right" title="Weighted average grant date fair value, ending">1.07</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821571472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 745,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid', window );">Maximum costs and expenses for post approval</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember', window );">Vitamins and IMVEXXY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member] | Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentUponFDAApproval', window );">Milestone payment upon FDA Approval</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">License rights acquired</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809610384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2013</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetRentableAreaLease', window );">Net rentable area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RentedAreaLease', window );">Rented area lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalAreaOfLeaseOccupied', window );">Additional area of lease occupied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber', window );">Number of options to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea', window );">Lease not yet commenced (area)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,764<span></span>
</td>
<td class="nump">$ 295,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SignificantSupplyCommitmentPercentagePayable', window );">Significant supply commitment percentage payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalAreaOfLeaseOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional rented area occupied under the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalAreaOfLeaseOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rented area to be occupied for administrative office space as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetRentableAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetRentableAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RentedAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RentedAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SignificantSupplyCommitmentPercentagePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SignificantSupplyCommitmentPercentagePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808082160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES (Details Narrative) - Affiliated Entity [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 1,303,000<span></span>
</td>
<td class="nump">$ 1,397,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800180800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqs0mBmK3lt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
2 &#8211; <span>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Interim
Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Risks
and Uncertainties</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to risks and uncertainties as a result of the&#160;COVID-19 pandemic. The extent of the impact of the&#160;COVID-19
pandemic on our business is highly uncertain and difficult to predict, as the response to the pandemic is in its incipient stages
and information is rapidly evolving. At this time,&#160;we continue to provide an uninterrupted supply of our portfolio of products
for patients. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
have activated virtual options to ensure business continuity. Our VitaCare Prescription Services patient model assists patients
in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice, including via
home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple third-party online
pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time access to both
diagnosis and treatment. We continue to support prescribers&#8217; needs with samples and product materials through our sales
force. If access is restricted, we currently have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for virtual detailing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
have also implemented measures to cut planned marketing expenses for 2020. However, we have the ability to re-accelerate our
planned marketing spend for ANNOVERA and IMVEXXY should market conditions improve, or to extend or expand the cost cuts
throughout 2020. We have also implemented cost savings which include negotiating lower fees or suspending services from third
party vendors; implementing a company-wide hiring freeze; delaying or cancelling non-critical IT projects; and eliminating
travel, entertainment, meeting, and event expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
savings can be extended further throughout 2020 or expanded depending on the impact of the COVID-19 pandemic. We already have
sufficient inventory of finished product in our warehouses to meet anticipated demand through at least early third quarter of
2020. However, capital markets and economies worldwide have also been negatively impacted by the&#160;COVID-19 pandemic, and it
is possible that it could cause a local and/or global economic recession. Such economic disruption could have a material adverse
effect on our business. Policymakers globally have responded with fiscal policy actions to support the healthcare industry and
economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
severity of the impact of the&#160;COVID-19 pandemic on our business will depend on a number of factors, including, but not limited
to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, all of which are uncertain
and cannot be predicted. Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding
receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives
or programs that we may undertake to address financial and operations challenges that we may face. As of the date of issuance
of these condensed consolidated financial statements, the extent to which the&#160;COVID-19 pandemic may materially impact our
financial condition, liquidity, or results of operations is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Recently
Issued Accounting Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020 and the adoption did not have a material effect
on our disclosures for the three months ended March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#8217;s expected credit losses. Effective January
1, 2020, we&#160;adopted&#160;ASU&#160;2016-13&#160;under a modified retrospective approach for all financial assets measured
at amortized cost. There was no adjustment recorded for the cumulative effect of adopting&#160;ASU 2016-13. The adoption expanded
disclosures about our credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799885520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020 (9 months)</a></td>
<td class="nump">$ 189,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">252,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">252,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">252,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">$ 252,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812248624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 12,250,657<span></span>
</td>
<td class="nump">$ 3,946,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">2,715,051<span></span>
</td>
<td class="nump">762,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,535,606<span></span>
</td>
<td class="nump">3,183,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">56,927,021<span></span>
</td>
<td class="nump">34,864,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,268,829<span></span>
</td>
<td class="nump">6,317,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">261,994<span></span>
</td>
<td class="nump">106,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">60,457,844<span></span>
</td>
<td class="nump">41,288,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(50,922,238)<span></span>
</td>
<td class="num">(38,105,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">335,482<span></span>
</td>
<td class="nump">688,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,262,046)<span></span>
</td>
<td class="num">(2,090,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(5,926,564)<span></span>
</td>
<td class="num">(1,401,297)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(56,848,802)<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,848,802)<span></span>
</td>
<td class="num">$ (39,506,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">271,459,522<span></span>
</td>
<td class="nump">241,006,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6824140992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,250,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,946,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,626,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,902,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,942,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember', window );">Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfInstallmentPayments', window );">Number of quarterly principal installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent', window );">Prepayment fee for first two years funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeThirdYearFundingPercent', window );">Prepayment fee third year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFourthYearFundingPercent', window );">Prepayment fee fourth year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFifthYearFundingPercent', window );">Prepayment fee fifth year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime
rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrimeRateFloor', window );">Prime rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentOfDebtWithNewCreditFacility', window );">Repayment of debt with new credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercentage', window );">Repayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,969,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">Number of tranches under term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of principal installment payments under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFifthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFifthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeForFirstTwoYearsFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFourthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFourthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeThirdYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeThirdYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrimeRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prime rate floor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrimeRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The repayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentOfDebtWithNewCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentOfDebtWithNewCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810368464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets, net consist of the following:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeaPRBKHtSa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zg2PJZsXwO0l" style="width: 12%; text-align: right" title="TOTAL FIXED ASSETS">301,096</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlKfWaau3kT" style="width: 12%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4Z0zOt08qw8" style="text-align: right" title="TOTAL FIXED ASSETS">1,640,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlZcRsPr7uN2" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFKrqFQ0kLal" style="text-align: right" title="TOTAL FIXED ASSETS">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlKp2iyTusak" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpvF7xSYPh7h" style="text-align: right" title="TOTAL FIXED ASSETS">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQsgGEW8GUb1" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zy5WtSAUOjmk" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmAhWN0pXa3h" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331_zVrOjJE771k2" style="text-align: right">3,497,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231_zpYZ6SytS7i4" style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20200331_zChgcuFWqYH" style="border-bottom: Black 1pt solid; text-align: right">(1,167,663</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_znrt2W1QZK68" style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20200331_zjtw6zANLYSf" style="border-bottom: Black 2.5pt double; text-align: right">2,330,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20191231_zFWC915SmO9i" style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812244592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcDsiscBqahk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86D_zVfQLBPHJG05">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency.
We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results
of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement,
economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current&#160;COVID-19
pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible
that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z11CO1OFronh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_zb5WXYUcbjo3">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of March 31, 2020 (as disclosed in Note 9), approximates fair value based on market activity for other debt
instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority
to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level
3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs,
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/>unobservable inputs for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020 and 2019, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the three months ended March
31, 2020 and 2019.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrmNc7Fxmvkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_z2ve2i6okDGd">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share
appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective
service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable
model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the
input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the
risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed
interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term
of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer
entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices </span>over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our
stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January
1, 2020, the average expected life of options was based on the contractual terms of the stock option using the simplified
method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of share-based awards represent our best
estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the
future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value
estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the
employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January
1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with
the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718
to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an
entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued
to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock awards and restricted stock awards for shares of common stock to employees. We value our restricted
stock awards and our performance-based stock awards by reference to our stock price on the date of grant. We have elected to recognize
compensation expense on a straight-line basis over the requisite service period of the entire award. The number of target shares
that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the
awards, restricted stock is issued based on the level of attainment. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at the grant date and through the date the restricted stock vests.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1NAqlekhAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zSAXok5ZTlTc">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains
control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled
to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine
revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect
to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract
with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance
obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we
began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started
selling ANNOVERA in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the
commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent
quarters. We sell our name brand and generic prescription products primarily through wholesale distributors and retail
pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is
to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies,
which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a
fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance
obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when
the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the
use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers
once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from
contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is
typically due between 30 and 60 days after an invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC,
determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated
product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts
earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is
payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to
determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either
utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract
or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to
the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence
that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the
magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may
differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates,
which would affect net product revenue and earnings in the period such changes in estimates become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_900_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200331__srt--RangeAxis__srt--MinimumMember_znIeOi1oJiaj" title="Return period of unsalable prescription products">six months</span> prior
to and up to <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200331__srt--RangeAxis__srt--MaximumMember_zo4Ui1stUbal" title="Return period of unsalable prescription products">12</span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_90B_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zAfK3GGRO4B1" title="Shelf life of prescription products following product expiration">24</span> months from the
date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zoUI68K6dNE7" title="Shelf life of prescription products following product expiration">18</span> months from the date of manufacture. We do not allow
product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that
may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue
is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped
to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history
of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the
inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product
returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in other current liabilities on the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based
on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current
liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking
into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons
and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice
discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained
by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions
paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance
based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple
performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require
continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zYG13U0vCP7c">The
following table provides information about disaggregated revenue by product mix</span> for the three months ended March 31, 2020 and
2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br/>March 31,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue">2,473,691</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue">1,935,971</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue">6,392,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue">2,010,680</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue">1,111,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">ANNOVERA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,272,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">12,250,657</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">3,946,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8AB_zui8XJd4ZQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock', window );">License Agreement with the Population Council</a></td>
<td class="text"><p id="xdx_845_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zf7maL1AmvPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_zp0XoJVfiNs">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span><span id="xdx_904_ecustom--MilestonePaymentUponFDAApproval_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzdSrj6ijlBd" title="Milestone payment upon FDA Approval">20,000,000</span></span>
within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_90E_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_pp0p0_uUSD_c20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzlQOnkG2JM8" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span>
within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_907_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zLVhFWipFgBk" title="License rights acquired">20,000,000</span> were recorded
as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once
ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license
rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the
product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic
benefit cannot be reliably determined. During the three months ended March 31, 2020, we recorded $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_uUSD_c20200101__20200331_zTaBPhlRojyd" title="Amortization of Intangible Assets">745,511</span>
in amortization expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zI4rHPgDmvrf" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of <span id="xdx_90A_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zvRXnSrtFUQk" title="Royalty (percent)">5</span>% of net sales;
(ii) for annual net sales greater than $<span id="xdx_909_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zEGIcUn3ZIz8" title="Net sales amount per step-based royalty">50,000,000</span> and less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zj2zgaONK7Qk" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of <span id="xdx_90E_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_z0pqRGQuYJYb" title="Royalty (percent)">10</span>% of such net sales;
and (iii) for net sales greater than $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z5vITeRv7bT8" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of <span id="xdx_906_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zzYyhvS5I8og" title="Royalty (percent)">15</span>% of such net sales. The annual royalty rate will be reduced
to <span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPejB3k4KuBi" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <span title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent">20</span>% of the initial rate. We are required to pay the Population Council milestone payments of $<span title="Required milestone payments upon cumulative net sales of specified levels">40 million</span> upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span title="Specified level one of cumulative net sales for required milestone payments">200 million</span>, $<span title="Specified level two of cumulative net sales for required milestone payments">400 million</span> and
$<span title="Specified level three of cumulative net sales for required milestone payments">1 billion</span>. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies
required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with
such post-approval study exceed $<span id="xdx_909_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zULvFtjWtpu7" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will be offset against royalties or other payments owed by us
to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible
for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional
desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CostOfSalesPolicyTextBlock_zQMqlFiuunV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_866_zi5XzR9WB6vk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zrGO2CXOx7me" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zhWkW75RPQ0g">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTRKuo0UCEoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement With Population Council</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821145328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 63,155<span></span>
</td>
<td class="nump">$ 40,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember', window );">Domestic US Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember', window );">Foreign Patents Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember', window );">Domestic Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember', window );">Foreign Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember', window );">Domestic Patents NonApproved BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember', window );">Domestic US Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember', window );">Domestic US Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember', window );">Domestic US Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember', window );">Foreign Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember', window );">Foreign Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember', window );">Foreign Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember', window );">Domestic Utility Patent Topical Cream Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember', window );">Domestic Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember', window );">Foreign Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember', window );">Domestic Utility Patent TX009HR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember', window );">Domestic Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember', window );">Foreign Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember', window );">Domestic Utility Patent Opera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTopicalCreamCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6820494960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951
Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,683,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821070512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">$ 616,559,938<span></span>
</td>
<td class="num">$ (519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">99,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">759,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 271,177<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
<td class="nump">$ 9,201,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,366,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,366,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(56,848,802)<span></span>
</td>
<td class="num">(56,848,802)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 271,678<span></span>
</td>
<td class="nump">706,789,283<span></span>
</td>
<td class="num">(752,270,081)<span></span>
</td>
<td class="num">$ (45,209,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,677,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">71,758<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 72,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">350,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of shares from release of restricted stock (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821433312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">33,846,282<span></span>
</td>
<td class="nump">24,320,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">25,155,221<span></span>
</td>
<td class="nump">21,447,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,858,490<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810313168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zbseyW5Kul43" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
3 &#8211; <span>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcDsiscBqahk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86D_zVfQLBPHJG05">Trade
Accounts Receivable and Allowance for Doubtful Accounts</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency.
We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results
of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement,
economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current&#160;COVID-19
pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible
that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.</span></p>

<p id="xdx_852_z0YGBG7DUQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z11CO1OFronh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_zb5WXYUcbjo3">Fair
Value of Financial Instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of March 31, 2020 (as disclosed in Note 9), approximates fair value based on market activity for other debt
instruments with similar characteristics and comparable risk (Level 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, <i>Fair Value Measurements, </i>or ASC 820<i>. </i>The fair value hierarchy gives the highest priority
to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level
3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs,
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
1</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
2</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Level
3</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b/>unobservable inputs for the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020 and 2019, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the three months ended March
31, 2020 and 2019.</span></p>

<p id="xdx_856_zv4cHFKehwo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrmNc7Fxmvkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_869_z2ve2i6okDGd">Share-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share
appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective
service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable
model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the
input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the
risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed
interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term
of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer
entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices </span>over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our
stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January
1, 2020, the average expected life of options was based on the contractual terms of the stock option using the simplified
method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of share-based awards represent our best
estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the
future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value
estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the
employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January
1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with
the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718
to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an
entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued
to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
grant performance-based stock awards and restricted stock awards for shares of common stock to employees. We value our restricted
stock awards and our performance-based stock awards by reference to our stock price on the date of grant. We have elected to recognize
compensation expense on a straight-line basis over the requisite service period of the entire award. The number of target shares
that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the
awards, restricted stock is issued based on the level of attainment. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at the grant date and through the date the restricted stock vests.</span></p>

<p id="xdx_858_zjel9ti0dSVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1NAqlekhAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zSAXok5ZTlTc">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
accordance with ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, revenue is recognized when a customer obtains
control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled
to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine
revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect
to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract
with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance
obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Prescription
Products</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we
began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started
selling ANNOVERA in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the
commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent
quarters. We sell our name brand and generic prescription products primarily through wholesale distributors and retail
pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is
to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies,
which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a
fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance
obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when
the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the
use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers
once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from
contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is
typically due between 30 and 60 days after an invoice is sent to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC,
determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated
product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts
earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is
payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to
determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either
utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract
or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to
the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence
that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the
magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may
differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates,
which would affect net product revenue and earnings in the period such changes in estimates become known.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_900_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200331__srt--RangeAxis__srt--MinimumMember_znIeOi1oJiaj" title="Return period of unsalable prescription products">six months</span> prior
to and up to <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200331__srt--RangeAxis__srt--MaximumMember_zo4Ui1stUbal" title="Return period of unsalable prescription products">12</span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_90B_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zAfK3GGRO4B1" title="Shelf life of prescription products following product expiration">24</span> months from the
date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zoUI68K6dNE7" title="Shelf life of prescription products following product expiration">18</span> months from the date of manufacture. We do not allow
product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that
may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue
is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped
to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history
of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the
inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product
returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in other current liabilities on the consolidated
balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based
on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current
liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking
into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons
and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice
discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained
by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions
paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance
based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">License
Revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple
performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require
continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Disaggregation
of revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zYG13U0vCP7c">The
following table provides information about disaggregated revenue by product mix</span> for the three months ended March 31, 2020 and
2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br/>March 31,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue">2,473,691</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue">1,935,971</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue">6,392,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue">2,010,680</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue">1,111,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">ANNOVERA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,272,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">12,250,657</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">3,946,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8AB_zui8XJd4ZQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_857_z6Hm98q6Y7Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_845_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zf7maL1AmvPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_zp0XoJVfiNs">License
Agreement with the Population Council</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#8220;test and learn&#8221; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span><span id="xdx_904_ecustom--MilestonePaymentUponFDAApproval_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzdSrj6ijlBd" title="Milestone payment upon FDA Approval">20,000,000</span></span>
within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_90E_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_pp0p0_uUSD_c20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzlQOnkG2JM8" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span>
within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_907_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zLVhFWipFgBk" title="License rights acquired">20,000,000</span> were recorded
as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once
ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license
rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the
product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic
benefit cannot be reliably determined. During the three months ended March 31, 2020, we recorded $<span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_uUSD_c20200101__20200331_zTaBPhlRojyd" title="Amortization of Intangible Assets">745,511</span>
in amortization expense related to the license fee which was recorded as a component of cost of sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zI4rHPgDmvrf" title="Net sales amount per step-based royalty">50,000,000</span>, a royalty of <span id="xdx_90A_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zvRXnSrtFUQk" title="Royalty (percent)">5</span>% of net sales;
(ii) for annual net sales greater than $<span id="xdx_909_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zEGIcUn3ZIz8" title="Net sales amount per step-based royalty">50,000,000</span> and less than or equal to $<span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zj2zgaONK7Qk" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of <span id="xdx_90E_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_z0pqRGQuYJYb" title="Royalty (percent)">10</span>% of such net sales;
and (iii) for net sales greater than $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z5vITeRv7bT8" title="Net sales amount per step-based royalty">150,000,000</span>, a royalty of <span id="xdx_906_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zzYyhvS5I8og" title="Royalty (percent)">15</span>% of such net sales. The annual royalty rate will be reduced
to <span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPejB3k4KuBi" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <span title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent">20</span>% of the initial rate. We are required to pay the Population Council milestone payments of $<span title="Required milestone payments upon cumulative net sales of specified levels">40 million</span> upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $<span title="Specified level one of cumulative net sales for required milestone payments">200 million</span>, $<span title="Specified level two of cumulative net sales for required milestone payments">400 million</span> and
$<span title="Specified level three of cumulative net sales for required milestone payments">1 billion</span>. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies
required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with
such post-approval study exceed $<span id="xdx_909_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zULvFtjWtpu7" title="Maximum costs and expenses for post approval">20,000,000</span>, half of such excess will be offset against royalties or other payments owed by us
to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible
for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional
desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council.</span></p>

<p id="xdx_852_zpryRNURyH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--CostOfSalesPolicyTextBlock_zQMqlFiuunV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_866_zi5XzR9WB6vk">Cost
of Sales</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.</span></p>

<p id="xdx_853_zu4iP95ikIj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zrGO2CXOx7me" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_867_zhWkW75RPQ0g">Segment
Reporting</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTRKuo0UCEoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806522800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other current assets consist of the following:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zdpQqp1SYAR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_z315oeVj3xmd" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_494_20191231_zvT6CFgvEhGl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_404_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_uUSD_maPEAOAzkyn_zs1RarO2Qbud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Prepaid sales and marketing costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">553,789</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,583,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DeferredFinanceCostsCurrentNet_iI_uUSD_maPEAOAzkyn_z0bbbNByTM9i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt financing fees on undrawn tranches (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,378</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">550,757</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_uUSD_maPEAOAzkyn_zSzus1ZnjEr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,064,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812,135</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--PrepaidManufacturing_iI_uUSD_maPEAOAzkyn_zxx7GgLpXD74" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">955,659</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,595,721</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_uUSD_maPEAOAzkyn_z7QgK5iLgiA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,769,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,787,482</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_uUSD_mtPEAOAzkyn_zn3jtKbW7UZj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,618,367</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,329,793</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806205616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">NOTE 16 &#8211; SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zR17Y1wtVQ08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Paycheck
Protection Program Loan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act, or the CARES Act, as administered by the U.S. Small Business Administration, or the SBA. The loan in the principal
amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_uUSD_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zR5vIxPGLC1j" title="Principal amount">6,477,094</span>, or the PPP Loan, was disbursed by Bank of America, NA, a national banking association, or BofA, pursuant
to a promissory note issued by the Company, or the Promissory Note.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The PPP
Loan matures on the two-year anniversary of the funding date and bears interest at a fixed rate of<span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zE0HdnO9pnyj" title="Interest rate"> 1.00</span>%
per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (discussed below), will
commence after the six-month anniversary of the funding date. We did not provide any collateral or guarantees for the PPP Loan,
nor did we pay any facility charge to obtain the PPP Loan. The Promissory Note provides for customary events of default,
including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material
adverse effects. We may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">All
or a portion of <span title="Description of PPP loan forgiven">the PPP Loan may be forgiven by the SBA and BofA upon application by us beginning 60 days but not later than 90
days after the funding date of the PPP Loan. Under the CARES Act, loan forgiveness is available for the sum of documented payroll
costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan.
For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $<span id="xdx_900_ecustom--IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zXo2YmzCzxuh" title="Individual employee annual compensation maximum for payroll costs under loan">100,000</span>, prorated annually.
Not more than <span id="xdx_90D_ecustom--MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zKijJPzNxrDd" title="Maximum percentage of forgiven amounts for nonpayroll costs under loan">25</span>% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines,
or if salaries and wages for employees with salaries of $<span id="xdx_907_ecustom--IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zCVCWquAIq24" title="Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness">100,000</span> or less annually are reduced by more than <span id="xdx_900_ecustom--IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zyBYuvBoUsLj" title="Individual employee salary reduction specified percentage for reduction of loan forgiveness">25</span>%.</span> Although we currently
believe that our use of the PPP Loan will meet the conditions for forgiveness of the loan, we cannot assure that the PPP Loan
will be forgiven, in whole or in part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Amendment
No. 2 to Financing Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with incurring the PPP Loan, we, together with our subsidiaries, amended the Financing Agreement to, among other things,
permit us to incur the PPP Loan and add certain affirmative covenants relating thereto.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810463952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8 &#8211; OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zYJU0DTf51nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
8 &#8211; OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zARa1nt0YMu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_zXU6bS3Y7usf" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_491_20191231_zUXEzD95cGAb" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_407_eus-gaap--AccruedSalariesCurrent_iI_maOLCzu3r_zu7w3AR93IA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,087,359</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_pp0p0_maOLCzu3r_zYayDvE07DA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,712,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0p0_maOLCzu3r_z5SyHQzqD0Xh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maOLCzu3r_zDCcuIpSRXeb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,874,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_pp0p0_maOLCzu3r_zBtGcJ050cz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,897,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzu3r_zby3Z8amvHs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">909,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maOLCzu3r_zSmzDQRsKmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,179,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLCzu3r_zteRE5GZDNH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,753,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedRebates_iI_pp0p0_maOLCzu3r_zEqtw8txrvNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,794,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maOLCzu3r_zGmyUO6kHg4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">823,694</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_mtOLCzu3r_zB9nSjMyVn86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,924,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zP6GSYBCgXwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806393008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">NOTE 4 &#8211; INVENTORY</a></td>
<td class="text"><p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zx9x6ABSzgO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
4 &#8211; INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z9HcyPKJavwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49E_20200331_zJ6OnGfW0RJ1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20191231_zy54QoRqwAMl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_z1MWAvfmBMF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,956,900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_zHqBoUQfxH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,554,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryRawMaterialsAndSupplies_iI_zeAitBvwQ9qa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,095,662</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iI_zJDL3HUjRQP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,607,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zROhD73x8m21" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806170320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 12 &#8211; INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">NOTE 12 &#8211; INCOME TAXES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zOK9h2MmOi8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
12 &#8211; INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the three months ended March 31, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#8220;more likely than not&#8221; that some component or all of the benefits of deferred tax assets will not
be realized. As of March 31, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810431056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_pp0p0_zNY6Q43yVFNk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information at:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zxV04oRYF49a" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20191231_zmdyR94QUFKl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXsktDN2sUf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Right-of-use asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,757,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zMvBIFJAm8nk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,753,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zgc1gXR5vOgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,782,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20200331_zgpKv29c3Da5" style="text-align: right">9
years</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zkV39ZTLEp8j" style="text-align: right">9
years</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_zUc06LuSM8O2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>Supplemental cash flow information <br/>
for the three
    months ended:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"/><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March 31,&#160;2020</b></span></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"/><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March
                                         31, 2019</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200331_zuL23QaCMZd5" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease">327,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeasePayments_pp0p0_c20190101__20190331_zuzqDRbG7V09" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease">279,742</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20200331_zThhmozWlRkf" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20190101__20190331_zLBPQS6oYC3c" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation">3,760,171</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet:</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMfhD1if9rfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>Year Ended December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20200331_zhIW313Tinf5"><b>&#160;</b></td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz43w_zCAZN4lRQIi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 44%">2020 (9 months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,239,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz43w_zpNF4VUEvJbk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,198,541</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz43w_zbebADZ5EjO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,262,302</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz43w_zsChrp9u3jZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,293,859</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz43w_z5JX4iD4rHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,326,206</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz43w_zEuArkid0XZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,036,931</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPz43w_z3WEFqQI4RUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,357,069</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zW2oDb4PO6sd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,821,296</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zidasaTE7p9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,535,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6917112944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 6,956,900<span></span>
</td>
<td class="nump">$ 4,976,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,554,891<span></span>
</td>
<td class="nump">1,182,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">5,095,662<span></span>
</td>
<td class="nump">5,701,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 14,607,453<span></span>
</td>
<td class="nump">$ 11,860,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6660316096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (9 months)</a></td>
<td class="nump">$ 1,239,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,198,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,262,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,293,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,326,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,036,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">15,357,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,821,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 10,535,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6823960720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="nump">$ 72,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 2,366,453<span></span>
</td>
<td class="nump">$ 2,586,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="nump">503,377<span></span>
</td>
<td class="nump">346,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 9,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">14,546,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">220,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">6,316,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">2,395,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">4,292,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">4,970,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NewSharesMember', window );">New Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">2,354,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 26,446<span></span>
</td>
<td class="nump">$ 85,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember', window );">Warrants - Cashless Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">Number of stock issued in cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">350,666<span></span>
</td>
<td class="nump">276,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="nump">$ 72,109<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="nump">$ 1,836,630<span></span>
</td>
<td class="nump">$ 2,143,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">25,155,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">4,474,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | 2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="nump">3,584,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,384,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="nump">2,384,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NewSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NewSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6917242880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (542,235)<span></span>
</td>
<td class="num">$ (478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">6,159,067<span></span>
</td>
<td class="nump">5,737,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">5,616,832<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Indefinite-Lived Trademarks</a></td>
<td class="nump">325,648<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">325,648<span></span>
</td>
<td class="nump">294,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">3,763,022<span></span>
</td>
<td class="nump">3,463,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(542,235)<span></span>
</td>
<td class="num">(478,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 3,220,787<span></span>
</td>
<td class="nump">$ 2,984,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">12 years 9 months<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 2,070,397<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 2,070,397<span></span>
</td>
<td class="nump">$ 1,979,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811719424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 781,419<span></span>
</td>
<td class="nump">$ 904,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">271,677,742<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810463952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NOTE 1 &#8211; THE COMPANY</a></td>
<td class="text"><p id="xdx_803_eus-gaap--NatureOfOperations_zCf0mFzoW4vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
1 &#8211; <span>THE COMPANY</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has <span id="xdx_905_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20200331_zg7eQzOXdG8f" title="Number of subsidiaries">three</span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup> and BIJUVA<sup>&#174;
</sup>are registered trademarks of our company and ANNOVERA&#8482; is a licensed trademark of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Nature
of Business</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as
the pandemic began to negatively affect our revenue growth. On July 30, 2018, we entered into an exclusive license agreement,
or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License
Agreement, with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply
agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY
outside of the U.S., excluding Canada and Israel, or the Theramex Territory.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6917257936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and financing fees</a></td>
<td class="num">$ (6,571,329)<span></span>
</td>
<td class="num">$ (5,365,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">TOTAL LONG-TERM DEBT</a></td>
<td class="nump">243,428,671<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001387131-20-004479-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-20-004479-xbrl.zip
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MGHQ@#^LQ:*E2YALIL5^(Q[AP7.(+V+ P1\-9<4+V/+'GB6WPQ/&;X E&0IX
M"!'4"]!Y0!+0!HIEH9PGF/6@FD-G//&C+(". =@%<'G #!P-=PJX1%Y!OHFB
M!7$XN*I5XP-!!1Q[][!:%@'X@2T$0-J,J8Q0/E5C$D9BJG(JD6S$%29E-*'X
MHQ4>1/4*C*!RB18B6Q'VI+ GA>V1PH=70@J#![CYPV'! MX%H6AA11AR>#2
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M7 K4_L/Q@VO.>3-S(]ML6+P)[::H6+%X%=I,>14OP-L;\7AQ_G]02P,$%
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M!\3M$.4+KD^(F_^M*I[2-\?V\73_?P%02P,$%     @ [HJF4*X:20:#!0
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M%0V1]$%6B,MNL<FECCQH!+IP-34&%R7YX-D57;O[2VLT]+I674BOU#$75)"
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M,(D<6AF36PJ52J?=TS^!-M0_CBY*P_[ **UCJPC/1WPM2"]GGA">FR"6,_.
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M SWN,2]?=[^&,9M!L@T9ZTXA]&/]Z\'4AE"D,"VDJ&R*<AP-AS@=Y%!!_3<
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M^P1AWG@"?#?.=FN)K,105/$TT(-'TV#'SM4M6XS^5%-E;U@T9.E>9T4L!QZ
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M.VEH#CP;YL&0&"KRLS:ROSX'ZI%!&X\&@F3LN3"FC,QZ:?G2CT3S^\KE_,$
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M[" ]\)%^@,2DO'7W-OB*8D<L4C=_J]^Y+;H/*M*8Y"-;4A1*,I+.AIB-7*P
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M_O.<5Z*,FL(][[*ER$^".M_*"J;47H^R.9AZ:Z4%UVLI%7$I89H:"3R/H&D
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M:O";^;\OD^V=R)A5A@)02(5%WN1J5U*<#.,07E=MDY?2Y F0./_3YC2UZ/W
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M-H9?/H.(/:0] 1)2?06QCZD^ AL/5+'B,SM3W9IMBF]I0:.QD6/1Y<3=B7-
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M-)FCTR25CSA87IBG3'CFJ=I[N?VC#-KET;0F%X\^_#$M%<)[^7:P40>Z\_S
M -^[ZH?OK"_FR<(.1LKW+O1@9BKFE]<?WMOL>3 A0Q8*^&RBS=N.=Q)DLM#E
ME18U.*N]'7TR$8V)05;$H*J)\G-=,A$#DG:M;LF.V']K0[[X[>OKK&ZQ;V9T
MTDSP@LJ)LJHKQL($HSX[@#% &CL?1"P$$5=8)+IW4-W+NHY; #B#26^Q M]
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M '&+"(\6VT1YH V1:--!!I;($PM!I:S!TQ9S\1"4]^^^WW56&8@[-LV[Y4/
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M]4-:!RU(L$3R=!$70'T>V0#PNH;K@8R5[R./@<#T[;R@H@P/4)$&SS3[H$
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M(N3@KO-[CM3(E1GIQ_N%6616P(H)X"3A UO\KK)MHX9^0*7*CLP:EY>FSGB
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M=M(R*"2]O97 #&=X$XM6#KT,8_"O7.5A":0*P+)FLGP6QHVI9I,7L'EU$,;
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M"=)QQ)0"_-K5+D4N[W 2*JV*=S0>8B:B5B8:$3$QR4N)4CE+PL/%6(]@NNS
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M<,;8H95F+E?'3AG=R[AY)!/Y_F.+:G;SWAUR?5 -73YCOS)]$Q,T*D[C(/+
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M>VLB;[C]\.!KX;3^+;.I6/??E< W%%RSF5CW*;VL'YCVC]ELJ*?U]\2TYV?
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M8@B$&:X-5.*:X<,?X:-ZZ'DHO)3**6!<H*XM:Z'HFB J!^:N-6$?6=D7%$/
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M)YS.F<@U7S+,.L_$T2;IH80S83J=NY\GA=H7);\]$_/HJU6>B;R<*\V7A+W
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M!O4 L5#>:V#UR'B_AM]@(R X-WBX\=0P60_?2F@?Z5T=IV".WRWA08-W@P
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M[.Z,RX&YQ$#<P<?-HPDWSL[.O[>N&F)ZROCD&@[A_$:=VV": XVU<_/?%AP
MAT'>"@+L;[9@3E <2\XP\\G $=.>J03JT[1>YH7<MI=Y3$)E7*OP=?8R+^3^
M';W,214(/MVP8SZW^7NB];A3W-$TY.*M[;OL_#!6!0I4QRZ)X/'!?WW#3C<?
M+>.1M\$#7<CJL<CP' 8[(,H^06: ;VBCO>79#MUN! U%.1@\FHX<><P8^>,3
MS#?K2=G#9H/^V!)OFP<ZW]#! PZ;#:B,X="C)\K;&%JLIV""NXKHWER?LW:
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M.C*9VR-ZXG;_>E^Z'N!%TP$/<$F-4!,[ZO;.!KL^:/#NL;@8'BB#58-K.\1
M)K\0 U-S(J4P'Q),AUK;/39A=*9;E8XFTNZ/.123AY*>78V6"M7[^R29AK'P
MQK/N)#]Q2H@&H>^C+V<_%O>W8CN"W>";@9S/1WJY*C\>/U]\/FGF?_O7M!>"
M!OQ.<%;271(%DBY12WM !?[C^_@5LC7<S[&$Y=.0*W*I6I5S]<1429]C+BXN
M2&S(E(.GZDX;@ZG$>P>*^4#W@Z0E%5DZ:P"/2JSS)U"R#=^3]^0X5D</&/'
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M^$?=8=EJR+CA]Z-YP.P0 O5CB@9?;H+0"VEP69 A.*&T_B<86*9$DB%&@@-
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MNI U>?5';#50*)DY7,PEM/7;(]<V,OJ/\#>BD=$(URL!WU/*PQ +6?PCP$[
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M"UXUY*S@I6^X!2H!!]-FA,$^$2%>V\,;5H,JJYA8XV^9MB IO!Z.2L-CMJ$
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M\VVC !2 :A6JT/4@A?[UFR<S[Z,*!1"D"!*4L!$[;1% U7WDS9N/DR?KC08
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MR:1I7&$9>)>ITGXXY?HL@9B*@0%NKFR"NYILAF0 .@^MN" I11>!K) NW<:
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M"J&8">I$PR'3Z\@ESY0U-6VDP?*YB;@?(HW'.'T#_L>/H 5KP^)#S:(?(8D
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MV1;7MX:[)(6UDFS:E7+WV[RW^H5N[2WM@-PTN.Q,>]N[?FTQ!8X7#"N^"[V
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MY=$4X(.T-'>^VG>2)[)EBP:X)Y"=-D=O9=*6HT/G-*;&C9RW@,2[$R PFP3
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M2-MW<T@Z?.*X1)U^(=E:LR;?:">[.U;'V.[,UY$7P!,E+!54K &JE!,-T'D
MC(PS4JVA]K;/(^YN.D#?^+A7^4@H0]!K^I<.,DEPV]ZT)$C%&'0((VF\6?N1
M<HHZ([T4;2SQ3*>")3>:P2_@ R%,TP59>,P4DS/G GK=>UT0Y](I@K#RFI9J
M<U+];>$:9GH\Q^9MKI&C(Y2N=<"T<^)L;Q(C28,KBSPZ$!'0+2+AV@0CHR.>
MP_6*YXMI$O!8**>UW\P4.73I+1G1OX7/"*\*)S!Q%'231]-*4NG@@[6_[V"A
M.2'OZDXE1L'=,\5]3.U!=%?K$,7.0!PYP1G2;8!?X&@F),J8$$E$$O\;?QG$
M(^:"CM*10D%H:!:?44*7]N7EY/V6%1-O0[:8M]L5%Z)%+7->6 06\TQ@8,UX
MM;4!/.UL>G%R\'K"[>>+S+(B!![]]<"5:3;IK*4CLB/_<%=O#TI;-9-2A^!$
M]&?]1%!H_CU%0DPZO8]0>43*-9NQKBY]  'H)V=L-)CVHOPH#T)E^LJ5K*F-
MG%['152;HC]:D>3ZA4QV"E\&]KP9RT(=;^MM'W#).H.HT(#4/X@J:>X>;[^6
ML3WU(C%[(&W[V071_TY[\*S3EA(P60V.MEH[*J6[<A]-4?W8VEIHB+Z6H/=<
M!N&DD4$X.PA>?1['O7@]W'OWO([.W_?]^Z;_?^LAU]S_A6&"1F.ZU1_?$C1H
M:?MR^^%V?W!Q$6V@=WIPTM)NR_>T6\,Q0M=L(C*/(*0J@PT1;&\)<^N%.CI9
M<:'XCYN_6"])X:YGI<Y.O[*58L>=;[BV!9MOY/1XAWK5@TS^6QX-_^N[Z/-Q
M=[][,"XG=UZ@X^Y!]S_LFH1?+$2W$9R[C?AM.)/QG0F^RP[^@09^OQ \)102
M4E VLA; J:=D$8-X!D8:ZD*D+.1D+Y2R$/D3:D/P)W]-GKR 'WVI@!]M!7SC
M!'RN)N";%?"C+]7@1Z3!MQ+^>!+^06,$W>/3PV!5??Y5"? 7:N@CTM!; =YL
M 9[3UT]=@.^V5-W#[L&;WS[\QT-O^)T'G/X8/FWA_-^?W_\JHWZCE5O!RZS/
M3-2,I>QV?]*2,_UT8#ZU-8;A=(J\J080N50GE,@S>=$A\[J@-HL+V( .PBN#
M,AP)A0S8DP?,^XI!>-6V;U+4 <FWS4N_W5/QX<4OVU/Q"*?B8_@Y2[/)C$R,
M$F@,4MH?^N-H$MIC\NW*Y(O+7[<RN1DR^2),^LR]3?_]:YQ^ AG_5D(/7KYZ
MO970S9#0E^!=B>L".F=R?+N2^NOESUM)W0Q)_37L1<E62%N$]-W[5ULAW0PA
M?2<M>L*M0FV5U9.MG#Y<"@*L"C)LKAF8BP"\1@1@3]"MS'M5U)Q[9C(2C+?4
M<BI2@5[>;<U$:'G$.EA'O0((9$3V31&$7W[1K$6I5UT<SI7;0([GBW7XRXLJ
M=70'PZK,ZL4RV#L#N3CTREU0PZ'_UZ_AJ,WAOFE5[ZF+.9=:U%"[^U\&V_T/
M-%8#ES JCA%0NG?HVMI&CJ%7>1H7XR7#OZ%:K+NM%MO$:K'NMEKLCM!^L^QK
MK1^P>WMG(-2'-W_[[?+C'^]??7C4BO$G6&?Q3J$)AO>NW@U7JYEN)("7'XY0
M:!%RTT+42*!< XD';>HJA$_**ZJ5<R@A0D/>:!PFP]T=I0A@(C)36P=-7*&^
MG!](M_(X8Z;0AV+$?(@=O3M;V.7'5W_9W7D;SN;2M5_%JGP),+J[)F#T_;IC
M]X4@KWDO-'+\^;^^.[HU6OQ+M# HR"[?O?KCXYL7']Z^[ 1O?GMQ4-/'&^8(
MZ_:?PIA?PR[<=3S'FS6<D_/[',_F[/\F+/*=Q_#S["_!TA'<Y&BL7Q_$?_VQ
M^)$^Z]&N!7\[ ,PF_G><":W/5B V=PQSL<"#[M&7F)@M(K#=_LT=PWUO_Y-"
MB6["!FS"&.Y;"/;>V5Y9<Y*PH8CW3=B&KVP,V\V]+^-OLVV_'\GX(]OO99C&
M41)<'@0OPKR\YACJUOS;]#'<M^IOEX*M!&SN&-9C 3Z1,HM-V(!-&,,:+4 G
M"8 ?@+*E8FJ]I0:A!1YL8!B^A<WCBT:X0?0L=X__- :Q+&U^M$V;;V+:_.BQ
MTN:;F!N_WS,)A=;+!C/6;.-RDM!__']02P,$%     @ [HJF4)7LU0[I&@
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MN$3,J8NZ+E?$I)7Z#(<-<1P.HPO&=U""9:L5@^$#!?_V'O7LG> VG0(%!OZ
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M*YXM<'H1%4<**L3=CU)*!."S(DD6:OE_61PA2 ?CCZPNB<IGV5X&H!=!22A
M%Z$_2J0\5)\32CF,7BXE@8$J8?NC?"H$TG*"J@"LEUAQ2*!J4.THM'2^Z35U
M";/E@ @,-C_2?/YI#D(OGF+7OC ?U?@FZ-N(.G_)8KGAMLV?8# H#1T)_L@L
M*O',I%CZ6:8/W'.!MV0^%W2.&S5C"JZ]1SL;@+8\T[UCZX"EOAP/VZ5>\+G
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M.S'\%=1_+O&=Q9>$.7V7+A$,* 5#'%8J#T$_"NZM/ISX?3$ T>'>8?_G/1+
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M+SZ9R'EP 55:@Q67?A HG8[S<W)9BXZOG*JM 4Z(#Q! M<?U.ZOO)M*+,]+
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M@8;ORU%4%A! K*5M&$'S9@*7AJ/J'B8Z,.SLQ>MPH\8"EX:C#A\F.DB'I3Z
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M.CIS[/#UO,1&&B>9.BO.G^,PS^[FGX>L]W=U1ESWE\/7K/^W%="0S :E<3^
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MJL;%3Y.2\S1ZQ@+T4NDI-48GU""8\I1Z7LFTZA6,D<X5<S #VD122G2GATU
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MAFUJW++/PU;?$SSXM-GPVY?75)R3/O?6(?/7'.&LWB/)X'Q&IU1F<6=GIRU
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M]TF1DU)KL?I^C,K^A:%)8@JW\[SUZT5:/)Q[C$X!I)EC_V%ADZ(=;!5Q-=%
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M?-[00LTB6RHZ&S@'%:2FFI46+JX-@=S?Y>0<JY=O4/F**U97@QO01@E7^PU
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M$C!)CJ,T?L55RS)H^H Q*M\M3KD*BJ ^XZ^KWU'>^6=+?DYC\[+ZF9?[C\9
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M:YS-KHB#1-];1D/R?UE\E]W_-AX&.DQ44X,W+KW7E%U+J=([0M@X=*T=6#8
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M+FAT;5!+ 0(4 Q0    ( .Z*IE#IHL\UP @  .0_   *              "
M ? (  !E>#,Q+3(N:'1M4$L! A0#%     @ [HJF4*X:20:#!0  <!X   H
M             ( !V!$  &5X,S(M,2YH=&U02P$"% ,4    " #NBJ90C+4N
M9*,%  #B'@  "@              @ &#%P  97@S,BTR+FAT;5!+ 0(4 Q0
M   ( .Z*IE#!-]9_=Y@! %S.#0 3              "  4X=  !T>&UD+3$P
M<5\P,S,Q,C N:'1M4$L! A0#%     @ [HJF4)7LU0[I&@  ,0T! !$
M         ( !]K4! '1X;60M,C R,# S,S$N>'-D4$L! A0#%     @ [HJF
M4"#6L'P0%P  */4  !4              ( !#M$! '1X;60M,C R,# S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( .Z*IE"- 8DF^3   %G_ @ 5
M  "  5'H 0!T>&UD+3(P,C P,S,Q7V1E9BYX;6Q02P$"% ,4    " #NBJ90
M^5.]XRB$   2_P8 %0              @ %]&0( ='AM9"TR,#(P,#,S,5]L
M86(N>&UL4$L! A0#%     @ [HJF4,C91/\P2@  /\ $ !4
M ( !V)T" '1X;60M,C R,# S,S%?<')E+GAM;%!+!08     "@ * &P"   [
%Z (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821231728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.54%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">63.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">65.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806446736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zz26GotF80U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of March 31, 2020 and December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization<br/>
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved hormone therapy
    drug&#160;candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zXYDMwse61td" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross">3,763,022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaYaXoZo6IQ4" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(542,235</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZXtiuvXLzR6" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,220,787</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zuNk95uCDdvh" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents&#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zQL8AYkzExfd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">2,070,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z0LxzXYIEQZj" style="text-align: right" title="Finite-Lived Intangible Assets, Net">2,070,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedTrademarks_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zPBhk7RG6V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">325,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zG6sPBcYD03f" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">325,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20200331_zq4h23lLuIF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">6,159,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331_zKOzPdRlfZf4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(542,235</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20200331_zUUFmVblveIb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)">5,616,832</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization<br/>
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved
    hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zWdHV07R0ln5" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlLY2WFRzgc" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z1w0tlUPrEFk" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z5znApwOIz0b" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period">13</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zC5bjbT3nExd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zdozuDJ6LcK2" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z29Jjza7Nu91" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z99mUIIQEEYa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zCT9dsXR8CKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231_ztH7zn4WIg4h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zySQa7F4hnLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z8wXdGjBstB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Estimated amortization expense,
based on current patent cost being amortized, for the next five years is as follows:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (9&#160;months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20200331_zc3KUbdVRHV4" style="width: 10%; text-align: right" title="2020 (9 months)">189,464</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20200331_zzf1CjRqXSY6" style="text-align: right" title="2021">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20200331_zGgaIHw2eKxh" style="text-align: right" title="2022">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20200331_zmn5PDCaunmk" style="text-align: right" title="2023">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20200331_zgrCptqyKUAd" style="text-align: right" title="2024">252,618</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592005200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">The following table provides information about disaggregated revenue by product mix</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BD_zYG13U0vCP7c">The
following table provides information about disaggregated revenue by product mix</span> for the three months ended March 31, 2020 and
2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><b>Three Months Ended <br/>March 31,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue">2,473,691</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue">1,935,971</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue">6,392,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue">2,010,680</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue">1,111,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">ANNOVERA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue">2,272,761</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;&#160;&#160;&#160;&#160;Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">12,250,657</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue">3,946,651</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806170320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 &#8211; BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--ConcentrationRiskDisclosureTextBlock_z4loBUXUHMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
14 &#8211; BUSINESS CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
purchase our prescription products from several suppliers with approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zbhYELJlr5Uh" title="Concentration risk">32</span>%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zQ1XMiUXW4Id" title="Concentration risk">28</span>%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zthVxpVKaYK5" title="Concentration risk">24</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zaoS24yqS4B5" title="Concentration risk">13</span>% of our purchases supplied by
four vendors each, respectively, during the three months ended March 31, 2020 and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zg5SqwrrnO57" title="Concentration risk">33</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z65UES1vk0k4" title="Concentration risk">29</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zkyrP7FmlPm9" title="Concentration risk">27</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zgtlqNsGTzW5" title="Concentration risk">11</span>% of our purchases supplied
by four vendors each, respectively, during the three months ended March 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months
ended March 31, 2020, <span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJWaOaYw1Hrj" title="Number of customers - revenue">four</span> customers each accounted for more than <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzqivXVzo4Og" title="Concentration risk">10</span>%
of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zxsFXqJcYeb6" title="Concentration risk">70</span>%
of our prescription revenue for the three months ended March 31, 2020. During the three months ended March 31, 2019, <span id="xdx_909_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvuebnY3r9V1">five</span>
customers each generated more than <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYlqDFn7kfh" title="Concentration risk">10</span>%
of our prescription revenues. Revenue generated from the five customers combined accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FiveCustomersConcentrationRiskMember_z4D7kWoziI3c" title="Concentration risk">83</span>%
of our prescription revenue for the three months ended March 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, Pillpack, Inc. accounted for approximately $<span id="xdx_90F_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zK3o0Jfpg52" title="Revenues">3,199,000</span> of our prescription revenue,
McKesson Corporation accounted for approximately $<span id="xdx_90C_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zzWQDVF6dl7b" title="Revenues">2,259,000</span> of our prescription revenue, Cardinal Health accounted for
approximately $<span id="xdx_90E_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_z15vUxEeXY27" title="Revenues">1,886,000</span> of our prescription revenue and Pharmacy Innovation PA accounted for approximately $<span id="xdx_90D_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zJ6qWO7XUeI4" title="Revenues">1,234,000</span> of our
prescription revenue. During the three months ended March 31, 2019, PI Services accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zS9jKAOiH47h" title="Revenues">967,000</span> of our </span>prescription
revenue, AmerisourceBergen accounted for approximately $<span id="xdx_908_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zv2ESvX08fr2" title="Revenues">787,000</span> of our prescription revenue, Pillpack, Inc. accounted for
approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_z1teRsXY3Nid" title="Revenues">534,000</span> of our prescription revenue, Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zk56pYPfTsmd" title="Revenues">525,000</span> of our prescription
revenue and McKesson Corporation accounted for approximately $<span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zQqIFZ9wbowk" title="Revenues">457,000</span> of our prescription revenue.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806435888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC7MnWRDtovb" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - NET LOSS PER SHARE (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pp0p0_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGDOUicyDozd" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">25,155,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZWiLD6NjQF5" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">21,447,719</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za9GAAGxKxOa" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNvvkwguDAok" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock awards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zACf9oP5p4k8" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,858,490</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znscYXL28Ha1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,040,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331_z9ILmNQb31l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">33,846,282</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331_zcJtI3mjRv6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">24,320,290</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811823040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about disaggregated revenue by product mix (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 12,250,657<span></span>
</td>
<td class="nump">$ 3,946,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,473,691<span></span>
</td>
<td class="nump">1,935,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember', window );">Imvexxy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">6,392,601<span></span>
</td>
<td class="nump">$ 2,010,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,111,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 2,272,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6917131712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed assets, net consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 3,497,853<span></span>
</td>
<td class="nump">$ 3,476,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="num">(1,167,663)<span></span>
</td>
<td class="num">(968,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">2,330,190<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,640,900<span></span>
</td>
<td class="nump">1,619,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,406,858<span></span>
</td>
<td class="nump">1,406,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 68,788<span></span>
</td>
<td class="nump">$ 68,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805332528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NOTE 10 &#8211; NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_zEhUrHtD0eNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
10 &#8211; NET LOSS PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and
disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common
stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_zv65xt6mS1D7" title="Common stock par value (in dollars per share)">0.001</span> per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average
number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the
period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were
excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net
loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net
loss per share allocable to common stockholders for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC7MnWRDtovb" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - NET LOSS PER SHARE (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pp0p0_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGDOUicyDozd" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">25,155,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZWiLD6NjQF5" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">21,447,719</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za9GAAGxKxOa" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNvvkwguDAok" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,832,571</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock awards</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zACf9oP5p4k8" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">6,858,490</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znscYXL28Ha1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,040,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331_z9ILmNQb31l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">33,846,282</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331_zcJtI3mjRv6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">24,320,290</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806287264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">NOTE 6 &#8211; FIXED ASSETS, NET</a></td>
<td class="text"><p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zARnJqTt9ku" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
6 &#8211; FIXED ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeaPRBKHtSa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Fixed
assets, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">Accounting system</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zg2PJZsXwO0l" style="width: 12%; text-align: right" title="TOTAL FIXED ASSETS">301,096</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlKfWaau3kT" style="width: 12%; text-align: right">301,096</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4Z0zOt08qw8" style="text-align: right" title="TOTAL FIXED ASSETS">1,640,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlZcRsPr7uN2" style="text-align: right">1,619,646</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFKrqFQ0kLal" style="text-align: right" title="TOTAL FIXED ASSETS">1,406,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlKp2iyTusak" style="text-align: right">1,406,858</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpvF7xSYPh7h" style="text-align: right" title="TOTAL FIXED ASSETS">80,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQsgGEW8GUb1" style="text-align: right">80,211</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zy5WtSAUOjmk" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmAhWN0pXa3h" style="border-bottom: Black 1pt solid; text-align: right">68,788</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331_zVrOjJE771k2" style="text-align: right">3,497,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231_zpYZ6SytS7i4" style="text-align: right">3,476,599</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20200331_zChgcuFWqYH" style="border-bottom: Black 1pt solid; text-align: right">(1,167,663</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_znrt2W1QZK68" style="border-bottom: Black 1pt solid; text-align: right">(968,824</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20200331_zjtw6zANLYSf" style="border-bottom: Black 2.5pt double; text-align: right">2,330,190</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20191231_zFWC915SmO9i" style="border-bottom: Black 2.5pt double; text-align: right">2,507,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AD_zom7GMcTy0m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense for the three months ended March 31, 2020 and 2019 was $<span id="xdx_90F_eus-gaap--Depreciation_c20200101__20200331_zIVpkYmOBeZ5" title="Depreciation expense">198,839</span>, and $<span id="xdx_90F_eus-gaap--Depreciation_c20190101__20190331_z01OVoVKKuXi" title="Depreciation expense">66,494</span>, respectively.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6807846752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - Paycheck Protection Program Loan [Member]<br></strong></div></th>
<th class="th">
<div>Apr. 27, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 6,477,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan', window );">Individual employee annual compensation maximum for payroll costs under loan</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan', window );">Maximum percentage of forgiven amounts for nonpayroll costs under loan</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness', window );">Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness</a></td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness', window );">Individual employee salary reduction specified percentage for reduction of loan forgiveness</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Individual employee annual compensation maximum for payroll costs under loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Individual employee salary reduction specified percentage for reduction of loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of forgiven amounts for nonpayroll costs under loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=txmd_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=txmd_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809302656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember', window );">Supplier One Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember', window );">Supplier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember', window );">Supplier 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierFourConcentrationRiskMember', window );">Supplier Four Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember', window );">Four Customers Concentration Risk Member | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FiveCustomersConcentrationRiskMember', window );">Five Customers Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember', window );">PillPack - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,199,000<span></span>
</td>
<td class="nump">$ 534,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember', window );">McKesson Corporation - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,259,000<span></span>
</td>
<td class="nump">457,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember', window );">Cardinal Health - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,886,000<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember', window );">Pharmacy Innovations PA - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember', window );">PI Services - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember', window );">AmerisourceBergen - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 787,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierOneConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierFourConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierFourConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FiveCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_FiveCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NOTE 1 ??? THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1Company</Role>
      <ShortName>NOTE 1 ??? THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - NOTE 4 ??? INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4Inventory</Role>
      <ShortName>NOTE 4 ??? INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNet</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNet</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NOTE 8 ??? OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</Role>
      <ShortName>NOTE 8 ??? OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTE 9 ??? DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9Debt</Role>
      <ShortName>NOTE 9 ??? DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShare</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquity</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NOTE 12 ??? INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note12IncomeTaxes</Role>
      <ShortName>NOTE 12 ??? INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - NOTE 13 ??? RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedParties</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - NOTE 14 ??? BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14BusinessConcentrations</Role>
      <ShortName>NOTE 14 ??? BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEvents</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - NOTE 4 ??? INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4InventoryTables</Role>
      <ShortName>NOTE 4 ??? INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note4Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NOTE 8 ??? OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables</Role>
      <ShortName>NOTE 8 ??? OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - NOTE 9 ??? DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtTables</Role>
      <ShortName>NOTE 9 ??? DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShareTables</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note10NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - NOTE 1 ??? THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative</Role>
      <ShortName>NOTE 1 ??? THE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note1Company</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails</Role>
      <ShortName>The following table provides information about disaggregated revenue by product mix (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Inventory consists of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails</Role>
      <ShortName>Inventory consists of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Other current assets consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails</Role>
      <ShortName>Other current assets consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Fixed assets, net consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails</Role>
      <ShortName>Fixed assets, net consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details</Role>
      <ShortName>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails</Role>
      <ShortName>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Other current liabilities consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails</Role>
      <ShortName>Other current liabilities consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails</Role>
      <ShortName>As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - NOTE 9 ??? DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtDetailsNarrative</Role>
      <ShortName>NOTE 9 ??? DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9DebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note10NetLossPerShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails</Role>
      <ShortName>The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails</Role>
      <ShortName>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Restricted stock and performance stock awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails</Role>
      <ShortName>Restricted stock and performance stock awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - NOTE 13 ??? RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note13RelatedParties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - NOTE 14 ??? BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>NOTE 14 ??? BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note14BusinessConcentrations</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Supplemental lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails</Role>
      <ShortName>Supplemental lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails</Role>
      <ShortName>The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="txmd-10q_033120.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note16SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="txmd-10q_033120.htm">txmd-10q_033120.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>txmd-20200331.xsd</File>
    <File>txmd-20200331_cal.xml</File>
    <File>txmd-20200331_def.xml</File>
    <File>txmd-20200331_lab.xml</File>
    <File>txmd-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6824253360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details) - Share-based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, beginning</a></td>
<td class="nump">25,030,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning</a></td>
<td class="nump">$ 3,668,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares under options, granted</a></td>
<td class="nump">636,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised</a></td>
<td class="num">(350,666)<span></span>
</td>
<td class="num">(276,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="nump">$ 725,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares under options, expired</a></td>
<td class="num">(50,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares under options, cancelled forfeited</a></td>
<td class="num">(110,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled forfeited</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, ending</a></td>
<td class="nump">25,155,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="nump">$ 787,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,668,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares under options, vested and exercisable ending</a></td>
<td class="nump">19,258,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable ending</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and exercisable</a></td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, vested and exercisable ending</a></td>
<td class="nump">$ 787,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares under options, unvested ending</a></td>
<td class="nump">5,896,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, unvested ending</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, unvested</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW=[]8^.KH&K@UUVH+U!+ P04    " #MBJ90F5R<(Q &  "<)P
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MIO2O77]IPW4S'A.--UU]F8[ LMLYW.9_4$L#!!0    ( .V*IE#>8RDKL $
M -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5-AC],P#/TK47[
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MVTYK-CD>^_D%L>49E[\!4$L#!!0    ( .V*IE"^KK]^M $  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5-A;]L@$/TKB!]0$B>MJ\BVU+2J
M.FF3HE;;/A/[;*,"YP*.NW]?P*[G;=:^ '?<>_?N.+(!S:MM 1QY5U+;G+;.
M=0?&;-F"XO8*.]#^ID:CN/.F:9CM#/ J@I1DR69SPQ07FA99])U,D6'OI-!P
M,L3V2G'SZP@2AYQNZ:?C632M"PY69!UOX 7<]^YDO,5FEDHHT%:@)@;JG-YM
M#\=]B(\!/P0,=G$FH9(SXFLPOE0YW01!(*%T@8'[[0+W(&4@\C+>)DXZIPS
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M+QO[WR Z\%)V-WZ$.O_!%D-"X\+QSI_--&:3X;"??Q!;OG'Y&U!+ P04
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M3/I7$K;JJ0;;Q&ERI#1#%R=YY5T&]I;'-WD/GZ;]7MA&=HZ<C<>7C?VOC?&
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M8+.AH/;Q^#Z<[3AFH^&QFWX0F[]Q\0=02P,$%     @ [8JF4#KR9Y>S 0
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M=',O<VAE970R-"YX;6QM4VUOFS 0_BN6?T"=.&DR18#4=)I6:9.B3EL_.W"
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M]ES0W5U&SEYHQAPF#%UA-@N"./6E!(V5.-!/=!JG;Z,.MX&^75=_2.("NZC
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M)==*67!6DAOGI753O 0":NNW=VZOI[<\!5;U\YB2Y;^B^ M02P,$%     @
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M."YX;6Q]E6^OFR 4QK^*\0-<!03TQIJL798MV9+F+KM[35M:S55Q0-N[;S]
MK[%(]D;^/><YOR,$RKN0;ZKF7$?O7=NK35QK/3PGB3K6O&/J20R\-RMG(3NF
MS5!>$C5(SDXNJ&L3F*8DZ5C3QU7IYO:R*L55MTW/]S)2UZYC\N^6M^*^B4'\
M,?'27&IM)Y*J'-B%_^3ZU["79I3,+J>FX[UJ1!])?M[$G\#S+K=Z)WAM^%TM
M^I&MY"#$FQU\.VWBU +QEA^U=6"FN?$=;UMK9##^3)[QG-(&+OL?[E]<[::6
M U-\)]K?S4G7FSB/HQ,_LVNK7\3]*Y_JP7$T%?^=WWAKY);$Y#B*5KEO=+PJ
M+;K)Q:!T['ULF]ZU]W&%TBDL' "G #@'@.R_ 6@*0%Y ,I*Y4C\SS:I2BGLD
MQ\T:F#T3X!F9GWFTD^[?N353K3*SMPI!4"8W:S1IMJ,&+C3P4;%;*T@Z2Q(#
M,%/ ( 5T\6@1#_(L;(""!L@99 ]E>)#;44.<IG<:C!'-"Z^6M0S@')$B#_-D
M09XLP(,\GE&#%XD@M4 >SUJ&<4HQ#>/@( X.X&0>#E[E 2G),N+S!'0Y@ #A
M,! ) I$ $/: R"I1@3'!_GZM91 7F"Y.\0,/#?+0  _Q>.@J$:*D2*FWK[NU
M+J,YS7(8!LJ#0'D B'I ^>JD$@+,4?5TN[4.  0+6B"/*%G<&O86_\'DI>E5
M=!#:7$#NFC@+H;DQ39],@;5Y..9!R\_:=JGIR_'Z' =:#-/+D,S/4_4/4$L#
M!!0    ( .V*IE ^E[Z)JP(  &\*   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;)56T6Z;,!3]%<3[BFW F"J)M&::-FF3JD[;GMW$25 !,]M)NK^?
M;2@B<+/0EX#-N<?GG/B"%V>I7O1!"!.\5F6ME^'!F.8^BO3F("JN[V0C:OMD
M)U7%C1VJ?:0;)?C6%U5E1!"B4<6+.EPM_-RC6BWDT91%+1Y5H(]5Q=7?!U'*
M\S+$X=O$4[$_&#<1K18-WXL?POQL'I4=13W+MJA$K0M9!TKLEN%'?+\FR!5X
MQ*]"G/7@/G!6GJ5\<8.OVV6(G")1BHUQ%-Q>3F(MRM(Q61U_.M*P7],5#N_?
MV#][\];,,]=B+<O?Q=8<EB$+@ZW8\6-IGN3YB^@,I6'0N?\F3J*T<*?$KK&1
MI?:_P>:HC:PZ%BNEXJ_MM:C]]=SQOY7!!:0K('T!3OY;$'<%\:@@:I5YJY^X
MX:N%DN= M?]6P]VFP/>Q#7/C)GUV_IEUJ^WL:143MHA.CJC#/+08,L"02\1Z
MBJ"HAT160*^"@"J(KX^'*[ $)HA!@M@3)!<V\I&-%D,]IFXQ29ZQ-!Z9@7 9
M3?,<%I2 @I*IH!B-!+68=+#0!XQI1NE8$0#,*6/D2D0IJ"@%%.&1HG2R$+&R
M<3Y2O@9P*<JR+(4%45 0!001F" #";+YNX:!!&S&KF$3JS80E--1(C=A%W)R
M4$X.!!+#!!C!W8SF1X*OO!#PC% ZT- NI@G*T7BC@$"<T^1*,!A^/V "1'/-
M%_R&P/$[HH%[&@--/8UFVJPX092E;!S-;>"E*+BM,=375_H0PXV(Z3NB@5L1
M9W.BR2:.&2(8CX.Y!;L4!+<V!GH[OK;IX';$^?Q8"-R/!,V(I0,-/SB496R\
M7V["6D'1X,OOCF+?N=H7M0Z>I;&'"/^IWTEIA*5$=S;C@SW]]8-2[(R[S>R]
M:H] [<#(ICO>1?T9<_4/4$L#!!0    ( .V*IE#1 /0_X0$  &@$   9
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MCBP#@3( B,$)<C!!?OVE$6 " 1!P;TM$4"HEC*>YMR.AC(@TQQ-7!B/X<T<
M4.9_[^@Z(D#W)M*$ V$ *9]( ;K''2;7GQ.&[0%3@"(P0AIN3,8I(O[MA82I
M%>9D @JV''R-YPPB]J[I0,*W7 ?#MH,!WV'(AV*!PU%"4);[Q@,(B<A3),0$
M%&P]&/ >AGTH2!0<'22:VB'8=C#@.VS"23%L//@_G ?#UH,A[PENM BW'V6(
MBN"<0B$6F2!3YT1@_R& _P279Q"]#P4(8:CDHAVJ9;MSG:..UNK8N+;U8G;L
M3N^(:Z=>Y'UK^ZUH=V6CHP=E;%/F6J>M4D9:'G1C+_/>=M/CH));T[UF]KWM
M6\I^8-1A:)>3L6=?_ -02P,$%     @ [8JF4 Y^([?< 0  _00  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#(N>&ULE93;;IPP$(9?!?$ ,9CCKEBD;JJH
ME5IIE:KIM1>&!<5@8GN7].WK XLH\4UNL#W\\W\S!KN8&'\5+8#TWGLZB(/?
M2CGN$1)5"ST1#VR$0;UI&.^)5$M^06+D0&J3U%.$@R!%/>D&ORQ,[,3+@ETE
M[08X<4]<^Y[POT>@;#KXH7\//'>75NH *HN17. 7R-_CB:L56ESJKH=!=&SP
M.#0'_TNX/V9:;P0O'4QB-?=T)V?&7O7B>WWP UT04*BD=B!JN,$C4*J-5!EO
MLZ>_('7B>GYW?S*]JU[.1, CHW^Z6K8'/_>]&AIRI?*93=]@[B?QO;GY'W #
MJN2Z$L6H&!7FZ557(5D_NZA2>O)NQVXPXS3[W]/<"7A.P$L"MKU8D*G\*Y&D
M+#B;/&[W?B3Z$X=[K/:FTD&S%>:=*EZHZ*V,DJ1 -VTT:XY6@U<:G$>+!BG_
M!8*=$&P,HI5!N O<!I'3(#(&\7]5IILJK28UFL%"\EV<QFY.[.3$#DZVX5A-
MLN+@!*=A[N8D3D[BX.0;3O(I3NKDI [.;L-)/\7)G)SL(R<--ISLP_=Q<M#J
MS]47PT_"+]T@O#.3ZA"87[5A3(*R#!Y4U:VZBY8%A4;J::;FW)Y(NY!LG"\;
MM-QXY3]02P,$%     @ [8JF4'8M%K[N P  ZA4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULE9AMC]HX%(7_2I0?T,2O"2- &EBM=J5=:=35MI\S
M8"!J$K-)&-I_W[R5,OC<KO,%$G-]?4_BQSYX>;7UE^9D3!M\+8NJ686GMCT_
M15&S.YDR:S[8LZFZ7PZV+K.VNZV/47.N3;8?.I5%Q.-81V665^%Z.;2]U.NE
MO;1%7IF7.F@N99G5WS:FL-=5R,(?#1_SXZGM&Z+U\IP=S3^F_??\4G=WT2W+
M/B]-U>2V"FIS6(7/[&FKAPY#Q*?<7)N[ZZ"7\FKME_[FS_TJC/N*3&%V;9\B
MZ[[>S-8419^IJ^._*6EX&[/O>'_](_OO@_A.S&O6F*TM/N?[]K0*TS#8FT-V
M*=J/]OJ'F02I,)C4_V7>3-&%]Y5T8^QLT0R?P>[2M+:<LG2EE-G7\3NOAN_K
M^(M*IVZX Y\Z\%L'SG[904P=Q$.':*QLD/I;UF;K96VO03V^K7/63PKV)+J'
MN>L;AV<W_-:I;;K6M[70;!F]]8FFF,T8P^]B?D9$7?;;$!P-L>%.=YZ*]T-L
MW1BA.1Y$0!UB2"#N$TBB2@D3R"&!O!<I%P\/8HS10TPUQ&C!E'K0XD;)6$J)
MBU&P&.44(V2*$VB80/L_C@0F2-P*],-+VZ 80F8*!TE! H43+&""A;],%N/Y
M'X,:]", 8Y"Z>Z6"&H; C(%A$B(%Q.B9\1EB,21,^(@5KMB8& :CQ%R6A":F
M+\, ,#5#+$: :1^QVA'+B'6'85 8HF!!I, 8L'2&6 P"6_B(73AB-;&08U@X
M@"4AY@;'('#FKY5C$#CWT#H%O9O%Q"B8%0Y82:A",0=<SM"*.>!@)W"U*D<K
M01O'J'" 2D)@P#$&/)FA%6/ T7;@:$T=K<0RRC$I')"2$%-#8 Q$[*]58 P$
MV@\>M4Y![Q8G8A1,B@"D),0.+0A?-<-8"8R!0-N!HU6Z6JFW@E$1 )6$<!,"
M<R!FV":!.1!H.W#$)KZ+D\"H"(!*0JSE G,@9G@GB3F0/MY)NMZ)$5N&Q*Q(
MP$I"0"\Q"'*&=Y(8!.GCG:3KG:A1B'\A@)6$6,PEYD#.L$X2<R!]K),$UHD8
M!:,B 2H)X9PDYD#.<$X2<R!]G)-TG1,Q 15&10%44@(#A3%0,YR3PA@H'^>D
MO)V3PJ0H0$I*%8HQ4#.<DR+^0OLX)^4Z)\+V*$R* J2D5 J,@9KAG!3&0/DX
M)^4Z)^I, I.B "DI,34TQD#/<$X:8Z!]G)/^?^<4W9V0E:8^#H>)3;"SEZKM
M3Z+N6F\'EL^\/V%[:-^PI^UX\O8SS7@*^G=6'_.J"5YMV]IR.&4[6-N:KL+X
M0U?;R63[VTUA#FU_F737]7CZ.-ZT]CR=K$:WX]WU=U!+ P04    " #MBJ90
M*[&H&\4"  "2"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q]ENUN
MFS 4AF\%<0'%7_BC2B(M3-,F;5+5:=UO-W$25, ,G*2[^]E (V*;25&PS7N.
MGW-L'[RZZNZM/REEDO>Z:OIU>C*F?<RR?G=2M>P?=*L:^^:@NUH:V^V.6=]V
M2NX'H[K*$  TJV79I)O5,/;4;5;Z;*JR44]=TI_K6G9_MZK2UW4*TX^!Y_)X
M,FX@VZQ:>50_E?G5/G6VE]V\[,M:-7VIFZ13AW7Z"3X6$#N#0?%2JFL_:R<N
ME%>MWUSGVWZ= D>D*K4SSH6TCXLJ5%4Y3Y;CS^0TO<WI#.?M#^]?AN!M,*^R
M5X6N?I=[<UJG/$WVZB#/E7G6UZ]J"BA/DRGZ[^JB*BMW)':.G:[ZX3_9G7NC
MZ\F+1:GE^_@LF^%Y'=\P-)G%#=!D@&X&D/S7 $\&V#/(1K(AU,_2R,VJT]>D
M&U>KE6Y3P$=LD[ES@T/NAG<VVMZ.7C:8DU5V<8XFS7;4H)D&W2N*4$'!39)9
M@!L%BE*@P1[/[*' <0<XZ@ /#LA=&+D7QJBA@Z:9(#G#N?"""74<$( 8CP.1
M*!") %$/:-3DLXD@8!!!!CVBF!!#BL0"4AY%RB-(S$/*@YFXP!C[ZQW*,.(Y
MI2C.0Z,\-,+#/1X:1LX9 =A+91'1$6K#6T@0BP*Q")"W.;8LC)P+AH4'7H0Z
MA(E=W(4,\2@0#X$$\(!X,)$  F)O88M01A#"LSS>X8@HCHC@>%MU*\*%@$P
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MM<IDKP59ISFZ6J$1\SQ@\ R#[Q&[1P2-)@@R!B87V.L".SZY<T'] L0K0)Q
M<B>0+<H8,-1A6H?Y0-,L)GB]J,8#3 E-29KY+25>2XG'TFIA:<"DLY5P0A*\
MHEF\\/2(C-<))0E-B-]4ZC65>DRM_0+4*T#__Z0RKT#VX"")HL6V9 \'@--H
M>!;;XD%&2^1@"LUNA.U0WYD\UZT*#D*;R^6N0"F$!J,:/9EMJDQ3G (.I;;3
MS,SET!J&0(MN['IH:KW%7U!+ P04    " #MBJ90"F)76K<$  !L&@  &0
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MS8(0I=Y5$_68;8>!(PP8$)YB'U) 6XHMG(7#^P2[.0+X@3T%LKI A@#=N7A
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M>@+E5P9M)'.^-&=B)P.LCR0I""V*'9&,*]S6L7<T;:TO3G %1X/L14IF?CV
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MX> ^YBQ)?'^\0@-AP,50=YT3QH\ ?HFM+ P.)?.=X1@<[L]PIA<-"2<*@#-
M*,R+ILT9CDGD +*$6T)@R#C=X(SE91.\;4Z=X9."61R'P)FI,*# [@RFE@,@
M;:L^QT#RX 9G,) <O'Q.G0DGD##Z!R4<D\L1N9;'"\>@\?B&BC%H'#RAQA6O
M>]'P$B>A_>87&$B!@+0\# 7F1[#Y!0O,CP /J4G!O6AXB:,8%.P-=JF%K/;M
MAKYV-NI4ZF8_..B]?#2X;_?1H_X'=K?NMOY_PW1?(KZDU3XK:^=):;.';G>Z
M.Z6T-&GZ[\P5.<AT>VGD<J>;T\B<5]T7@*ZAU;'_NN%=/K&L_@!02P,$%
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M:]'-J6ZC>-O/8##\$5C]!U!+ P04    " #NBJ90:_+]PC<"  "P!@  &0
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MONO6@$*KS#33<S&?^#E0?%PN,[S>J-4_4$L#!!0    ( .Z*IE +QMHZO74
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M&G.(%YJ+]V9MM']>%'%9?%?[.2J>:[QXL4 *5@1YO(B3E^AQ'8=!&I=!M@H
MH-EK!/<V *DE6&:[QW*U6P>1?@4>^68R[87#WBR [0;?S+K#L#OLAC!8L8T)
M#=8UP%VF+[#&AO.^*9\!&Q:RAXCV4,/\#.G!X6<^)%\ 5_@WVDOS1"U NDH6
M<5K$09X\/;>\#U@.%RP!4!V:Y0X'0!CMBKAEI;R00SO-WGRB^3>-"5=)])BL
M0>2)ZSLU1[^-]GCNA\]C;4<Z?"@''KS*TJ?3ASC?'%P7/57B4\OXL7YX6R0&
M>(?7<020U=/5T(E7M3:#O;F! P_0]7[.ULLX+_Y7<'(>@RB1E.^"BU^!H^YK
M.[C-XU4,T%@&!=&%TQKE_S[H=4,07/ _D>:#:%<^9WGRCWCY?9!F^MND*':(
MSG"_LE:Z@CK'=\4V6L3_^B=0*HHX?XG_]&]!"S=J7]1@=&!5WP7]22\<3R;A
M9-BG!>'?/?B[.QFWK/,P*0 V3](X '\;)<O3) T6T3:!PVC U=UFMR8NL&3H
M-Q]BX9_44I]43"?UYL'3^OTQFM\\EI"?W$9X*Y[C$H3/]0'"3L(2B?U ,CXD
M*=#=!,623!26=OUK?IA,MR.G2"6P0A32: '+X#,A!&@LS,W>?%MXWMR@R;%O
M7!+"'/OT(9[JR5A?M1O_U3>WTO1XV+*1YF>/%0WN'^"?CQ?7@$TW'X*;6]"7
M'B[A@>.$!$?5KPL)J,5LXL#B6SMF@=R^W"U*N,/ LG=Q(YL[ Q$=4?8IRY9%
M4,"MJ3X!LA:(\ML\6]4OK:7F\9<M\MTZ.[B/U@BYISB%1]<AW=!HN4E2TC"1
ML-0X+Q# *%\\TZ-+6/LZVVX:I-#S&&@EW#*Z7S3L!N7>?] 7+?RXMMX#_"FK
MRZ',4Q,^@A,9HWY^H+N#Z!FE<;8KY.D&(20&E"KU0@[)#RV/7.&Y/,9 -6*]
MI#+Z4M\2J6\% @D)S*$GKT%P;-HVS624G3!XC(IDP<>3K'> S+53UR,=?*OZ
MTD\QRES(A5[@$$!Y2$F=0_1<".OC*^YQJ#>'/7 S[Q]NSO[ZX\W5^<7=/0H&
M%Q\NSRX?0##XVZ?+AY^/NZV>"O$?'V-<<IW(6U9Y*ZSRC%EEZRMW<1F!,K0,
M+J(\A9T6K4\2KM3T_!@T)7P/ +1&]A**L!"5@:N%3(]X4<L2;[QY[XD\B&SQ
MESA?)"#FP1%F6P0 L^C7*$?K4K/D_1N'"4X2C2!U[HQ?GP*FP(" 2GB=&JG$
M!>%4 \0.DN3J6Q9<!U\[]H2.>;'YA-Y<:=/^FLQ+1^RO_MI1Y_C;,>#-0T?&
M3G(5O"-+7N79!M@AJQ[P-5+@/%F46M3_ X8XM*(#E.AL?O]C\.'JYJ<C903G
M^0]W-Q^UC'']0S _>[C\?/EP>7%?)T+_N2M*9*5%4&9H,LA 2@4U.-74&K[%
MSXNH>$:]=PG<PN&99!EJ5OH\7@Q063E*?&T9#IO&9Y.J/EYC)EEZ2DO**LIC
M"V,\N8.= 0O9P^CO4')QV-^;\G5U=4LMT*Y8J(?)5W&==59?6XL= IZM'1W9
M]XH*;&GG1-76QRC]UM[3\$B.UT9+.*S3'6L,N#[F^-]"QLOKSQ?W;R#C+<BO
ML)0%R)]UB64'XI_<KT.85%MLDK[ =?RZQ7ZXO ;M[XW%YMDBCI=R^]]B1X??
M_F#P:/Z4QW&39'L;[;4J>23Z&4@0MB_A^<>]\TH[-$"=R.DN@:[-G]X%I,?7
M;8UH?P1QRS ?6-V6/&/-#\:(=FV/W.^VVS7M'22@)<C+0'YV.4&4MK$"G1C6
MP>[6!D9MQ&<T/-2 <?-P$?2"?_F?TWZO]WWP\.-%<';S\79^_7--GL^?HE1N
M;1B<P4%FZV1I-8I;-,; &O6MMHJ]T;^* PH8+D0U+B1X@/L8;>-=F2R*C^>A
M@G/H@'(47,<OT3(*'$]52)X<[W'\!BZTMFV' 5P6^ *P">;J38;?'_I'74<E
M@%K!=K2Y/?@I5L"P8/I7T U26N_D^R)XCJ-U^;S GQ8\5?":E*"8!1O@S0(3
MQ!J^<BD)5QN\'-$Z^0=^!ZB2O9"6AYB)VB@QF0*.'^@E;D*MDU5<P-@X%DW/
MUP3XR1,">X^?T.2,T\$>L]W3<P!/9=L(;GTGF)=56 :OM-Q']**A^Q%94QKO
M<CRV8IOD21D&BS4HH(MHK9!* N$N8M9,'S5$@,&@_>@YV>)Z10NM;3$6$*'B
MO&-"4#Z#7!2G2)F!E[X&I*A$^;)@W,[9S$,;[:B;7>Z\FI/?AW8? 6+#=4W+
M4^#199ZMU_$R9&OH.F(*1S]$BWA+T(5%1LL7E%66P3/<&O2&E007 "!((QMX
M<D=&+*4/H@/''D3K(@LV4;I; 0+C#61%"F6:1U"F@D=8U%(,@Z3#@ZZ%)LI%
MGA#EPS_2"&\QT)<(U/HBV,$+C)_XU<=X"0@+KROT//X .)K"WS0LK  !@)BP
M@GN7$;G06+)"CSE,#%,T(25[-V RPJ=XA79" -=Z#R<GVF.&P$7K \V^B?)?
M8@+<%L18?.DI!QJ##R$OI5>C+9)/F-2"Z!SP!MY!=2>D/7WJW'>"#UG&(#G/
M=T#''7.&W-</Y_-0A@.((Y_ C7KG8+=*M]?$-N">X6%]X?1E6&8P"= <6*8#
M&D "' .7F+>8311L%;'!>\N_I0<6UPDNT^#?=S K@P#NUCK:I8MG629L]+0*
MMC"X_/CYXN]__UF=H' <+9,,T","O@$# X; A2O>T35 @)9(/S2[VV1+<A:>
MEMEI@0<9!\L]4(<\WJ5)%)SH48#LIR@49"ASPLQ$EHKXRPZ@+<QN_P[I:;'?
M;$N ((S]LEN_1#F!1P\3P=7:/N_IR#Y_AB-;[N@J.?0%MC_?YLF:]*G#^]<W
M*WA_^>^?/L\#9_<X*?P*8A_P+3B-=V@I+W9D&L-AJE>6Z9?A.X])=II0$ 2>
M36_R+_^SWQ]\?^J-K_R'W-F0HP,HX*C1/9AA0$:1K<JG>*V7$1Y]'"]1D6VR
M$IX6T.(.<O7YXWT=>C@ODW1A&T!1\AWCU,VBS-"X8\ *@D6$RRR1K9,<#.B<
M!GQO44E@X&I!'J"FFI OF%]?WWP&92@X*6(+ <!L"F? @>/R.4GWZZ".G,4>
MGM^\XYN^2G)929:N]ZJ)(&]1LEL"V3Q= 6$+R=*:%Z3*>$32I]4L,SI\()@#
M12/&]LI*#:F3 $FZJ$#3%:UGMUX[5U?P$(_);#E)G97_RK%6^ "JYW ;@!(B
MF=BMZ7#Q21@!;B-<IG(/3#D'[LJZ/DD7-Y\OST][,]@Y4/1-LJ!CHH-=T@.'
MU\)D2#O2-!T.+!T&FEDF)!N@+D12P6,1_[I#W).UPRL%[5TO0;"$]-2GB-U2
M0;1: <2$E).IFVA[^0S\18C7H!M: A:3\+CD26&T^,MB#7S_)39:6Z0E\U#)
MM;C-MNB_PG/#F"%0FP/M:C9B?,AHWOQX&+"(USI>: Y<"Q>J>J[$>^#N1&)-
M#)&8O[4_NRGTC:'<O7?VI]?SUY3\W;(G5=V3_.Q*6G8__"/<AEV.YI(2-_+Z
MG"P(G9]0)8+%R B-X"XSY4M5PC]HR4),R6*:HFR,7UX6>12OY7SA>H]#2TB.
M.%X#"56'!.UQ$W]I/5_SP(]_"S[]%1[;H*W&BNGP4_TL]39H\<(=T8P-!%O?
M13S=D%=+=["VW?H2'^!V)1B,48N_(QVH;U2/]_/[2[(SW=Y=W%]</Y ["N[J
M>7!W<09_7_T<7-[??[HX!R7X[.;3-2GOMW<WU_#YC*U4+:8(7.DM2&\+=+^^
MH0K]H>OA:*5DHQJ5,@"10A,/"5&XQITVJB%>X'M(E$7=L^HUN:#-(' P5=V"
MD9ZQ.TGQJ%C0?'T&EK /LE>4WY"0)<LDR@$FH2J M*]!M8@#C!<F[3I+_Q/N
M/-U^0S+T\MY>%F)$F@&?)'$A!E23E;#!!E8S3U.0A"023,$L'T"^"'K=T[\:
M/K_'R-*89/MSD'_)T:+-QL0J5LE:"U;XO 2H:2>["5-#]P<K@P8][R_.0I9;
M"4X*[B2($<F+L WO6+S=BH4YH)AJ7 ,<0&UQ'3R3X"O.5C4"\3EZ09DC)@T&
M!4P"'@Z;+VD1++)8) <A$ ;9(A\39R82T@4R=7Z7[G!*RR!$I.7/-Z@R1<1'
M?IC/;T-QPO$R[<H<6P?;DC3<05XN<Y9[2-71)_DW>FP.NNL"I(U>%R>[BY\T
M4[D__7L'@^]@-RCV[0$-,803AX15D\>0EV!!$M9/Y[=<FF6&R&DN!X;U92O%
M6_'WR#B<8X1&SA8KA! !"->PCLNX<8H_" /R>+5&N0%7&%G3>$BO)JQD U!3
M7/,:E420C\C.X3Y+ZCZY-P4#LBW(-2RUXTT$U1IT418E4D#EHHCR/6GKP2I*
M<KL>S058/BO,/=7[83M:07(E<KAE1Q- \PH>*X)>SY, @B8@SRU(4%+LK#"#
M1RQ0$AW /T'7S,2][<YH9,H=F@<ZP5U2_%(H/+Y/1G9$HB F)"!]_XE 1?\"
M/DD'O?.>;!!#M:AIY#P^XOA+Z4 F@=->U%XQTBG*0@AQ8\))X)*#S % ,/.+
M=0.M!3@[+!(UZP155K*@$?BW&<LD@2=X)F2P3TIRZ"=;5 7P\$##(&"XN)V@
M*6>;+&'F^"5;OP#2D)T*U Z8)-G$8J)"NL(:DUAM45H!/1?AG^^(K(B\I@T(
M3982A8<IR@E<#>MIADM/\[#1'T:1FXD! T4<TXF;N6C=#$ )R&,1QJ[1,Q*9
M28S."T\ AR/=X#'>9^F2MRM(A" BBEOLM*DFD$#CBN$!@(5'POPWA9?2I;D+
M>CE+=S'&NN*8M13-11,0H7I)\G)'\1^&CH)HASLQV")CP\;9*O4Y*:,SQ.A;
M5Y&[C_,7$ L+#7#2D"F*$PB&^;90",I'Q#B*-8F*O9@.,7A6-H]W5+ LR3UU
MD>^G,0\A@0&\A-'6&EA[N07PXN(Y2Q9$?K3<^))$ZAEC/&!E";G!:B_S-&0
M9$BA%1"88)F2Y$S,!RA'O$4!@;PTFPT@9FELB5H,V, U0IZ(AYTO3W&(/:K+
M %-5>;2,T> /EPWMLH+PN=A+R385^(HR7N?<L278,]-0YK6#4+4^Q5OEP/01
M*)D" >PIS>!@>'IMUZ!=NXBMC=%R!"!K%&)L!$J*;ALV+D6;K=9A-<[#?8_1
MK%P8P[2Q.>*M7*#Y:*67A53!^(HK-Y,VLH$S(IXC2  XM%U'$A<(AUW$=D)K
MNV4YIH[%"LV<O%R@37G$4L2..+^,R[R+[:@XA[XE2T(7HEKF*N%4R49\-G@!
M :EWZ ]'*K$KR:B:QJYZ;_R/.#0:(#K!C]DK&DAH\S0L"1R6W.3Q:63R!<C"
M4Q^V0)RD,3U+@]881=@6JQ&:1Q.!YH;L1"RD9LQ:E@&%%FP)/XB^%"7N!FT.
M=)Z@H<G2O9OB H+>*:(7BM#Q]8(T?LK(PD'19*_ 6M%UAW,6.]H&[4=3%!*8
MZ1HIOD9 *I997GQOIR/I0UN&3U^18\#SY!,$%?4?\?=XY2,2B%"&0C%V32B5
MH@<=I7>DL)</B,#(I6%LLH>M$[(MPY,*;M\+:IJD1",!8\5W$Q/TV4E"[AAS
MOL2JBUAI&,"TR D8P"@D[G(2*RH@M:"GF& -CBP]P.L=\8#0'_4IOCS*X2N)
MSE!@]W&:%,^.>5"8W"N0=EA+P1B\(7T#+:?)5H*4-XP4?*WAGF#$ 6PZPMQ%
M.B7'OJ8JZ"U1T(*%? DQV"+;(#%\S?+UD@_/8!0I(HY)B_?/0G$C!/@DDE(A
MC\T*MCG2A4X0[?$.+(AL1H!Z>.KP^+< \J=U!EJ67LV"?!^DO76"^QW@KOEA
MF11:+N#A>+&&!*&["2AEK&*QOOG25X>- OM-] M2>9Y64SH6LI::TZPXUW%+
M+Q#7%A[MN E=7R1P)A# <^*IBA>\9ZD2M?"89<<-$/^D) T$[_D+*6P!+Q9@
M3-22T:N(S9QYC!F\A148:2Q%IF_*J3LDB0:MDNAKLEX+CN-OD1/8B$(,7'*'
M?X?P7DF"VIHM2ZK,6#5;[G*K/%779";7Q$R$YZ9G]?IYF<!Z2Q 7<!&LK D9
M0U ;0)"0"U<;U_48:[$9M1 4EE@Y,.H%Q47$O%@=TP)*WA*7L-#&$,&?"K(3
M 6/>QT$0/)H-^%0V\@4#?BD81@1.T=3DQ0#31F!/(D(OGE'^MUA=T4SDQH<&
M?/:,64XVMFK%LME3'FU$>GE%;-NSW[,$?&=G+*= 6LV3T-!"!=:S7L<4".0.
M OB 3FV-F\&2..&*8N&0GBN#L\C;D  ?83$*780PQMEFW,5%Z#MNSH9XL1W9
ML-70'BPQUF8$2+P+=2?>5L6!]X%K1\SA+N.C?/"7J9KOG@ ['?>K-?8Y[]T;
M'_O[#/XQAJ@/\_OWH0XC;'S^TQ:A1B_,[S^Q#?VT-Q##E6:,<$8&36RLBA@N
M>*THD)!"SR&5(A[9WXCX8,XAF@3UJT"Z=X] ],PO%&O ,\1*3XE1!%73":@=
MR0I?*$C0;UX4$T($@O8':PN<SN"G"1L!<T83<,(U&:_F]V=A, 6^'16D*1!2
MXMW+,XR4<->P0N,T<+E?M)RA#:91LJ$9119CK*Q29#M0(;8')<;.K-G@]"@>
M<1$?O&.AJ[58,]L6+6:!5PJGWJ#H!FL!%A.1W&!A#',!\\P+;;IJ-T/AZ3S!
M%2";(6"ZV4_MV!E'F->AU:5P8JFB%4H2QM;9&[&MDSB<:S#45B#DFP2<#&,,
MG3&!=J0\XSY@]1MXB'@3&0K1$A2,($Y$*"-_28*6&SE[O OH\&2NHH,G423&
MP!9](T@W0QS95U .!3.<(18#@!TV#?X=M'8T?TG L*&U] *"?9F05; F:S!0
ME3 L%T.,VYJBGS9<0(,%SX\4#:&CD]%<ILA7!( =AX8^&/)P_RFXSCKT*U"
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M D00H:V,BK=9"ADM6(S1UAU2XG^:GX6J27)$3%J+(P"C8DU\/7%**I!;!Q4
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M:(WIVC]5&8<72X/8M&-!_)$Y,KF1B9MK:ZBHA+C!J@!B+[WD^>O<,XY'<2/
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M"C@R[0L"-4(6,7?<FX:#\811:="?A9/9H!F5QN:8/ES^'1L-T2!A<'WQT-#
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MPFF%6K7.@89TJAH%G&(4!O_>P5."-5,* L6Z1L::5S&4AFPEWU++"AN20T;
MP#4"XA]G()2O20S#>,#@@Q/EI?#?T!1I]&/7=)B([JCD#U.ODD-F?ON42/HI
M%7[$F-N<S4NZR$3'!J(4RIO!"R3BFL9<W8_%97S"VZ '&.XC@('!91G';I9
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M\MQ;W,Y6=)M7W1&2 ,ZE[AW+7>(OV#&U44 .V6VE^S;[LNEF%SO*$4&ZJL_
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M.-*:'?VDM!?&5ZUD,";/)K4LQ=2!QYS+P2PYWTN,D?6,,XL*^H8T)Z#IWB_
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MEX_T4N#):;PV+E=#>XQGP\&PPF0:4&<-7KTN7IP XZ%<(K(HX'7#R$[1NW5
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M_W%^=]%ZSO5'CSJ3IA9A%G9<3DOJ9@',0% "AHN-J0"MX>Y.X)F?*/:O)'H
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M0;\S&@9_5I\MY,>#SF@0C$>=21]^'_<Z4^RD^(#%Z4Y@Z20YOPO&P;@S@?^
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M*W*9_#+<G/9<6$JTXU2GNUWQPU]02P,$%     @ [HJF4*Q.*80\ @  @ H
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MW^T(X(Y\N2.@._+MC@#OR-=;@-["UUN WG*%9VWTL,W76X#>PM=;@-["UUN
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M<U!+ 0(4 Q0    ( .V*IE GZ(<.@@   +$    0              "  >D
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ [8JF4)"BY;SN    *P(
M !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ [8JF4)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #MBJ90>'=5J3H#  "=#P  &
M        @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ [8JF4,5=[K),!   TA(  !@              ( !9PP  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .V*IE"["WH26 (  $T(   8
M              "  >D0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #MBJ90UED>LH8#  #D#0  &               @ %W$P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ [8JF4 YG3P+; P
MDQ   !@              ( !,Q<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( .V*IE"YM)Y2;P0  ),3   8              "  40;
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #MBJ90WF,I
M*[ !  #2 P  &               @ 'I'P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ [8JF4+ZNOWZT 0  T@,  !@
M ( !SR$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .V*
MIE".7$9_M $  -(#   8              "  ;DC  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #MBJ90QWT&4;(!  #2 P  &0
M        @ &C)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( .V*IE /@:S,M0$  -(#   9              "  8PG  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ [8JF4-4)576T 0  T@,
M !D              ( !>"D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #MBJ90\47NYK4!  #2 P  &0              @ %C*P
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .V*IE#*!#K6
MM $  -(#   9              "  4\M  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ [8JF4.H8ER*U 0  T@,  !D
M ( !.B\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #M
MBJ90,A7$U+0!  #2 P  &0              @ $F,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .V*IE Z\F>7LP$  -(#   9
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M970R,2YX;6Q02P$"% ,4    " #MBJ90FDY/L+4!  #2 P  &0
M    @ &I/   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M .V*IE :58X$%0(  )P&   9              "  94^  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ [8JF4.Z_?TRT 0  T@,  !D
M             ( !X4   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #MBJ90^FW^3+D!  #2 P  &0              @ ',0@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .V*IE 3O2*5M@$
M -(#   9              "  ;Q$  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ [8JF4+E099&W 0  T@,  !D              ( !
MJ48  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #MBJ90
M"/!3#L,!   W!   &0              @ &72   >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( .V*IE#],YE9MP$  -(#   9
M      "  9%*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ [8JF4&[QOM:T 0  T@,  !D              ( !?TP  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #MBJ90FUA6Q;@!  #2 P
M&0              @ %J3@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( .V*IE"OQ74XS0$  )P$   9              "  5E0  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ [8JF4#EH/%S"
M 0  -P0  !D              ( !75(  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #MBJ90 Z'@GYH!  !6 P  &0
M@ %65   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .V*
MIE#,ZHQW?0(  'L(   9              "  2=6  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ [8JF4/7O'(IA P  1!$  !D
M         ( !VU@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " #MBJ90457D:! "  "-!0  &0              @ %S7   >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .V*IE",<KI'00(  *H&
M   9              "  ;I>  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ [8JF4#Z7OHFK @  ;PH  !D              ( !,F$
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #MBJ90T0#T
M/^$!  !H!   &0              @ $49   >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( .V*IE!,NMU$]@(  +\+   9
M  "  2QF  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M[8JF4 Y^([?< 0  _00  !D              ( !66D  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #MBJ90=BT6ONX#  #J%0  &0
M            @ %L:P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( .V*IE KL:@;Q0(  )()   9              "  9%O  !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ [8JF4.T^I#H$ @
MA@4  !D              ( !C7(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #MBJ90"F)76K<$  !L&@  &0              @ '(
M=   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .V*IE![
M*@XX8 (  +4'   9              "  ;9Y  !X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ [8JF4$OSF2"S 0  U ,  !D
M     ( !37P  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Z*IE!7LM\C]@$  /D$   9              "
M 4..  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ [HJF
M4/=/7":! P  ;A$  !D              ( !<)   'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #NBJ90)B*\]H,"   4"   &0
M        @ $HE   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( .Z*IE!K\OW"-P(  + &   9              "  >*6  !X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ [HJF4%C*^AI] @  R0@
M !D              ( !4)D  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #NBJ90Z35IM.0!  !=!0  &0              @ $$G
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .Z*IE +QMHZ
MO74  %:F 0 4              "  1^>  !X;"]S:&%R9613=')I;F=S+GAM
M;%!+ 0(4 Q0    ( .Z*IE"L3BF$/ (  ( *   -              "  0X4
M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ [HJF4&597Y!W!0  Z28   \
M             ( !=18! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .Z*
MIE U TT!"0(  #,C   :              "  1D< 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .Z*IE";Z.7DWP$  - B   3
M          "  5H> 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $,
*1Q(  &H@ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6917230736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 553,789<span></span>
</td>
<td class="nump">$ 1,583,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing fees on undrawn tranches (Note 9)</a></td>
<td class="nump">275,378<span></span>
</td>
<td class="nump">550,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,064,468<span></span>
</td>
<td class="nump">1,812,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturing', window );">Prepaid manufacturing</a></td>
<td class="nump">955,659<span></span>
</td>
<td class="nump">2,595,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">3,769,073<span></span>
</td>
<td class="nump">4,787,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 6,618,367<span></span>
</td>
<td class="nump">$ 11,329,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806393008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zuYWva5GXJfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020 and December 31, 2019, <span>the carrying value of our debt consisted</span> of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zdBxYTuLbYf1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49C_20191231_zpRZ2jcdfYq8" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Financing Agreement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zapwzyTEff58" style="width: 12%; text-align: right" title="Long-term Debt, Gross">250,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zYDRx6oDWyG3" style="width: 12%; text-align: right" title="Long-term Debt, Gross">200,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_uUSD_zA0yZPzpbaal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Debt discount and financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,571,329</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,365,357</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_uUSD_zFY2FfjOmEPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL LONG-TERM DEBT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">243,428,671</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">194,634,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10q_033120.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 164,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10q_033120.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20200331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 506,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 21,
    "http://xbrl.sec.gov/dei/2019-01-31": 91,
    "total": 112
   },
   "keyCustom": 53,
   "keyStandard": 318,
   "memberCustom": 56,
   "memberStandard": 22,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://therapeuticsmd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - NOTE 4 \u2013 INVENTORY",
     "role": "http://therapeuticsmd.com/role/Note4Inventory",
     "shortName": "NOTE 4 \u2013 INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssets",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNet",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNet",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - NOTE 8 \u2013 OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities",
     "shortName": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - NOTE 9 \u2013 DEBT",
     "role": "http://therapeuticsmd.com/role/Note9Debt",
     "shortName": "NOTE 9 \u2013 DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShare",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquity",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - NOTE 12 \u2013 INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/Note12IncomeTaxes",
     "shortName": "NOTE 12 \u2013 INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - NOTE 13 \u2013 RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/Note13RelatedParties",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - NOTE 14 \u2013 BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/Note14BusinessConcentrations",
     "shortName": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEvents",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - NOTE 4 \u2013 INVENTORY (Tables)",
     "role": "http://therapeuticsmd.com/role/Note4InventoryTables",
     "shortName": "NOTE 4 \u2013 INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - NOTE 8 \u2013 OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables",
     "shortName": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - NOTE 9 \u2013 DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/Note9DebtTables",
     "shortName": "NOTE 9 \u2013 DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShareTables",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityTables",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative",
     "shortName": "NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
     "shortName": "The following table provides information about disaggregated revenue by product mix (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_custom_PrescriptionVitaminsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Inventory consists of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails",
     "shortName": "Inventory consists of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Other current assets consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails",
     "shortName": "Other current assets consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Fixed assets, net consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
     "shortName": "Fixed assets, net consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
     "shortName": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails",
     "shortName": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Other current liabilities consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
     "shortName": "Other current liabilities consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
     "shortName": "As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - NOTE 9 \u2013 DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
     "shortName": "NOTE 9 \u2013 DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - NET LOSS PER SHARE (Details)",
     "role": "http://therapeuticsmd.com/role/NetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)",
     "role": "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails",
     "shortName": "The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expec (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
     "shortName": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Restricted stock and performance stock awards (Details)",
     "role": "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails",
     "shortName": "Restricted stock and performance stock awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2019-01-012019-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "txmd:NumberOfStockOptionsExercisedInCashlessExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - NOTE 14 \u2013 BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative",
     "shortName": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Supplemental lease information (Details)",
     "role": "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails",
     "shortName": "Supplemental lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
     "shortName": "The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": "0",
      "lang": null,
      "name": "txmd:NoncashOperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NOTE 1 \u2013 THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Note1Company",
     "shortName": "NOTE 1 \u2013 THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "role": "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements",
     "shortName": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_033120.htm",
      "contextRef": "From2020-01-01to2020-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r213",
      "r310",
      "r311",
      "r313",
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r214",
      "r215",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r214",
      "r215",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r141",
      "r207",
      "r208",
      "r326",
      "r362",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r141",
      "r207",
      "r208",
      "r326",
      "r362",
      "r364"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r363",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r363",
      "r365"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AdditionalAreaOfLeaseOccupied": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional rented area occupied under the lease.",
        "label": "Additional area of lease occupied"
       }
      }
     },
     "localname": "AdditionalAreaOfLeaseOccupied",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The drug name.",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA and ANNOVERA",
        "label": "BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "BijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA [Member]",
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CapitalLeaseObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total term (in months) of the company's outstanding lease obligation.",
        "label": "Non-cancelable operating lease term"
       }
      }
     },
     "localname": "CapitalLeaseObligationsTerm",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_CouncilLicenseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreement1Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 1",
        "label": "Council License Agreement Step 1"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep1Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 2",
        "label": "Council License Agreement Step 2"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep2Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 3",
        "label": "Council License Agreement Step 3"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep3Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationAmerisourceBergenRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Custome rConcentration AmerisourceBergen Risk Member",
        "label": "AmerisourceBergen - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationAmerisourceBergenRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationCardinalHealthRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Concentration Cardinal Health Risk Member",
        "label": "Cardinal Health - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationCardinalHealthRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationMcKessonCorporationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "McKesson Corporation - Major Customer",
        "label": "McKesson Corporation - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationMcKessonCorporationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPIServicesRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PI Services",
        "label": "PI Services - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPIServicesRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmacy Innovations PA - Major Customer",
        "label": "Pharmacy Innovations PA - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPharmacyInnovationsPaRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPillPackRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major customers in concentration of sales.",
        "label": "PillPack - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPillPackRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DebtTrancheDomain"
       }
      }
     },
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Bijuva",
        "label": "Domestic Patents BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsNonApprovedBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents NonApproved Bijuva",
        "label": "Domestic Patents NonApproved BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsNonApprovedBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Progesterone Formulations",
        "label": "Domestic Patents Progesterone Formulations"
       }
      }
     },
     "localname": "DomesticPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Design Patents IMVEXXY",
        "label": "Domestic US Design Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents IMVEXXY",
        "label": "Domestic US Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents",
        "label": "Domestic US Patents"
       }
      }
     },
     "localname": "DomesticUSPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Utility Patents IMVEXXY",
        "label": "Domestic US Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentOperaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Opera",
        "label": "Domestic Utility Patent Opera"
       }
      }
     },
     "localname": "DomesticUtilityPatentOperaMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTopicalCreamCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Topical Cream Candidates",
        "label": "Domestic Utility Patent Topical Cream Candidates [Member]"
       }
      }
     },
     "localname": "DomesticUtilityPatentTopicalCreamCandidatesMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Transdermal Patch",
        "label": "Domestic Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "DomesticUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTx009HRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent TX009HR",
        "label": "Domestic Utility Patent TX009HR"
       }
      }
     },
     "localname": "DomesticUtilityPatentTx009HRMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FiveCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Five Customers Concentration Risk",
        "label": "Five Customers Concentration Risk [Member]"
       }
      }
     },
     "localname": "FiveCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Design Patents IMVEXXY",
        "label": "Foreign Design Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents BIJUVA",
        "label": "Foreign Patents BIJUVA"
       }
      }
     },
     "localname": "ForeignPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents IMVEXXY",
        "label": "Foreign Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Member",
        "label": "Foreign Patents Member"
       }
      }
     },
     "localname": "ForeignPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Progesterone Formulations",
        "label": "Foreign Patents Progesterone Formulations"
       }
      }
     },
     "localname": "ForeignPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patent Transdermal Patch",
        "label": "Foreign Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "ForeignUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patents IMVEXXY",
        "label": "Foreign Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FourCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Four Customers Concentration Risk Member",
        "label": "Four Customers Concentration Risk Member"
       }
      }
     },
     "localname": "FourCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyBijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMVEXXY, BIJUVA and ANNOVERA",
        "label": "IMVEXXY, BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "ImvexxyBijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "Imvexxy [Member]"
       }
      }
     },
     "localname": "ImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Individual employee annual compensation maximum for payroll costs under loan.",
        "label": "Individual employee annual compensation maximum for payroll costs under loan"
       }
      }
     },
     "localname": "IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness.",
        "label": "Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness"
       }
      }
     },
     "localname": "IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Individual employee salary reduction specified percentage for reduction of loan forgiveness.",
        "label": "Individual employee salary reduction specified percentage for reduction of loan forgiveness"
       }
      }
     },
     "localname": "IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LesseeOperatingLeaseExistenceOfOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number of options to extend lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtendNumber",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future rented area to be occupied for administrative office space as defined in lease.",
        "label": "Lease not yet commenced (area)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedArea",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseAgreementWithPopulationCouncilPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement With Population Council",
        "label": "License Agreement with the Population Council"
       }
      }
     },
     "localname": "LicenseAgreementWithPopulationCouncilPolicyTextBlock",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights, net"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "Maximum costs and expenses for post approval"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum percentage of forgiven amounts for nonpayroll costs under loan.",
        "label": "Maximum percentage of forgiven amounts for nonpayroll costs under loan"
       }
      }
     },
     "localname": "MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments upon FDA approval.",
        "label": "Milestone payment upon FDA Approval"
       }
      }
     },
     "localname": "MilestonePaymentUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksForVitaminsSupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiple Trademarks For Vitamins Supplements Member.",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksForVitaminsSupplementsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetRentableAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area as defined in lease.",
        "label": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableAreaLease",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NewSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New shares",
        "label": "New Shares [Member]"
       }
      }
     },
     "localname": "NewSharesMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of customers - revenue"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of principal installment payments under credit and security agreement.",
        "label": "Number of quarterly principal installment payments"
       }
      }
     },
     "localname": "NumberOfInstallmentPayments",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to warrants exercised in cashless transaction.",
        "label": "Number of stock issued in cashless exercise of warrants"
       }
      }
     },
     "localname": "NumberOfStockIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of subsidiaries for period reported.",
        "label": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "Number of tranches under term loan facility"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Paycheck Protection Program Loan",
        "label": "Paycheck Protection Program Loan [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrepaidManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid manufacturing costs.",
        "label": "Prepaid manufacturing"
       }
      }
     },
     "localname": "PrepaidManufacturing",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFeeFifthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fifth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFifthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeForFirstTwoYearsFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee for first two years funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeForFirstTwoYearsFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeFourthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fourth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFourthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeThirdYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee third year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeThirdYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrimeRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prime rate floor.",
        "label": "Prime rate floor"
       }
      }
     },
     "localname": "PrimeRateFloor",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RentedAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rented area as defined in lease.",
        "label": "Rented area lease"
       }
      }
     },
     "localname": "RentedAreaLease",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_RepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The repayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Repayment fee percentage"
       }
      }
     },
     "localname": "RepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RepaymentOfDebtWithNewCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.",
        "label": "Repayment of debt with new credit facility"
       }
      }
     },
     "localname": "RepaymentOfDebtWithNewCreditFacility",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ReturnPeriodOfUnsalablePrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the company accepts returns of unsalable prescription products from customers following product expiration.",
        "label": "Return period of unsalable prescription products"
       }
      }
     },
     "localname": "ReturnPeriodOfUnsalablePrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Supplemental lease information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.",
        "label": "Range - exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Weighted average exercise price, unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShelfLifeOfPrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period shelf life of prescription products from date of manufacture.",
        "label": "Shelf life of prescription products following product expiration"
       }
      }
     },
     "localname": "ShelfLifeOfPrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_SignificantSupplyCommitmentPercentagePayable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.",
        "label": "Significant supply commitment percentage payable"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentPercentagePayable",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SupplierFourConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplier Four Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierFourConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierOneConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplier One Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierOneConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierThreeConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Three Concentration Risk Member",
        "label": "Supplier 3"
       }
      }
     },
     "localname": "SupplierThreeConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierTwoConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Two Concentration Risk Member",
        "label": "Supplier 2"
       }
      }
     },
     "localname": "SupplierTwoConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Three as defined in financing agreement.",
        "label": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two as defined in financing agreement.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_VitaminsAndImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vitamins and IMVEXXY",
        "label": "Vitamins and IMVEXXY [Member]"
       }
      }
     },
     "localname": "VitaminsAndImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsCashlessExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants - Cashless Exercise",
        "label": "Warrants - Cashless Exercise [Member]"
       }
      }
     },
     "localname": "WarrantsCashlessExerciseMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Member",
        "label": "Warrants Member"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20200331",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r40",
      "r92",
      "r312",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Amounts due to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r24",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts of $781,419 and $904,040, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r9",
      "r43",
      "r211"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r79",
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r217",
      "r219",
      "r256",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r146",
      "r151",
      "r152",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r63",
      "r79",
      "r295"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing fees",
        "verboseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r79",
      "r159",
      "r167"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r124",
      "r133",
      "r139",
      "r149",
      "r274",
      "r276",
      "r283",
      "r342",
      "r354"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r54",
      "r87",
      "r149",
      "r274",
      "r276",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r220",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r36",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r284"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r196",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r196",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r180",
      "r346",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - See Note 15"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note10NetLossPerShareDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 350,000,000 shares authorized: 271,677,742 and 271,177,076 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r116",
      "r117",
      "r143",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r143",
      "r280",
      "r281",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r143",
      "r280",
      "r281",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r116",
      "r117",
      "r143",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r114",
      "r116",
      "r117",
      "r118",
      "r280",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r116",
      "r117",
      "r143",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65",
      "r326"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r115",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r343",
      "r344",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r183",
      "r344",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r45",
      "r185",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r46",
      "r90",
      "r191",
      "r192",
      "r193",
      "r194",
      "r293",
      "r294",
      "r296",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r293",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r184",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Debt discount and financing fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r53",
      "r295"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt financing fees on undrawn tranches (Note 9)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred financing fees"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r172"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r79",
      "r172"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "The following table provides information about disaggregated revenue by product mix"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss per share, basic and diluted:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "NOTE 10 \u2013 NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r112",
      "r150",
      "r190",
      "r195",
      "r251",
      "r252",
      "r253",
      "r264",
      "r265",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r84",
      "r278",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "2020 (9 months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r160",
      "r163",
      "r166",
      "r170",
      "r327",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r166",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r160",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r166",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "License rights acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r79",
      "r187",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "NOTE 7 \u2013 INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r64",
      "r87",
      "r124",
      "r132",
      "r135",
      "r138",
      "r140",
      "r149",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r124",
      "r132",
      "r135",
      "r138",
      "r140",
      "r341",
      "r347",
      "r351",
      "r360"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r266",
      "r268",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "NOTE 12 \u2013 INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note12IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r104",
      "r105",
      "r123",
      "r260",
      "r267",
      "r269",
      "r361"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r162",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r162",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r158",
      "r164"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r57",
      "r122",
      "r292",
      "r295",
      "r350"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r69",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r76",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "NOTE 4 \u2013 INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r52"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "verboseLabel": "TOTAL INVENTORY"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "The following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities recorded on the balance sheet:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2020 (9 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r87",
      "r134",
      "r149",
      "r275",
      "r276",
      "r277",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r87",
      "r149",
      "r283",
      "r345",
      "r356"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r87",
      "r149",
      "r275",
      "r276",
      "r277",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r20",
      "r21",
      "r87",
      "r149",
      "r275",
      "r276",
      "r277",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "verboseLabel": "TOTAL LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "NOTE 9 \u2013 DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfMarch312020AndDecember312019CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r113",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NOTE 1 \u2013 THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r60",
      "r80",
      "r87",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r124",
      "r132",
      "r135",
      "r138",
      "r140",
      "r149",
      "r283",
      "r348",
      "r359"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r124",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtMarch312020ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term operating lease liability (included in Other current liabilities)",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r300",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for amounts included in the measurement of lease liabilities for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r305",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAmortizationOfDeferredCharges": {
     "auth_ref": [
      "r66",
      "r79"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization of other deferred costs recognized in the income statement.",
        "label": "Amortization of license fee"
       }
      }
     },
     "localname": "OtherAmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "NOTE 5 \u2013 OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other current liabilities consist of the following:"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "verboseLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r6",
      "r157"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r220",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r6",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r72",
      "r91"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Financing Agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r250"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "NOTE 6 \u2013 FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "TOTAL FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r175",
      "r357"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "verboseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Fixed assets, net consist of the following:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r61",
      "r153"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "(Recovery of) provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r30",
      "r84",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r213",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Amount billed"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r213",
      "r310",
      "r313",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r308",
      "r309",
      "r311",
      "r314",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "NOTE 13 \u2013 RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r259",
      "r378"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r195",
      "r254",
      "r355",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r150",
      "r251",
      "r252",
      "r253",
      "r264",
      "r265",
      "r366",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r120",
      "r121",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r206",
      "r207",
      "r326"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Product revenue, net",
        "terseLabel": "Total revenue, net",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r58",
      "r87",
      "r120",
      "r121",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r149",
      "r283",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r116",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "As of March 31, 2020 and December 31, 2019, the carrying value of our debt consisted of the following:"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r160",
      "r165",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfMarch312020AndDecember312019Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory consists of the following:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Other current assets consist of the following:"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r89",
      "r312",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r233",
      "r237",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Restricted stock and performance stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r220",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r225",
      "r237",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and 2019 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average grant date fair value, granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, ending",
        "periodStartLabel": "Number of shares, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, ending",
        "periodStartLabel": "Weighted average grant date fair value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, vested/released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted average grant date fair value, vested/released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r226",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares under options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares under options, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares under options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r227",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, ending",
        "periodStartLabel": "Number of shares under options, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending",
        "periodStartLabel": "Weighted average exercise price, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number of shares under options, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r218",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/RestrictedStockAndPerformanceStockAwardsDetails",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r84",
      "r220",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r243",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ValuationMethodologyUsedToDetermineFairValueOfStockOptionsIsBlack-scholesModel.Black-scholesModelRequiresUseOfNumberOfAssumptionsIncludingVolatilityOfStockPriceRisk-freeInterestRateAndExpecDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Number of shares under options, unvested ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r112",
      "r150",
      "r190",
      "r195",
      "r251",
      "r252",
      "r253",
      "r264",
      "r265",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r112",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r216",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r22",
      "r23",
      "r190",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Issuance of shares from release of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r190",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r190",
      "r195",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued for exercise of options, net (in shares)",
        "negatedLabel": "Number of shares under options, exercised",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringThreeMonthsEndedMarch312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r190",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Issuance of shares from release of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r190",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued for exercise of options, net",
        "verboseLabel": "Stock Issued During Period, Value, Stock Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r87",
      "r148",
      "r149",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' (Deficit) Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r291",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r291",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r291",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r291",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "NOTE 16 \u2013 SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r381": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r382": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r388": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r389": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r391": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r392": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r393": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r394": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r395": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r396": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r397": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806484496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY (Details Narrative)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiaries', window );">Number of subsidiaries</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaries for period reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806524048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1Xqlb9M1Gl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
11 &#8211; STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, we had <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pii_uShares_c20200331_znrHRL9qs4Hc" title="Preferred Stock, Shares Authorized">10,000,000</span> shares of Preferred Stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_za1QWerwgQbb" title="Preferred Stock, Par or Stated Value Per Share">0.001</span>, authorized for issuance, of which <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dco_uShares_c20200331_zKrCmd6DN4Qe" title="Preferred Stock, Shares Outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_dco_uShares_c20200331_zkQ2gUpduxol" title="Preferred Stock, Shares Issued">no</span></span> shares of
Preferred Stock were issued or outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, we had <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pii_uShares_c20200331_z94hCnJ5EfC3" title="Common Stock, Shares Authorized">350,000,000</span> shares of Common Stock authorized for issuance, of which <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pii_uShares_c20200331_zihrDmrHmcY6" title="Common Stock, Shares, Issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pii_uShares_c20200331_zmYcMTHm3u28" title="Common Stock, Shares, Outstanding">271,677,742</span></span> shares of Common Stock
were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three Months ended March 31, 2020</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgFFhaU8wdVa">350,666</span> shares
of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxaNWM1oU1xb">72,109</span> in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Issuances
During the Three Months ended March 31, 2019</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2019, certain individuals exercised stock options to purchase an aggregate of<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi55ceFgC474"> 276,383</span> shares
of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6Jmo87fggl6">100,107</span> in cash. Also, during the same period, stock options to purchase an aggregate of <span id="xdx_90D_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_pii_uShares_c20190101__20190331_z0r9opzOofEl" title="Number of stock options exercised in cashless exercise (in shares)">12,097</span> shares of
Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_90E_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_pii_uShares_c20190101__20190331_zfBXB9X0ObPl" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)">11,834</span> shares
of Common Stock were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants
to Purchase Common Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, we had warrants outstanding to purchase an aggregate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_uUSD_c20200331_zMyMyga61Fzb" title="Warrants and Rights Outstanding">1,832,571</span> shares of Common Stock with a weighted-average
contractual remaining life of approximately <span id="xdx_901_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200331_z5py9rYo5zn5" title="Weighted-average contractual remaining life">1.70</span> years, and exercise prices ranging from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zg9qg43sgDcg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.24</span> to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zZrlLqRCeP21" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">8.20</span> per share, resulting in
a weighted average exercise price of $<span id="xdx_905_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2HwQfHCzLda" title="Weighted average exercise price of warrants (in dollars per share)">2.62</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020, no warrants were granted. During the three months ended March 31, 2019, we granted
warrants to purchase an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z43EwiFLovu" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted">75,000</span>
shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zLu6Ri5v0Ldi" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">5.63</span>.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of <span title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term">five </span>years;
volatility of <span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy4rxCZ0thV8" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate">60.8</span>%;
risk free rate of<span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zDsSrF0xkOp9" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate">
2.52</span>%; and dividend yield of<span id="xdx_90B_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zkFxhg4ltlai" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate">
0</span>%. The grant date fair value of the warrants was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNz27QtBvNph" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value">3.00</span>
per share. The warrants vested ratably over a <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HN4rtQyoAe" title="Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period">12</span>-month
period and have an expiration date of February 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the three months ended March 31, 2020, no warrants were exercised</span><span style="font: 10pt Times New Roman, Times, Serif">.
<span style="background-color: white">During the three months ended March 31, 2019, warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQC1Yf7JAvP8" title="Warrants exercised">1,250,000</span>
shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, wherein an aggregate of <span id="xdx_90C_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zhsHssI0ZHJf" title="Number of stock issued in cashless exercise of warrants">471,184</span>
shares of Common Stock were issued.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zuAfZEz40GZ8" title="Share-based Payment Arrangement, Noncash Expense">26,446</span> and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zzM2jcypKTc4" title="Share-based Payment Arrangement, Noncash Expense">85,716</span> for the three months ended
March 31, 2020 and 2019, respectively, in the accompanying consolidated financial statements. At March 31, 2020, there was no
unrecognized estimated compensation expense related to unvested warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options
to Purchase Common Stock of the Company</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of March 31, 2020, there were non-qualified
stock options to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zXeLwbqbYKqi" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">14,546,246</span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our
adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made
under the 2009 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of March 31, 2020, there were non-qualified stock options to purchase an aggregate
of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zaH8D5lv078g" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">6,316,474</span> shares of Common Stock outstanding and an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjStbGeUG8j7" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number">890,000</span> restricted stock awards under the 2012 Plan. Effective
upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, there were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4CqiMq1gYb" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">4,970,994</span> shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NewSharesMember_zxxsuA3aeEma">2,354,764</span>
new shares, (ii) <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zGNvI4t8Ib98" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">2,395,333</span> unallocated shares previously available for issuance under the 2012 Plan that were not then subject
to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii) <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z25uuN8xGTCc" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized">220,897</span> unallocated shares previously available for
issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any
shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan
that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for
cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered
or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which
those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance,
again be available for delivery with respect to Awards under the 2019 Plan. As of March 31, 2020, there were non-qualified stock
options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zbPiaDrJqWS9" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number">4,292,501</span> shares of Common Stock outstanding under the 2019 Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--Plan2019Member_z4AxfPTi3V2j" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">3,584,245</span> restricted stock awards and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--Plan2019Member_zY5W37PTsAS5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number">2,384,245</span>
performance stock awards outstanding under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmiZZrXoInTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and
2019 are set forth in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Weighted average grant date fair value</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKT3HpcC3Ctk" style="width: 12%; text-align: right" title="Weighted average grant date fair value">0.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKCm4GBhbZ64" style="width: 12%; text-align: right" title="Weighted average grant date fair value">3.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAoURtu9Slh2" style="font: 10pt Times New Roman, Times, Serif">1.32</span><span style="font: 10pt Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrhE696UcnGe">1.68</span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zclHBCYrH4Y8" style="text-align: right" title="Risk-free interest rate">2.54</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKbbd5VICeke" title="Volatility - minimum">63.53</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyNJb5gWKHf9" title="Volatility - maximum">65.72</span></span></td><td style="text-align: left">&#160;%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zp37dwdC0gd" style="text-align: right" title="Volatility">61.85</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zBqThQyn9EH2" title="Term">6</span>-<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zI3qCxPIUrU9" title="Term">6.7</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm4RzCP1iPK" style="text-align: right" title="Term">6.25</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRCbPvXZsR1g" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z97xFrXVFlxg" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td></tr>
</table>

<p id="xdx_8AA_zr8Sxn6nkEO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCouQC6ZD5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Under Options</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Remaining Contractual <br/>Life
    in Years</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 39%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF74Vd7stZY6" style="width: 11%; text-align: right" title="Number of shares under options, beginning">25,030,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg5erwQ0O0H1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning">4.65</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlNh1WMeN8Tk" style="width: 11%; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nHUxpATmu4" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning">3,668,171</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIrW2Q4UU0yl" style="text-align: right" title="Number of shares under options, granted">636,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKkPU4yQi8b" style="text-align: right" title="Weighted average exercise price, granted">1.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPDM0gLWg4I4" style="text-align: right" title="Number of shares under options, exercised">(350,666</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEkpJ98J88v9" style="text-align: right" title="Weighted average exercise price, exercised">0.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKMQTcpYeBii" style="text-align: right" title="Aggregate intrinsic value, exercised">725,199</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9eD9aqL6MO8" style="text-align: right" title="Number of shares under options, expired">(50,472</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gOKEtgi3Al" style="text-align: right" title="Weighted average exercise price, expired">0.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">&#160;&#160;Cancelled/Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyA0VXRGp0Xc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited">(110,375</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HEMrytqGP7" style="text-align: right" title="Weighted average exercise price, cancelled forfeited">4.48</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR85TrJIPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending">25,155,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35NKobVHVH5" style="text-align: right" title="Weighted average exercise price, ending">4.65</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvu9zkcQx5pg" style="text-align: right" title="Weighted average remaining contractual life">5.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjmPJFz78dti" style="text-align: right" title="Aggregate intrinsic value, ending">787,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vested and Exercisable at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTP5Y15iGVAc" style="text-align: right" title="Number of shares under options, vested and exercisable ending">19,258,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7MNd8qOHPMd" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending">5.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ye87I9gl87" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable">4.77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_uUSD_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zucj29CP0SH6" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">787,178</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHbMwgnL9hrg" style="text-align: right" title="Number of shares under options, unvested ending">5,896,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKAsY49mCuXg" style="text-align: right" title="Weighted average exercise price, unvested ending">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3rZDaT0F483" style="text-align: right" title="Weighted average remaining contractual life, unvested">9.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_za27Ur5hVJU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
March 31, 2020, our outstanding options had exercise prices ranging from $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MinimumMember_z2zcK2shnuD8" title="Range - exercise price of options">0.19</span> to $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MaximumMember_zsWv4cXD5p69" title="Range - exercise price of options">8.92</span> per share. Share-based compensation expense
related to options recognized in our results of operations for the three months ended March 31, 2020 and 2019 was approximately
$<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8Oalng9xOC3" title="Share-based Payment Arrangement, Noncash Expense">1,836,630</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8ophyRUIDAl" title="Share-based Payment Arrangement, Noncash Expense">2,143,239</span>, respectively, and it is based on awards vested. At March 31, 2020, total unrecognized estimated compensation
expense related to unvested options was approximately $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_uUSD_c20200331_zRML7RPGHnm5" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount">9,800,000</span>, which may be adjusted for future changes in forfeitures. This
cost is expected to be recognized over a weighted-average period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaONmS9Je3Ak" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">2.3</span> years. No tax benefit was realized due to a continued
pattern of operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Restricted
Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Performance
stock awards will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into common stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. Based upon the expected
levels of achievement, stock-based compensation is recognized on a straight-line basis over the awards&#8217; requisite service
periods. The expected levels of achievement are reassessed over the requisite service periods and, to the extent that the expected
levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2020 and 2019, we recorded $<span id="xdx_907_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20200101__20200331_zymRAM7dloi3" title="Restricted Stock or Unit Expense">503,377</span> and $<span id="xdx_903_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20190101__20190331_z55Q3WhfHaLb" title="Restricted Stock or Unit Expense">346,414</span>, respectively, in share-based compensation expense
related to restricted stock units and performance stock awards. At March 31, 2020, total unrecognized estimated compensation expense
related to unvested restricted stock units and performance stock awards was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_uUSD_c20200331_zGZpPEt96H98" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount">9,830,000</span>, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7TixGtmu7T2" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">2.6</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8Mso4923Ztl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock and performance stock awards (Details)">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Restricted
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Performance
Stock Awards</b></span></p>

</td><td style="padding-bottom: 1pt; text-align: left"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
                                         of Shares</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b/></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
                                         Average Grant Date Fair Value</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance at December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfs80wXB0Y6" style="width: 12%; text-align: right" title="Number of shares, beginning">1,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1gikQdahEX7" style="text-align: right" title="Weighted average grant date fair value, beginning">3.56</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right" title="Number of shares, beginning">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Weighted average grant date fair value, beginning">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDPV5o0aOG94" style="text-align: right" title="Number of shares, granted">3,384,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgCPBNvZ4a9i" style="text-align: right" title="Weighted average grant date fair value, granted">1.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8L3oT6dXQG6" style="text-align: right" title="Number of shares, granted">2,384,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhdvXun1r73j" style="text-align: right" title="Weighted average grant date fair value, granted">1.07</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">&#160;&#160;Vested/Released</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsSLdiyKRYI7" style="text-align: right" title="Number of shares, vested/released">(150,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znw5y3XsKQba" style="text-align: right" title="Weighted average grant date fair value, vested/released">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">&#160;&#160;Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1kzQucs7e08" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">4,474,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKxgxHQZES9d" style="text-align: right" title="Weighted average grant date fair value, ending">2.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zCUDguZmo065" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending">2,384,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5SxZglFc9d2" style="text-align: right" title="Weighted average grant date fair value, ending">1.07</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"/>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806487664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">NOTE 7 &#8211; INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zchYb4KgHkol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
7 &#8211; INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zz26GotF80U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of March 31, 2020 and December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization<br/>
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved hormone therapy
    drug&#160;candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zXYDMwse61td" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross">3,763,022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaYaXoZo6IQ4" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(542,235</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZXtiuvXLzR6" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net">3,220,787</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zuNk95uCDdvh" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period">12.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents&#160;(pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zQL8AYkzExfd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">2,070,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z0LxzXYIEQZj" style="text-align: right" title="Finite-Lived Intangible Assets, Net">2,070,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedTrademarks_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zPBhk7RG6V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">325,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zG6sPBcYD03f" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">325,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20200331_zq4h23lLuIF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">6,159,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331_zKOzPdRlfZf4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(542,235</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20200331_zUUFmVblveIb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)">5,616,832</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization<br/>
    Period (yrs.)</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%">Approved
    hormone therapy drug candidate patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zWdHV07R0ln5" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross">3,463,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlLY2WFRzgc" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(478,983</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z1w0tlUPrEFk" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net">2,984,099</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z5znApwOIz0b" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period">13</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Hormone therapy drug candidate
    patents (pending)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zC5bjbT3nExd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zdozuDJ6LcK2" style="text-align: right" title="Finite-Lived Intangible Assets, Net">1,979,299</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.4pt">Non-amortizable intangible assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z29Jjza7Nu91" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z99mUIIQEEYa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)">294,813</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"><span style="font: 10pt Times New Roman, Times, Serif">indefinite</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zCT9dsXR8CKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)">5,737,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231_ztH7zn4WIg4h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization">(478,983</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zySQa7F4hnLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)">5,258,211</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zjAVe5tarN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
remaining useful life of approximately <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4AdkH3TiQAl" title="Finite-Lived Intangible Asset, Useful Life">20 years</span>, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the three months
ended March 31, 2020 and 2019, there was no impairment recognized related to intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020, we had <span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zlYMmPLfutXc" title="Number of issued patents">31</span> issued domestic patents and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zF99eSKBW4L1" title="Number of issued patents">30</span> issued foreign patents, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_ztaC2pG7aWte" title="Number of issued patents">12</span>
                                         domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zDHTu95403lc" title="Number of issued patents">six</span> foreign patents that relate to BIJUVA as well as <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zz9qg1mEZT2j" title="Number of issued patents">three</span> domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa,
                                         and South Korea.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zCHpH7QebU58" title="Number of issued patents">Eight</span>
                                         domestic patents (<span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zshl8nuM7qpc" title="Number of issued patents">seven</span> utility and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_z1LgpjXnxlt4" title="Number of issued patents">one</span> design) and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zNqvYmWd0nj6" title="Number of issued patents">13</span> foreign patents (<span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zHw275ubTqX2" title="Number of issued patents">three</span> utility
                                         and <span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zMyw6z8tSNda" title="Number of issued patents">ten</span> design) that relate to IMVEXXY. These patents establish an important intellectual
                                         property foundation for IMVEXXY and are owned by us. The domestic patents will expire
                                         in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
                                         design patents provide protection expiring no earlier than 2025. In certain countries,
                                         the foreign design patents provide protection through at least 2037. In addition, we
                                         have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia,
                                         Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and
                                         South Korea.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zALZa2wd5yU5" title="Number of issued patents">One</span>
                                         domestic utility patent that relates to our topical-cream candidates, which is owned
                                         by us. The domestic patent will expire in 2035.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zAp0jQPvCoy4" title="Number of issued patents">One</span>
                                         domestic utility patent and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_z6AbjCt5eGO9" title="Number of issued patents">seven</span> foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zxwEj0sV9UVb" title="Number of issued patents">Three</span>
                                         domestic utility patents that relate to TX-009HR, a progesterone and estradiol product
                                         candidate, which are owned by us and will expire in 2037.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_z7u8Ezm78BP7" title="Number of issued patents">Two</span>
                                         domestic and <span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zeNjMqryknu1" title="Number of issued patents">four</span> foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033. In addition, we have pending patent applications
                                         with respect formulations containing progesterone in the U.S., Australia, Brazil, Canada,
                                         Europe, and Mexico.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zVQ7EaGrZpF9" title="Number of issued patents">One</span>
                                         domestic utility patent that relates to our OPERA information-technology platform, which
                                         is owned by us and will expire in 2031.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Amortization
expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200331_z311hmLPbDl3" title="Amortization of intangible assets">63,155</span>
and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190331_zUPwGLWCClea" title="Amortization of intangible assets">40,444</span>
for the three months ended March 31, 2020 and 2019, respectively.</span></p>

<p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z8wXdGjBstB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Estimated amortization expense,
based on current patent cost being amortized, for the next five years is as follows:</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2020 (9&#160;months)</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20200331_zc3KUbdVRHV4" style="width: 10%; text-align: right" title="2020 (9 months)">189,464</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20200331_zzf1CjRqXSY6" style="text-align: right" title="2021">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20200331_zGgaIHw2eKxh" style="text-align: right" title="2022">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20200331_zmn5PDCaunmk" style="text-align: right" title="2023">252,618</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20200331_zgrCptqyKUAd" style="text-align: right" title="2024">252,618</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AE_zFb5bb3Ku6s7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809186912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental lease information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 9,757,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,109,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability (included in Other current liabilities)</a></td>
<td class="nump">1,753,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 8,782,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,145,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities for operating lease</a></td>
<td class="nump">$ 327,386<span></span>
</td>
<td class="nump">$ 279,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,760,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809165408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted stock and performance stock awards (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, beginning | shares</a></td>
<td class="nump">1,240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning | $ / shares</a></td>
<td class="nump">$ 3.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">3,384,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested/released | shares</a></td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested/released | $ / shares</a></td>
<td class="nump">$ 2.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending | shares</a></td>
<td class="nump">4,474,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">2,384,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending | shares</a></td>
<td class="nump">2,384,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810366864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810400176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 198,839<span></span>
</td>
<td class="nump">$ 66,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6820896992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 170,097,813<span></span>
</td>
<td class="nump">$ 160,829,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $781,419 and $904,040, respectively</a></td>
<td class="nump">20,664,009<span></span>
</td>
<td class="nump">24,395,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,607,453<span></span>
</td>
<td class="nump">11,860,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,618,367<span></span>
</td>
<td class="nump">11,329,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">211,987,642<span></span>
</td>
<td class="nump">208,416,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">2,330,190<span></span>
</td>
<td class="nump">2,507,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights, net</a></td>
<td class="nump">38,475,797<span></span>
</td>
<td class="nump">39,221,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,616,832<span></span>
</td>
<td class="nump">5,258,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">9,757,167<span></span>
</td>
<td class="nump">10,109,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other assets</a></td>
<td class="nump">473,009<span></span>
</td>
<td class="nump">473,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">54,322,805<span></span>
</td>
<td class="nump">55,061,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">268,640,637<span></span>
</td>
<td class="nump">265,985,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">28,714,327<span></span>
</td>
<td class="nump">19,181,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">32,924,485<span></span>
</td>
<td class="nump">33,823,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">61,638,812<span></span>
</td>
<td class="nump">53,004,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">243,428,671<span></span>
</td>
<td class="nump">194,634,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">8,782,274<span></span>
</td>
<td class="nump">9,145,049<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">252,210,945<span></span>
</td>
<td class="nump">203,779,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">313,849,757<span></span>
</td>
<td class="nump">256,784,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (Deficit) Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized: 271,677,742 and 271,177,076 issued and outstanding, respectively</a></td>
<td class="nump">271,678<span></span>
</td>
<td class="nump">271,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">706,789,283<span></span>
</td>
<td class="nump">704,351,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(752,270,081)<span></span>
</td>
<td class="num">(695,421,279)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(45,209,120)<span></span>
</td>
<td class="nump">9,201,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 268,640,637<span></span>
</td>
<td class="nump">$ 265,985,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811963184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (56,848,802)<span></span>
</td>
<td class="num">$ (39,506,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">198,839<span></span>
</td>
<td class="nump">66,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">63,155<span></span>
</td>
<td class="nump">40,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">351,987<span></span>
</td>
<td class="nump">219,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">(Recovery of) provision for doubtful accounts</a></td>
<td class="num">(122,621)<span></span>
</td>
<td class="nump">82,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,366,453<span></span>
</td>
<td class="nump">2,586,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="nump">319,408<span></span>
</td>
<td class="nump">120,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of license fee</a></td>
<td class="nump">745,511<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">3,854,569<span></span>
</td>
<td class="num">(3,963,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,746,737)<span></span>
</td>
<td class="num">(1,688,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets</a></td>
<td class="nump">4,436,047<span></span>
</td>
<td class="nump">987,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">9,533,115<span></span>
</td>
<td class="nump">2,621,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,261,904)<span></span>
</td>
<td class="nump">268,939<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,110,980)<span></span>
</td>
<td class="num">(38,163,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(421,775)<span></span>
</td>
<td class="num">(403,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(21,254)<span></span>
</td>
<td class="num">(262,418)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(443,029)<span></span>
</td>
<td class="num">(665,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">72,109<span></span>
</td>
<td class="nump">100,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">48,822,109<span></span>
</td>
<td class="nump">100,107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash</a></td>
<td class="nump">9,268,100<span></span>
</td>
<td class="num">(38,729,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">160,829,713<span></span>
</td>
<td class="nump">161,613,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">170,097,813<span></span>
</td>
<td class="nump">122,883,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 5,892,639<span></span>
</td>
<td class="nump">$ 1,913,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>txmd-10q_033120_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20200331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20200331.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_VitaminsAndImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUSPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticPatentsNonApprovedBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUSPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUSUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUSDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTopicalCreamCandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUtilityPatentTx009HRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ForeignPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_DomesticUtilityPatentOperaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-16</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_WarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_WarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_WarrantMember348335407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_WarrantsCashlessExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_NewSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NewSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RestrictedStockMember_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_PerformanceSharesMember_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SupplierFourConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierFourConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_SupplierOneConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierOneConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_custom_SupplierFourConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierFourConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_FiveCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FiveCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPharmacyInnovationsPaRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2013-06-302013-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2013-06-30</startDate>
            <endDate>2013-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="AsOf2019-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-01</instant>
        </period>
    </context>
    <context id="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-27</instant>
        </period>
    </context>
    <context id="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">txmd:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-26</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-03-31" id="xdx2ixbrl0049">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-03-31"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-03-31"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-01to2020-03-31"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-01-012019-03-31"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-012019-03-31"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-012019-03-31"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      id="xdx2ixbrl0891"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-01-01to2020-03-31"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2020-01-01to2020-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2020-01-01to2020-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-03-31">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-03-31">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-03-31">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-03-31">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-03-31">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-01-01to2020-03-31">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-03-31">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-03-31">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-03-31">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-03-31">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-03-31">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-03-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-03-31">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-03-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-05-01" decimals="INF" unitRef="Shares">271683266</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">170097813</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">781419</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">20664009</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">24395958</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">14607453</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6618367</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">211987642</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">208416180</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2330190</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">38475797</txmd:LicenseRights>
    <txmd:LicenseRights contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">39221308</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">5616832</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">9757167</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">54322805</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">55061682</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">268640637</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">28714327</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">19181212</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">32924485</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">61638812</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">53004825</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">243428671</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">8782274</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">252210945</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">203779692</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">313849757</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">256784517</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">271677742</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">271677742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">271678</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">271177</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">706789283</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">704351222</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-752270081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-695421279</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-45209120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">268640637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">12250657</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">3946651</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">2715051</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">762827</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">9535606</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">3183824</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">56927021</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">34864082</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">3268829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">6317882</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">261994</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">106938</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">60457844</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">41288902</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-50922238</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-38105078</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">335482</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">688721</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">6262046</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2090018</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-5926564</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-1401297</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-03-31"
      decimals="INF"
      unitRef="Shares">271459522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="Shares">241006032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">759401</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">759</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">99348</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">100107</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">619234655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-558782655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">60693222</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">704351222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-695421279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">350666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">351</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">71758</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">72109</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2366453</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">2366453</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271677742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">706789283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-752270081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-45209120</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-56848802</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">198839</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">66494</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">63155</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">40444</us-gaap:AmortizationOfIntangibleAssets>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">351987</txmd:NoncashOperatingLeaseExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">219765</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-122621</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">82284</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">2366453</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2586948</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">319408</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">745511</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-3854569</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">3963214</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">2746737</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">1688045</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-4436047</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-987794</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">9533115</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2621402</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-1261904</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">268939</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-39110980</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-38163418</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">421775</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">403496</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">21254</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">262418</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">-443029</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-665914</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">72109</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">100107</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">1250000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">48822109</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">100107</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">9268100</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-38729225</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">170097813</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">122883852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">5892639</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">1913956</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zCf0mFzoW4vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
1 &#x2013; &lt;span&gt;THE COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has &lt;span id="xdx_905_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20200331_zg7eQzOXdG8f" title="Number of subsidiaries"&gt;three&lt;/span&gt; wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#x201c;our company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d;
TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;, BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt; and BIJUVA&lt;sup&gt;&#xae;
&lt;/sup&gt;are registered trademarks of our company and ANNOVERA&#x2122; is a licensed trademark of our company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Nature
of Business&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the
lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical
expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women.
Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical
products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and
BocaGreenMD brands. Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and
marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval
of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development
to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY
(estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved
product BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#xdf;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our
FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only
patient-controlled, procedure-free, reversible prescription contraceptive option for women. Although we expected to commence
the full commercial launch of ANNOVERA in the first quarter of 2020, as a result of the uncertainty surrounding the COVID-19
pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as
the pandemic began to negatively affect our revenue growth. On July 30, 2018, we entered into an exclusive license agreement,
or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize
ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License
Agreement, with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply
agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY
outside of the U.S., excluding Canada and Israel, or the Theramex Territory.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiaries contextRef="AsOf2020-03-31" decimals="INF" unitRef="Pure">3</txmd:NumberOfSubsidiaries>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqs0mBmK3lt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
2 &#x2013; &lt;span&gt;BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Interim
Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2019. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are subject to risks and uncertainties as a result of the&#160;COVID-19 pandemic. The extent of the impact of the&#160;COVID-19
pandemic on our business is highly uncertain and difficult to predict, as the response to the pandemic is in its incipient stages
and information is rapidly evolving. At this time,&#160;we continue to provide an uninterrupted supply of our portfolio of products
for patients. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional
product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture
of our products.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have activated virtual options to ensure business continuity. Our VitaCare Prescription Services patient model assists patients
in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice, including via
home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple third-party online
pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time access to both
diagnosis and treatment. We continue to support prescribers&#x2019; needs with samples and product materials through our sales
force. If access is restricted, we currently have mailing options in place for these materials. We also have business continuity
plans and infrastructure in place that allows for virtual detailing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have also implemented measures to cut planned marketing expenses for 2020. However, we have the ability to re-accelerate our
planned marketing spend for ANNOVERA and IMVEXXY should market conditions improve, or to extend or expand the cost cuts
throughout 2020. We have also implemented cost savings which include negotiating lower fees or suspending services from third
party vendors; implementing a company-wide hiring freeze; delaying or cancelling non-critical IT projects; and eliminating
travel, entertainment, meeting, and event expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
savings can be extended further throughout 2020 or expanded depending on the impact of the COVID-19 pandemic. We already have
sufficient inventory of finished product in our warehouses to meet anticipated demand through at least early third quarter of
2020. However, capital markets and economies worldwide have also been negatively impacted by the&#160;COVID-19 pandemic, and it
is possible that it could cause a local and/or global economic recession. Such economic disruption could have a material adverse
effect on our business. Policymakers globally have responded with fiscal policy actions to support the healthcare industry and
economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
severity of the impact of the&#160;COVID-19 pandemic on our business will depend on a number of factors, including, but not limited
to, the duration and severity of the pandemic and the extent and severity of the impact on our customers, all of which are uncertain
and cannot be predicted. Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding
receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives
or programs that we may undertake to address financial and operations challenges that we may face. As of the date of issuance
of these condensed consolidated financial statements, the extent to which the&#160;COVID-19 pandemic may materially impact our
financial condition, liquidity, or results of operations is uncertain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which
eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose
certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification,
or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the
notes to financial statements by focusing on requirements that clearly communicate the most important information to users of
the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and
for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions
that eliminate or modify requirements. We adopted this standard on January 1, 2020 and the adoption did not have a material effect
on our disclosures for the three months ended March 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments. The amendments in this update require a financial asset (or a group of financial assets) measured at amortized
cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and
reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the
first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an
other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach
and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13
requires expanded quantitative and qualitative disclosures about the Company&#x2019;s expected credit losses. Effective January
1, 2020, we&#160;adopted&#160;ASU&#160;2016-13&#160;under a modified retrospective approach for all financial assets measured
at amortized cost. There was no adjustment recorded for the cumulative effect of adopting&#160;ASU 2016-13. The adoption expanded
disclosures about our credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified
Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial
position.&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zbseyW5Kul43" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
3 &#x2013; &lt;span&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcDsiscBqahk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zVfQLBPHJG05"&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency.
We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results
of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement,
economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current&#160;COVID-19
pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible
that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_z0YGBG7DUQFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z11CO1OFronh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zb5WXYUcbjo3"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of March 31, 2020 (as disclosed in Note 9), approximates fair value based on market activity for other debt
instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, &lt;i&gt;Fair Value Measurements, &lt;/i&gt;or ASC 820&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the highest priority
to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level
3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs,
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
1&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
2&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
3&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;unobservable inputs for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
March 31, 2020 and 2019, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the three months ended March
31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_856_zv4cHFKehwo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrmNc7Fxmvkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_z2ve2i6okDGd"&gt;Share-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share
appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective
service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable
model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the
input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the
risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed
interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term
of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer
entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices &lt;/span&gt;over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our
stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January
1, 2020, the average expected life of options was based on the contractual terms of the stock option using the simplified
method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of share-based awards represent our best
estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the
future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value
estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the
employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January
1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with
the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718
to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an
entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued
to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
grant performance-based stock awards and restricted stock awards for shares of common stock to employees. We value our restricted
stock awards and our performance-based stock awards by reference to our stock price on the date of grant. We have elected to recognize
compensation expense on a straight-line basis over the requisite service period of the entire award. The number of target shares
that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the
awards, restricted stock is issued based on the level of attainment. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at the grant date and through the date the restricted stock vests.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_zjel9ti0dSVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1NAqlekhAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zSAXok5ZTlTc"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer obtains
control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled
to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine
revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect
to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract
with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance
obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription
Products&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we
began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started
selling ANNOVERA in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the
commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent
quarters. We sell our name brand and generic prescription products primarily through wholesale distributors and retail
pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is
to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies,
which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a
fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance
obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when
the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the
use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers
once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from
contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is
typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC,
determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated
product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts
earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is
payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to
determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either
utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract
or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to
the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence
that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the
magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may
differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates,
which would affect net product revenue and earnings in the period such changes in estimates become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_900_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200331__srt--RangeAxis__srt--MinimumMember_znIeOi1oJiaj" title="Return period of unsalable prescription products"&gt;six months&lt;/span&gt; prior
to and up to &lt;span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200331__srt--RangeAxis__srt--MaximumMember_zo4Ui1stUbal" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt; months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_90B_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zAfK3GGRO4B1" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt; months from the
date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zoUI68K6dNE7" title="Shelf life of prescription products following product expiration"&gt;18&lt;/span&gt; months from the date of manufacture. We do not allow
product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that
may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue
is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped
to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history
of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the
inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product
returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in other current liabilities on the consolidated
balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based
on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current
liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking
into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons
and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice
discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained
by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions
paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance
based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple
performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require
continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation
of revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BD_zYG13U0vCP7c"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt; for the three months ended March 31, 2020 and
2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue"&gt;2,473,691&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue"&gt;1,935,971&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue"&gt;6,392,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue"&gt;2,010,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue"&gt;1,111,604&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;ANNOVERA&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,272,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;12,250,657&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;3,946,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zui8XJd4ZQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_857_z6Hm98q6Y7Zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zf7maL1AmvPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zp0XoJVfiNs"&gt;License
Agreement with the Population Council&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#x201c;test and learn&#x201d; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $&lt;span&gt;&lt;span id="xdx_904_ecustom--MilestonePaymentUponFDAApproval_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzdSrj6ijlBd" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;
within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span id="xdx_90E_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_pp0p0_uUSD_c20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzlQOnkG2JM8" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;
within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_907_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zLVhFWipFgBk" title="License rights acquired"&gt;20,000,000&lt;/span&gt; were recorded
as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once
ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license
rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the
product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic
benefit cannot be reliably determined. During the three months ended March 31, 2020, we recorded $&lt;span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_uUSD_c20200101__20200331_zTaBPhlRojyd" title="Amortization of Intangible Assets"&gt;745,511&lt;/span&gt;
in amortization expense related to the license fee which was recorded as a component of cost of sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zI4rHPgDmvrf" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_90A_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zvRXnSrtFUQk" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net sales;
(ii) for annual net sales greater than $&lt;span id="xdx_909_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zEGIcUn3ZIz8" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt; and less than or equal to $&lt;span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zj2zgaONK7Qk" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_z0pqRGQuYJYb" title="Royalty (percent)"&gt;10&lt;/span&gt;% of such net sales;
and (iii) for net sales greater than $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z5vITeRv7bT8" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_906_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zzYyhvS5I8og" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty rate will be reduced
to &lt;span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPejB3k4KuBi" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to &lt;span title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;% of the initial rate. We are required to pay the Population Council milestone payments of $&lt;span title="Required milestone payments upon cumulative net sales of specified levels"&gt;40 million&lt;/span&gt; upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $&lt;span title="Specified level one of cumulative net sales for required milestone payments"&gt;200 million&lt;/span&gt;, $&lt;span title="Specified level two of cumulative net sales for required milestone payments"&gt;400 million&lt;/span&gt; and
$&lt;span title="Specified level three of cumulative net sales for required milestone payments"&gt;1 billion&lt;/span&gt;. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies
required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with
such post-approval study exceed $&lt;span id="xdx_909_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zULvFtjWtpu7" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will be offset against royalties or other payments owed by us
to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible
for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional
desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_852_zpryRNURyH1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CostOfSalesPolicyTextBlock_zQMqlFiuunV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zi5XzR9WB6vk"&gt;Cost
of Sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_853_zu4iP95ikIj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zrGO2CXOx7me" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zhWkW75RPQ0g"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTRKuo0UCEoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_846_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcDsiscBqahk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zVfQLBPHJG05"&gt;Trade
Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Trade
accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts
and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables,
historical collection information, reasonable supportable forecasts and existing economic conditions and we record an allowance
that presents the net amount expected to be collected. We evaluate trade accounts receivable for delinquency.
We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results
of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement,
economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current&#160;COVID-19
pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible
that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z11CO1OFronh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zb5WXYUcbjo3"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Our
financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The
carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the
short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount
for long-term debt as of March 31, 2020 (as disclosed in Note 9), approximates fair value based on market activity for other debt
instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy
as defined by ASC 820, &lt;i&gt;Fair Value Measurements, &lt;/i&gt;or ASC 820&lt;i&gt;. &lt;/i&gt;The fair value hierarchy gives the highest priority
to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level
3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs,
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
1&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
2&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability,
either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt 1.5in; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level
3&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;unobservable inputs for the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
March 31, 2020 and 2019, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in
connection with any required impairment test. There was no impairment of intangible assets during the three months ended March
31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_840_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zrmNc7Fxmvkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_z2ve2i6okDGd"&gt;Share-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the
costs in the financial statements over the period during which employees are required to provide services. Share-based
compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share
appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective
service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable
model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the
input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the
risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed
interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument.
Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term
of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer
entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices &lt;/span&gt;over
a period equal to the expected term of the awards. On January 1, 2020, we began calculating the expected term of our
stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January
1, 2020, the average expected life of options was based on the contractual terms of the stock option using the simplified
method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current
intention to pay cash dividends. The assumptions used in calculating the fair value of share-based awards represent our best
estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if
factors change and we use different assumptions, our share-based compensation expense could be materially different in the
future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value
estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the
employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January
1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with
the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718
to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an
entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued
to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
grant performance-based stock awards and restricted stock awards for shares of common stock to employees. We value our restricted
stock awards and our performance-based stock awards by reference to our stock price on the date of grant. We have elected to recognize
compensation expense on a straight-line basis over the requisite service period of the entire award. The number of target shares
that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the
awards, restricted stock is issued based on the level of attainment. We recognize performance-based restricted stock as compensation
expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning
at the grant date and through the date the restricted stock vests.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z1NAqlekhAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zSAXok5ZTlTc"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
accordance with ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, revenue is recognized when a customer obtains
control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled
to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine
revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect
to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract
with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate
the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance
obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription
Products&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we
began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started
selling ANNOVERA in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the
commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent
quarters. We sell our name brand and generic prescription products primarily through wholesale distributors and retail
pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is
to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies,
which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a
fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance
obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when
the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the
use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers
once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from
contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is
typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring
promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC,
determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated
product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts
earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is
payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to
determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either
utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract
or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to
the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when
the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable
consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence
that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the
facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the
magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may
differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates,
which would affect net product revenue and earnings in the period such changes in estimates become known.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_900_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dt_c20200101__20200331__srt--RangeAxis__srt--MinimumMember_znIeOi1oJiaj" title="Return period of unsalable prescription products"&gt;six months&lt;/span&gt; prior
to and up to &lt;span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20200101__20200331__srt--RangeAxis__srt--MaximumMember_zo4Ui1stUbal" title="Return period of unsalable prescription products"&gt;12&lt;/span&gt; months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_90B_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zAfK3GGRO4B1" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt; months from the
date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_90C_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zoUI68K6dNE7" title="Shelf life of prescription products following product expiration"&gt;18&lt;/span&gt; months from the date of manufacture. We do not allow
product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that
may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue
is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped
to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history
of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the
inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product
returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in other current liabilities on the consolidated
balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales
and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience
and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates
and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based
on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current
liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking
into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons
and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice
discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible
enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product
at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party
vendors. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize
the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current
level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively
or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction
price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company.
As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant
revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained
by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions
paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance
based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology,
and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple
performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require
continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation
of revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BD_zYG13U0vCP7c"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt; for the three months ended March 31, 2020 and
2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue"&gt;2,473,691&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue"&gt;1,935,971&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue"&gt;6,392,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue"&gt;2,010,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue"&gt;1,111,604&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;ANNOVERA&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,272,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;12,250,657&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;3,946,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zui8XJd4ZQ3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-03-31_srt_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2020-01-012020-03-31_srt_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-03-31_custom_VitaminsAndImvexxyMember">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2020-01-012020-03-31_custom_BijuvaAndAnnoveraMember">P18M</txmd:ShelfLifeOfPrescriptionProducts>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zIiEiIa6XqOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BD_zYG13U0vCP7c"&gt;The
following table provides information about disaggregated revenue by product mix&lt;/span&gt; for the three months ended March 31, 2020 and
2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzaBOZ6PI264" style="width: 12%; text-align: right" title="Net revenue"&gt;2,473,691&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zp7qvjmjmkG3" style="width: 12%; text-align: right" title="Net revenue"&gt;1,935,971&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--ImvexxyMember_zjHg5T025k7l" style="text-align: right" title="Net revenue"&gt;6,392,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331__srt--ProductOrServiceAxis__custom--ImvexxyMember_za2TzITyh3Dd" style="text-align: right" title="Net revenue"&gt;2,010,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--BijuvaMember_zuwsZEYXJb21" style="text-align: right" title="Net revenue"&gt;1,111,604&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;ANNOVERA&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember_zh9VCFzvouAa" style="border-bottom: Black 1pt solid; text-align: right" title="Net revenue"&gt;2,272,761&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20200101__20200331_zODTwOBGs7Ib" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;12,250,657&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20190101__20190331_zY50eNSLg3M5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenue"&gt;3,946,651&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">2473691</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">1935971</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">6392601</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">2010680</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-31_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">1111604</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">2272761</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">12250657</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">3946651</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_845_ecustom--LicenseAgreementWithPopulationCouncilPolicyTextBlock_zf7maL1AmvPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zp0XoJVfiNs"&gt;License
Agreement with the Population Council&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling
ANNOVERA in a &#x201c;test and learn&#x201d; market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first
quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $&lt;span&gt;&lt;span id="xdx_904_ecustom--MilestonePaymentUponFDAApproval_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzdSrj6ijlBd" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt;&lt;/span&gt;
within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span id="xdx_90E_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_pp0p0_uUSD_c20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zzlQOnkG2JM8" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt;
within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_907_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pp0p0_uUSD_c20200101__20200331__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zLVhFWipFgBk" title="License rights acquired"&gt;20,000,000&lt;/span&gt; were recorded
as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once
ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license
rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the
product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic
benefit cannot be reliably determined. During the three months ended March 31, 2020, we recorded $&lt;span id="xdx_906_eus-gaap--AdjustmentForAmortization_pp0p0_uUSD_c20200101__20200331_zTaBPhlRojyd" title="Amortization of Intangible Assets"&gt;745,511&lt;/span&gt;
in amortization expense related to the license fee which was recorded as a component of cost of sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible
for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates
and permitted licensees as follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zI4rHPgDmvrf" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_90A_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zvRXnSrtFUQk" title="Royalty (percent)"&gt;5&lt;/span&gt;% of net sales;
(ii) for annual net sales greater than $&lt;span id="xdx_909_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zEGIcUn3ZIz8" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt; and less than or equal to $&lt;span id="xdx_904_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zj2zgaONK7Qk" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_90E_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_z0pqRGQuYJYb" title="Royalty (percent)"&gt;10&lt;/span&gt;% of such net sales;
and (iii) for net sales greater than $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_pp0p0_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z5vITeRv7bT8" title="Net sales amount per step-based royalty"&gt;150,000,000&lt;/span&gt;, a royalty of &lt;span id="xdx_906_ecustom--RoyaltyPercent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zzYyhvS5I8og" title="Royalty (percent)"&gt;15&lt;/span&gt;% of such net sales. The annual royalty rate will be reduced
to &lt;span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_uPure_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPejB3k4KuBi" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to &lt;span title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;% of the initial rate. We are required to pay the Population Council milestone payments of $&lt;span title="Required milestone payments upon cumulative net sales of specified levels"&gt;40 million&lt;/span&gt; upon cumulative
net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $&lt;span title="Specified level one of cumulative net sales for required milestone payments"&gt;200 million&lt;/span&gt;, $&lt;span title="Specified level two of cumulative net sales for required milestone payments"&gt;400 million&lt;/span&gt; and
$&lt;span title="Specified level three of cumulative net sales for required milestone payments"&gt;1 billion&lt;/span&gt;. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies
required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval
study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with
such post-approval study exceed $&lt;span id="xdx_909_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_uUSD_c20200101__20200331__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zULvFtjWtpu7" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;, half of such excess will be offset against royalties or other payments owed by us
to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible
for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional
desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council.&lt;/span&gt;&lt;/p&gt;

</txmd:LicenseAgreementWithPopulationCouncilPolicyTextBlock>
    <txmd:MilestonePaymentUponFDAApproval
      contextRef="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="AsOf2020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2020-01-012020-03-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">745511</us-gaap:AdjustmentForAmortization>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep1Member"
      decimals="INF"
      unitRef="Pure">0.05</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep2Member"
      decimals="INF"
      unitRef="Pure">0.10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreementStep3Member"
      decimals="INF"
      unitRef="Pure">0.15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member"
      decimals="INF"
      unitRef="Pure">0.50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid
      contextRef="From2020-01-012020-03-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_842_eus-gaap--CostOfSalesPolicyTextBlock_zQMqlFiuunV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zi5XzR9WB6vk"&gt;Cost
of Sales&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and
handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such
royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related
to licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zrGO2CXOx7me" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zhWkW75RPQ0g"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women.
Our business operations are managed by a single management team that reports to the President of our company. We do not operate
separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect
to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one
reportable operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTRKuo0UCEoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations,
or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal
R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO
activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include
assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes,
and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs
associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal
R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms,
which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services
that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather
than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed
and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO
costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which
the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_807_eus-gaap--InventoryDisclosureTextBlock_zx9x6ABSzgO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
4 &#x2013; INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z9HcyPKJavwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20200331_zJ6OnGfW0RJ1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20191231_zy54QoRqwAMl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_z1MWAvfmBMF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Finished products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,956,900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_zHqBoUQfxH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,554,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryRawMaterialsAndSupplies_iI_zeAitBvwQ9qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,095,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryNet_iI_zJDL3HUjRQP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,607,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zROhD73x8m21" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z9HcyPKJavwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory
consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20200331_zJ6OnGfW0RJ1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20191231_zy54QoRqwAMl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_z1MWAvfmBMF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Finished products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,956,900&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,976,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_zHqBoUQfxH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,554,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,182,059&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryRawMaterialsAndSupplies_iI_zeAitBvwQ9qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Raw materials&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,095,662&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,701,747&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryNet_iI_zJDL3HUjRQP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,607,453&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,860,716&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6956900</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4976910</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2554891</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1182059</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">5095662</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5701747</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">14607453</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_802_eus-gaap--OtherCurrentAssetsTextBlock_zDZvXy7VLrS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
5 &#x2013; &lt;span&gt;OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zdpQqp1SYAR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_493_20200331_z315oeVj3xmd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20191231_zvT6CFgvEhGl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_uUSD_maPEAOAzkyn_zs1RarO2Qbud" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;553,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredFinanceCostsCurrentNet_iI_uUSD_maPEAOAzkyn_z0bbbNByTM9i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt financing fees on undrawn tranches (Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_uUSD_maPEAOAzkyn_zSzus1ZnjEr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,064,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--PrepaidManufacturing_iI_uUSD_maPEAOAzkyn_zxx7GgLpXD74" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;955,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_uUSD_maPEAOAzkyn_z7QgK5iLgiA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,769,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_uUSD_mtPEAOAzkyn_zn3jtKbW7UZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,618,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zyRjQ5Y3nUai" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zdpQqp1SYAR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_493_20200331_z315oeVj3xmd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20191231_zvT6CFgvEhGl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_uUSD_maPEAOAzkyn_zs1RarO2Qbud" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;Prepaid sales and marketing costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;553,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,583,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredFinanceCostsCurrentNet_iI_uUSD_maPEAOAzkyn_z0bbbNByTM9i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Debt financing fees on undrawn tranches (Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;550,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_uUSD_maPEAOAzkyn_zSzus1ZnjEr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,064,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,812,135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--PrepaidManufacturing_iI_uUSD_maPEAOAzkyn_zxx7GgLpXD74" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;955,659&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,595,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_uUSD_maPEAOAzkyn_z7QgK5iLgiA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,769,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,787,482&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_uUSD_mtPEAOAzkyn_zn3jtKbW7UZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,618,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,329,793&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">553789</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1583698</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">275378</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1064468</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1812135</us-gaap:PrepaidInsurance>
    <txmd:PrepaidManufacturing contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">955659</txmd:PrepaidManufacturing>
    <txmd:PrepaidManufacturing contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2595721</txmd:PrepaidManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3769073</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4787482</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6618367</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zARnJqTt9ku" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
6 &#x2013; FIXED ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeaPRBKHtSa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed
assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zg2PJZsXwO0l" style="width: 12%; text-align: right" title="TOTAL FIXED ASSETS"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlKfWaau3kT" style="width: 12%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4Z0zOt08qw8" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,640,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlZcRsPr7uN2" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFKrqFQ0kLal" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlKp2iyTusak" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpvF7xSYPh7h" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQsgGEW8GUb1" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zy5WtSAUOjmk" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmAhWN0pXa3h" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331_zVrOjJE771k2" style="text-align: right"&gt;3,497,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231_zpYZ6SytS7i4" style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20200331_zChgcuFWqYH" style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,167,663&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_znrt2W1QZK68" style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20200331_zjtw6zANLYSf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,330,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20191231_zFWC915SmO9i" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zom7GMcTy0m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation
expense for the three months ended March 31, 2020 and 2019 was $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20200101__20200331_zIVpkYmOBeZ5" title="Depreciation expense"&gt;198,839&lt;/span&gt;, and $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20190101__20190331_z01OVoVKKuXi" title="Depreciation expense"&gt;66,494&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeaPRBKHtSa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fixed
assets, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: left"&gt;Accounting system&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zg2PJZsXwO0l" style="width: 12%; text-align: right" title="TOTAL FIXED ASSETS"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zlKfWaau3kT" style="width: 12%; text-align: right"&gt;301,096&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z4Z0zOt08qw8" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,640,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlZcRsPr7uN2" style="text-align: right"&gt;1,619,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zFKrqFQ0kLal" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zlKp2iyTusak" style="text-align: right"&gt;1,406,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zpvF7xSYPh7h" style="text-align: right" title="TOTAL FIXED ASSETS"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQsgGEW8GUb1" style="text-align: right"&gt;80,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zy5WtSAUOjmk" style="border-bottom: Black 1pt solid; text-align: right" title="TOTAL FIXED ASSETS"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmAhWN0pXa3h" style="border-bottom: Black 1pt solid; text-align: right"&gt;68,788&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20200331_zVrOjJE771k2" style="text-align: right"&gt;3,497,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231_zpYZ6SytS7i4" style="text-align: right"&gt;3,476,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20200331_zChgcuFWqYH" style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,167,663&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20191231_znrt2W1QZK68" style="border-bottom: Black 1pt solid; text-align: right"&gt;(968,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20200331_zjtw6zANLYSf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,330,190&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20191231_zFWC915SmO9i" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,507,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1640900</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1619646</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3497853</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3476599</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1167663</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">968824</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2330190</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">198839</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">66494</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_80F_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zchYb4KgHkol" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
7 &#x2013; INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zz26GotF80U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of March 31, 2020 and December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization&lt;br/&gt;
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%"&gt;Approved hormone therapy
    drug&#160;candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zXYDMwse61td" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;3,763,022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaYaXoZo6IQ4" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(542,235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZXtiuvXLzR6" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,220,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zuNk95uCDdvh" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Hormone therapy drug candidate
    patents&#160;(pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zQL8AYkzExfd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;2,070,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z0LxzXYIEQZj" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;2,070,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedTrademarks_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zPBhk7RG6V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;325,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zG6sPBcYD03f" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;325,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20200331_zq4h23lLuIF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;6,159,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331_zKOzPdRlfZf4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(542,235&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20200331_zUUFmVblveIb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)"&gt;5,616,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization&lt;br/&gt;
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%"&gt;Approved
    hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zWdHV07R0ln5" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlLY2WFRzgc" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z1w0tlUPrEFk" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z5znApwOIz0b" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Hormone therapy drug candidate
    patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zC5bjbT3nExd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zdozuDJ6LcK2" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z29Jjza7Nu91" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z99mUIIQEEYa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zCT9dsXR8CKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231_ztH7zn4WIg4h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zySQa7F4hnLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zjAVe5tarN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent
is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated
remaining useful life of approximately &lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4AdkH3TiQAl" title="Finite-Lived Intangible Asset, Useful Life"&gt;20 years&lt;/span&gt;, which is the life of intellectual property patents. If the patent is not granted,
we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the three months
ended March 31, 2020 and 2019, there was no impairment recognized related to intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, we had &lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zlYMmPLfutXc" title="Number of issued patents"&gt;31&lt;/span&gt; issued domestic patents and &lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zF99eSKBW4L1" title="Number of issued patents"&gt;30&lt;/span&gt; issued foreign patents, including:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_ztaC2pG7aWte" title="Number of issued patents"&gt;12&lt;/span&gt;
                                         domestic patents and &lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zDHTu95403lc" title="Number of issued patents"&gt;six&lt;/span&gt; foreign patents that relate to BIJUVA as well as &lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zz9qg1mEZT2j" title="Number of issued patents"&gt;three&lt;/span&gt; domestic
                                         patents that relate to estradiol and progesterone product candidates. These patents establish
                                         an important intellectual property foundation and are owned by us. The domestic patents
                                         will expire in 2032. The foreign patents will expire no earlier than 2032. In addition,
                                         we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia,
                                         Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa,
                                         and South Korea.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zCHpH7QebU58" title="Number of issued patents"&gt;Eight&lt;/span&gt;
                                         domestic patents (&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zshl8nuM7qpc" title="Number of issued patents"&gt;seven&lt;/span&gt; utility and &lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_z1LgpjXnxlt4" title="Number of issued patents"&gt;one&lt;/span&gt; design) and &lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zNqvYmWd0nj6" title="Number of issued patents"&gt;13&lt;/span&gt; foreign patents (&lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zHw275ubTqX2" title="Number of issued patents"&gt;three&lt;/span&gt; utility
                                         and &lt;span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_zMyw6z8tSNda" title="Number of issued patents"&gt;ten&lt;/span&gt; design) that relate to IMVEXXY. These patents establish an important intellectual
                                         property foundation for IMVEXXY and are owned by us. The domestic patents will expire
                                         in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign
                                         design patents provide protection expiring no earlier than 2025. In certain countries,
                                         the foreign design patents provide protection through at least 2037. In addition, we
                                         have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia,
                                         Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and
                                         South Korea.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTopicalCreamCandidatesMember_zALZa2wd5yU5" title="Number of issued patents"&gt;One&lt;/span&gt;
                                         domestic utility patent that relates to our topical-cream candidates, which is owned
                                         by us. The domestic patent will expire in 2035.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zAp0jQPvCoy4" title="Number of issued patents"&gt;One&lt;/span&gt;
                                         domestic utility patent and &lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_z6AbjCt5eGO9" title="Number of issued patents"&gt;seven&lt;/span&gt; foreign patents that relate to our transdermal-patch
                                         candidates, which are owned by us. The domestic utility patent will expire in 2032. The
                                         foreign patents will expire no earlier than 2033. We have pending patent applications
                                         with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico,
                                         and South Africa.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zxwEj0sV9UVb" title="Number of issued patents"&gt;Three&lt;/span&gt;
                                         domestic utility patents that relate to TX-009HR, a progesterone and estradiol product
                                         candidate, which are owned by us and will expire in 2037.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_z7u8Ezm78BP7" title="Number of issued patents"&gt;Two&lt;/span&gt;
                                         domestic and &lt;span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zeNjMqryknu1" title="Number of issued patents"&gt;four&lt;/span&gt; foreign patents that relate to formulations containing progesterone,
                                         which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign
                                         patents will expire no earlier than 2033. In addition, we have pending patent applications
                                         with respect formulations containing progesterone in the U.S., Australia, Brazil, Canada,
                                         Europe, and Mexico.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2022;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zVQ7EaGrZpF9" title="Number of issued patents"&gt;One&lt;/span&gt;
                                         domestic utility patent that relates to our OPERA information-technology platform, which
                                         is owned by us and will expire in 2031.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Amortization
expense was $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20200101__20200331_z311hmLPbDl3" title="Amortization of intangible assets"&gt;63,155&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_uUSD_c20190101__20190331_zUPwGLWCClea" title="Amortization of intangible assets"&gt;40,444&lt;/span&gt;
for the three months ended March 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z8wXdGjBstB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Estimated amortization expense,
based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated Amortization&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (9&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20200331_zc3KUbdVRHV4" style="width: 10%; text-align: right" title="2020 (9 months)"&gt;189,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20200331_zzf1CjRqXSY6" style="text-align: right" title="2021"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20200331_zGgaIHw2eKxh" style="text-align: right" title="2022"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20200331_zmn5PDCaunmk" style="text-align: right" title="2023"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20200331_zgrCptqyKUAd" style="text-align: right" title="2024"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zFb5bb3Ku6s7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_897_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zz26GotF80U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets
as of March 31, 2020 and December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization&lt;br/&gt;
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%"&gt;Approved hormone therapy
    drug&#160;candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zXYDMwse61td" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;3,763,022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaYaXoZo6IQ4" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(542,235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZXtiuvXLzR6" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;3,220,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20200101__20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zuNk95uCDdvh" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;12.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Hormone therapy drug candidate
    patents&#160;(pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zQL8AYkzExfd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;2,070,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20200331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_z0LxzXYIEQZj" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;2,070,397&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedTrademarks_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zPBhk7RG6V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;325,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20200331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zG6sPBcYD03f" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;325,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20200331_zq4h23lLuIF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;6,159,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20200331_zKOzPdRlfZf4" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(542,235&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20200331_zUUFmVblveIb" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)"&gt;5,616,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization&lt;br/&gt;
    Period (yrs.)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; width: 30%"&gt;Approved
    hormone therapy drug candidate patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zWdHV07R0ln5" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;3,463,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zlLY2WFRzgc" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(478,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z1w0tlUPrEFk" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;2,984,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z5znApwOIz0b" style="width: 12%; text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Hormone therapy drug candidate
    patents (pending)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zC5bjbT3nExd" style="text-align: right" title="Finite-Lived Intangible Assets, Gross"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zdozuDJ6LcK2" style="text-align: right" title="Finite-Lived Intangible Assets, Net"&gt;1,979,299&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Non-amortizable intangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z29Jjza7Nu91" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-Lived Trademarks"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z99mUIIQEEYa" style="border-bottom: Black 1pt solid; text-align: right" title="Indefinite-lived Intangible Assets (Excluding Goodwill)"&gt;294,813&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Finite-Lived Intangible Assets, Remaining Amortization Period"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zCT9dsXR8CKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Gross (Excluding Goodwill)"&gt;5,737,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20191231_ztH7zn4WIg4h" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite-Lived Intangible Assets, Accumulated Amortization"&gt;(478,983&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zySQa7F4hnLe" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible Assets, Net (Excluding Goodwill)"&gt;5,258,211&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3763022</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">-542235</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3220787</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P12Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2070397</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-03-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2070397</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">325648</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2020-03-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">325648</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6159067</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-542235</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">5616832</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3463082</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">-478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2984099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5737194</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUSPatentsMember"
      decimals="INF"
      unitRef="Pure">31</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignPatentsMember"
      decimals="INF"
      unitRef="Pure">30</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">6</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticPatentsNonApprovedBijuvaMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUSPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">8</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUSUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">7</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUSDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTopicalCreamCandidatesMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">7</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentTx009HRMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="Pure">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_ForeignPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2020-03-31_custom_DomesticUtilityPatentOperaMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">63155</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">40444</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_z8wXdGjBstB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Estimated amortization expense,
based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated Amortization&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020 (9&#160;months)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_c20200331_zc3KUbdVRHV4" style="width: 10%; text-align: right" title="2020 (9 months)"&gt;189,464&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2021&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20200331_zzf1CjRqXSY6" style="text-align: right" title="2021"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20200331_zGgaIHw2eKxh" style="text-align: right" title="2022"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20200331_zmn5PDCaunmk" style="text-align: right" title="2023"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20200331_zgrCptqyKUAd" style="text-align: right" title="2024"&gt;252,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">189464</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">252618</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">252618</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">252618</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">252618</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_80B_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zYJU0DTf51nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
8 &#x2013; OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zARa1nt0YMu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_493_20200331_zXU6bS3Y7usf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20191231_zUXEzD95cGAb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--AccruedSalariesCurrent_iI_maOLCzu3r_zu7w3AR93IA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,087,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_pp0p0_maOLCzu3r_zYayDvE07DA5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,712,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0p0_maOLCzu3r_z5SyHQzqD0Xh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maOLCzu3r_zDCcuIpSRXeb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,874,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_pp0p0_maOLCzu3r_zBtGcJ050cz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,897,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzu3r_zby3Z8amvHs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;909,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maOLCzu3r_zSmzDQRsKmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,179,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLCzu3r_zteRE5GZDNH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AccruedRebates_iI_pp0p0_maOLCzu3r_zEqtw8txrvNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,794,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maOLCzu3r_zGmyUO6kHg4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;823,694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_mtOLCzu3r_zB9nSjMyVn86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,924,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zP6GSYBCgXwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zARa1nt0YMu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_493_20200331_zXU6bS3Y7usf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20191231_zUXEzD95cGAb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--AccruedSalariesCurrent_iI_maOLCzu3r_zu7w3AR93IA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;6,087,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,040,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_pp0p0_maOLCzu3r_zYayDvE07DA5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,712,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,316,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0p0_maOLCzu3r_z5SyHQzqD0Xh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued sales and marketing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;893,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,285,662&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maOLCzu3r_zDCcuIpSRXeb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued compensated absences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,874,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,463,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_pp0p0_maOLCzu3r_zBtGcJ050cz9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued wholesale distributor fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,897,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzu3r_zby3Z8amvHs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;909,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;422,336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maOLCzu3r_zSmzDQRsKmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,179,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,049,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLCzu3r_zteRE5GZDNH7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--AccruedRebates_iI_pp0p0_maOLCzu3r_zEqtw8txrvNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accrued rebates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,794,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,916,672&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maOLCzu3r_zGmyUO6kHg4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;823,694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,480,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_mtOLCzu3r_zB9nSjMyVn86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,924,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;33,823,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6087359</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">8040278</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">10712171</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10316298</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">893332</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3285662</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1874036</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1463878</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3897398</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2347122</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">909137</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">422336</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1179065</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1049603</txmd:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1753499</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <txmd:AccruedRebates contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">4794794</txmd:AccruedRebates>
    <txmd:AccruedRebates contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3916672</txmd:AccruedRebates>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">823694</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1480225</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">32924485</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z82LLu6cLDFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
9 &#x2013; &lt;span&gt;DEBT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 24, 2019, we entered into a Financing Agreement, as amended, or the Financing Agreement, with TPG Specialty Lending, Inc.,
as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors, which provides us with a $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zWPkSvsXL9h1" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;300,000,000&lt;/span&gt; first lien secured term loan credit facility,
or the Facility. The Facility provides for availability to us in three tranches: (i) $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3Ll7wDx1wG4" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;200,000,000&lt;/span&gt; was drawn upon entering into
the Financing Agreement; (ii) $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zYsC9VY9MIPl" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;50,000,000&lt;/span&gt; will be available to us in the Administrative Agent&#x2019;s sole and absolute discretion
either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such
earlier date as the Administrative Agent shall have consented to; and (iii) $&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pp0p0_uUSD_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zoLD73qIGCig" title="Proceeds from Financing Agreement"&gt;50,000,000&lt;/span&gt; was drawn on February 18, 2020 following
our achievement of more than $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_uUSD_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zGtCJgVwZ2W3" title="Total revenue, net"&gt;11,000,000&lt;/span&gt; in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings
under the Facility accrue interest at either (i) &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zN0gfsr3sTQj" title="Debt Instrument, Description of Variable Rate Basis"&gt;3-month LIBOR&lt;/span&gt; plus &lt;span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKMLQ3reYHj" title="Debt Instrument, Basis Spread on Variable Rate"&gt;7.75&lt;/span&gt;%, subject to a LIBOR floor of &lt;span id="xdx_90D_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zzvzcptvKy61" title="LIBOR floor rate"&gt;2.70&lt;/span&gt;% or (ii) the &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zDSXBczIiu9c" title="Debt Instrument, Description of Variable Rate Basis"&gt;prime
rate&lt;/span&gt; plus&lt;span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zVaCXkW2EqNg" title="Debt Instrument, Basis Spread on Variable Rate"&gt; 6.75&lt;/span&gt;%, subject to a prime rate floor of &lt;span id="xdx_909_ecustom--PrimeRateFloor_iI_pip0_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zFKwSneXwckf" title="Prime rate floor"&gt;5.2&lt;/span&gt;% as selected by us. Interest on amounts borrowed under the Facility is payable
quarterly. The outstanding principal amount of the Facility is payable in &lt;span id="xdx_907_ecustom--NumberOfInstallmentPayments_iI_pp0p0_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zrSUU2CqKBI8" title="Number of quarterly principal installment payments"&gt;four&lt;/span&gt; equal quarterly installments beginning on June
30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or
in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) &lt;span id="xdx_904_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zjKBjGlANUAa" title="Prepayment fee for first two years funding (percent)"&gt;30.0&lt;/span&gt;% for the first two years following
the initial funding date of the applicable borrowing, (ii) &lt;span id="xdx_90E_ecustom--PrepaymentFeeThirdYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zL5GMcTY54E8" title="Prepayment fee third year funding (percent)"&gt;5.0&lt;/span&gt;% for the third year following the initial funding date of the applicable
borrowing, (iii) &lt;span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zpxVfOTjgUh7" title="Prepayment fee fourth year funding (percent)"&gt;3.0&lt;/span&gt;% for the fourth year following the initial funding date of the applicable borrowing and (iv) &lt;span id="xdx_900_ecustom--PrepaymentFeeFifthYearFundingPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zD71f1AmJPW2" title="Prepayment fee fifth year funding (percent)"&gt;1.0&lt;/span&gt;% for the
fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the
initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to &lt;span id="xdx_909_ecustom--FacilityFeePaidPercent_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJW687VTUUul" title="Facility fee paid (percent)"&gt;2.5&lt;/span&gt;% of the initial amount
borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are
also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses.
The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary
for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of
$&lt;span id="xdx_909_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_pp0p0_uUSD_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo4Eg4yeOU1f" title="Minimum cash balance requirement under credit agreement"&gt;60,000,000&lt;/span&gt;, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY,
BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes
other representations, warranties, indemnities and events of default that are customary for financings of this type, including
an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent
and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable
and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries
under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority
perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under
the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap,
as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender,
the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to
$&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zDTdjYS5Aboj" title="Line of Credit Facility, Maximum Borrowing Capacity"&gt;200,000,000&lt;/span&gt;, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in &lt;span id="xdx_907_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_pp0p0_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z3NpDGkghri8" title="Number of tranches under term loan facility"&gt;three&lt;/span&gt; separate
tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed
under the Term Loan bore interest at a rate equal to the sum of (i) &lt;span id="xdx_90D_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_pp0p0_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zADPCpIJOxxl" title="Debt Instrument, Description of Variable Rate Basis"&gt;one-month LIBOR&lt;/span&gt; (subject to a LIBOR floor of &lt;span id="xdx_90B_ecustom--LiborFloorRate_iI_pip0_dp_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zAGkdJaSJU29" title="LIBOR floor rate"&gt;1.50&lt;/span&gt;%) plus (ii)
&lt;span id="xdx_90E_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pip0_dp_uPure_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zZ5k1Fi7hZSl" title="Debt Instrument, Basis Spread on Variable Rate"&gt;7.75&lt;/span&gt;% per annum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;On
April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement
in the amount of approximately $&lt;span id="xdx_90F_ecustom--RepaymentOfDebtWithNewCreditFacility_pp0p0_uUSD_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zAoKWmSzHmFf" title="Repayment of debt with new credit facility"&gt;81,661,000&lt;/span&gt; was used to repay all amounts outstanding under the Credit Agreement, which included
a prepayment fee of &lt;span id="xdx_90B_ecustom--PrepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zvRGWtRwnkAk" title="Prepayment fee percentage"&gt;4&lt;/span&gt;%, a repayment fee of &lt;span id="xdx_909_ecustom--RepaymentFeePercentage_pip0_dp_uPure_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zi6WrZzuK6E1" title="Repayment fee percentage"&gt;4&lt;/span&gt;% and other fees and expenses payable to the lenders under the Credit Agreement. As
a result of the termination of the Credit Agreement, we recorded $&lt;span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_dxL_uUSD_c20190101__20190331_zNzeyMeQDmKg" title="Loss on extinguishment of debt::XDX::-10057632"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;10,057,632&lt;/span&gt;&lt;/span&gt; in loss on extinguishment of debt in the second quarter
of 2019. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the three
months ended March 31, 2019 related to the Credit Agreement was $&lt;span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zlpbCVvShyTg" title="Interest Expense, Debt"&gt;1,969,872&lt;/span&gt;. During the three months ended March 31, 2019, we amortized
$&lt;span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20190101__20190331__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zNXj11pAtXag" title="Amortization of deferred financing costs"&gt;120,146&lt;/span&gt; of debt issuance costs as interest expense in the accompanying unaudited consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;As
of March 31, 2020, we had $&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z66dY4kGWlYg" title="Long-term Debt, Gross"&gt;250,000,000&lt;/span&gt;
in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
consolidated financial statements. We incurred $&lt;span id="xdx_90C_eus-gaap--DeferredFinanceCostsGross_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zpSNKaTaHGF1" title="Deferred financing fees"&gt;7,902,270&lt;/span&gt;
in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing
Agreement have been allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to
the two tranches of borrowings that we received of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_uUSD_c20200331_zicw1GXgnUYf" title="Debt Instrument, Unamortized Discount"&gt;7,626,891&lt;/span&gt;
have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with an unfunded tranche are deferred as assets until such tranche has been drawn. As of March 31,
2020, deferred financing fees related to the unfunded tranche of $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_uUSD_c20200331__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zI6pEfqmQys1"&gt;50,000,000&lt;/span&gt;
were included in other current assets in the accompanying consolidated financial statements. During the three months ended
March 31, 2020, we amortized $&lt;span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_pp0p0_uUSD_c20200101__20200331__custom--DebtTrancheAxis__custom--TrancheTwoMember_zc8F2LSPivWk" title="Amortization of deferred financing costs"&gt;319,408&lt;/span&gt; &lt;span style="background-color: white"&gt;of
deferred financing fees related to the two tranches that have been received as interest expense in the accompanying
consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in
arrears. Interest expense for the three months ended March 31, 2020 was $&lt;span id="xdx_90D_eus-gaap--InterestExpenseBorrowings_pp0p0_uUSD_c20200101__20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zdWYXM1Y1Ql6" title="Interest Expense, Borrowings"&gt;5,942,639&lt;/span&gt;.
The overall effective interest rate under the Financing Agreement was approximately &lt;/span&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pip0_dp_uPure_c20200331_zZxV3QA7ITL6" title="Debt Instrument, Interest Rate, Effective Percentage"&gt;11&lt;/span&gt;&lt;span style="background-color: white"&gt;%
as of March 31, 2020&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zuYWva5GXJfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020 and December 31, 2019, &lt;span&gt;the carrying value of our debt consisted&lt;/span&gt; of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20200331_zdBxYTuLbYf1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20191231_zpRZ2jcdfYq8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zapwzyTEff58" style="width: 12%; text-align: right" title="Long-term Debt, Gross"&gt;250,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zYDRx6oDWyG3" style="width: 12%; text-align: right" title="Long-term Debt, Gross"&gt;200,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_uUSD_zA0yZPzpbaal" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,571,329&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,365,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_uUSD_zFY2FfjOmEPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;243,428,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;194,634,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zIY9DzQZVFSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember">3-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">prime
rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:PrimeRateFloor
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.052</txmd:PrimeRateFloor>
    <txmd:NumberOfInstallmentPayments
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="Pure">4</txmd:NumberOfInstallmentPayments>
    <txmd:PrepaymentFeeForFirstTwoYearsFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.300</txmd:PrepaymentFeeForFirstTwoYearsFundingPercent>
    <txmd:PrepaymentFeeThirdYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeeThirdYearFundingPercent>
    <txmd:PrepaymentFeeFourthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:PrepaymentFeeFourthYearFundingPercent>
    <txmd:PrepaymentFeeFifthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.010</txmd:PrepaymentFeeFifthYearFundingPercent>
    <txmd:FacilityFeePaidPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="Pure">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloorRate
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.0150</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:RepaymentOfDebtWithNewCreditFacility
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">81661000</txmd:RepaymentOfDebtWithNewCreditFacility>
    <txmd:PrepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:PrepaymentFeePercentage>
    <txmd:RepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:RepaymentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2019-01-012019-03-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">1969872</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-03-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-03-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2020-03-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">7902270</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">7626891</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2020-03-31_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2020-01-012020-03-31_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">319408</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2020-01-012020-03-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">5942639</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-03-31" decimals="INF" unitRef="Pure">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zuYWva5GXJfc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020 and December 31, 2019, &lt;span&gt;the carrying value of our debt consisted&lt;/span&gt; of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20200331_zdBxYTuLbYf1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49C_20191231_zpRZ2jcdfYq8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20200331__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zapwzyTEff58" style="width: 12%; text-align: right" title="Long-term Debt, Gross"&gt;250,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_uUSD_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zYDRx6oDWyG3" style="width: 12%; text-align: right" title="Long-term Debt, Gross"&gt;200,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_uUSD_zA0yZPzpbaal" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Debt discount and financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,571,329&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,365,357&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_uUSD_zFY2FfjOmEPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;243,428,671&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;194,634,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2020-03-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6571329</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5365357</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">243428671</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_zEhUrHtD0eNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
10 &#x2013; NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and
disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common
stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_zv65xt6mS1D7" title="Common stock par value (in dollars per share)"&gt;0.001&lt;/span&gt; per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average
number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the
period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were
excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net
loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net
loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC7MnWRDtovb" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - NET LOSS PER SHARE (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pp0p0_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGDOUicyDozd" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;25,155,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZWiLD6NjQF5" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;21,447,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za9GAAGxKxOa" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNvvkwguDAok" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock awards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zACf9oP5p4k8" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,858,490&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znscYXL28Ha1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,040,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331_z9ILmNQb31l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;33,846,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331_zcJtI3mjRv6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;24,320,290&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC7MnWRDtovb" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - NET LOSS PER SHARE (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pp0p0_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGDOUicyDozd" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;25,155,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZWiLD6NjQF5" style="width: 12%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;21,447,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_za9GAAGxKxOa" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNvvkwguDAok" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,832,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock awards&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zACf9oP5p4k8" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;6,858,490&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znscYXL28Ha1" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,040,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200331_z9ILmNQb31l5" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;33,846,282&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20190101__20190331_zcJtI3mjRv6i" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;24,320,290&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">25155221</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">21447719</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">6858490</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-03-31"
      decimals="INF"
      unitRef="Shares">33846282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="Shares">24320290</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1Xqlb9M1Gl5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
11 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
March 31, 2020, we had &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pii_uShares_c20200331_znrHRL9qs4Hc" title="Preferred Stock, Shares Authorized"&gt;10,000,000&lt;/span&gt; shares of Preferred Stock, par value $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_uUSDPShares_c20200331_za1QWerwgQbb" title="Preferred Stock, Par or Stated Value Per Share"&gt;0.001&lt;/span&gt;, authorized for issuance, of which &lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pii_dco_uShares_c20200331_zKrCmd6DN4Qe" title="Preferred Stock, Shares Outstanding"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_dco_uShares_c20200331_zkQ2gUpduxol" title="Preferred Stock, Shares Issued"&gt;no&lt;/span&gt;&lt;/span&gt; shares of
Preferred Stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
March 31, 2020, we had &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pii_uShares_c20200331_z94hCnJ5EfC3" title="Common Stock, Shares Authorized"&gt;350,000,000&lt;/span&gt; shares of Common Stock authorized for issuance, of which &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pii_uShares_c20200331_zihrDmrHmcY6" title="Common Stock, Shares, Issued"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pii_uShares_c20200331_zmYcMTHm3u28" title="Common Stock, Shares, Outstanding"&gt;271,677,742&lt;/span&gt;&lt;/span&gt; shares of Common Stock
were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances
During the Three Months ended March 31, 2020&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended March 31, 2020, certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgFFhaU8wdVa"&gt;350,666&lt;/span&gt; shares
of Common Stock for $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxaNWM1oU1xb"&gt;72,109&lt;/span&gt; in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances
During the Three Months ended March 31, 2019&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended March 31, 2019, certain individuals exercised stock options to purchase an aggregate of&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pii_uShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi55ceFgC474"&gt; 276,383&lt;/span&gt; shares
of Common Stock for $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6Jmo87fggl6"&gt;100,107&lt;/span&gt; in cash. Also, during the same period, stock options to purchase an aggregate of &lt;span id="xdx_90D_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_pii_uShares_c20190101__20190331_z0r9opzOofEl" title="Number of stock options exercised in cashless exercise (in shares)"&gt;12,097&lt;/span&gt; shares of
Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein an aggregate of &lt;span id="xdx_90E_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_pii_uShares_c20190101__20190331_zfBXB9X0ObPl" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"&gt;11,834&lt;/span&gt; shares
of Common Stock were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Warrants
to Purchase Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, we had warrants outstanding to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_uUSD_c20200331_zMyMyga61Fzb" title="Warrants and Rights Outstanding"&gt;1,832,571&lt;/span&gt; shares of Common Stock with a weighted-average
contractual remaining life of approximately &lt;span id="xdx_901_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20200101__20200331_z5py9rYo5zn5" title="Weighted-average contractual remaining life"&gt;1.70&lt;/span&gt; years, and exercise prices ranging from $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zg9qg43sgDcg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.24&lt;/span&gt; to $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zZrlLqRCeP21" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;8.20&lt;/span&gt; per share, resulting in
a weighted average exercise price of $&lt;span id="xdx_905_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z2HwQfHCzLda" title="Weighted average exercise price of warrants (in dollars per share)"&gt;2.62&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the
term of the warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended March 31, 2020, no warrants were granted. During the three months ended March 31, 2019, we granted
warrants to purchase an aggregate of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z43EwiFLovu" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"&gt;75,000&lt;/span&gt;
shares of Common Stock to outside consultants at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zLu6Ri5v0Ldi" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;5.63&lt;/span&gt;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of &lt;span title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term"&gt;five &lt;/span&gt;years;
volatility of &lt;span id="xdx_901_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zy4rxCZ0thV8" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"&gt;60.8&lt;/span&gt;%;
risk free rate of&lt;span id="xdx_904_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zDsSrF0xkOp9" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"&gt;
2.52&lt;/span&gt;%; and dividend yield of&lt;span id="xdx_90B_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zkFxhg4ltlai" title="Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"&gt;
0&lt;/span&gt;%. The grant date fair value of the warrants was $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNz27QtBvNph" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"&gt;3.00&lt;/span&gt;
per share. The warrants vested ratably over a &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HN4rtQyoAe" title="Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"&gt;12&lt;/span&gt;-month
period and have an expiration date of February 12, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;During
the three months ended March 31, 2020, no warrants were exercised&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
&lt;span style="background-color: white"&gt;During the three months ended March 31, 2019, warrants to purchase an aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQC1Yf7JAvP8" title="Warrants exercised"&gt;1,250,000&lt;/span&gt;
shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, wherein an aggregate of &lt;span id="xdx_90C_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_pii_uShares_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zhsHssI0ZHJf" title="Number of stock issued in cashless exercise of warrants"&gt;471,184&lt;/span&gt;
shares of Common Stock were issued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
recorded share-based compensation expense related to warrants previously issued of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zuAfZEz40GZ8" title="Share-based Payment Arrangement, Noncash Expense"&gt;26,446&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zzM2jcypKTc4" title="Share-based Payment Arrangement, Noncash Expense"&gt;85,716&lt;/span&gt; for the three months ended
March 31, 2020 and 2019, respectively, in the accompanying consolidated financial statements. At March 31, 2020, there was no
unrecognized estimated compensation expense related to unvested warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Options
to Purchase Common Stock of the Company&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees,
directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder
value by providing them stock options and other stock and cash incentives, or the Awards. As of March 31, 2020, there were non-qualified
stock options to purchase an aggregate of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zXeLwbqbYKqi" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;14,546,246&lt;/span&gt; shares of Common Stock outstanding under the 2009 Plan. Effective upon our
adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made
under the 2009 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012
Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
consultants and advisors of our company. As of March 31, 2020, there were non-qualified stock options to purchase an aggregate
of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zaH8D5lv078g" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;6,316,474&lt;/span&gt; shares of Common Stock outstanding and an aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjStbGeUG8j7" title="Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"&gt;890,000&lt;/span&gt; restricted stock awards under the 2012 Plan. Effective
upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers,
directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options,
stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or
cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board
of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any.
The expiration date is generally ten years from the date the option is issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020, there were &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zc4CqiMq1gYb" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;4,970,994&lt;/span&gt; shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NewSharesMember_zxxsuA3aeEma"&gt;2,354,764&lt;/span&gt;
new shares, (ii) &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zGNvI4t8Ib98" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;2,395,333&lt;/span&gt; unallocated shares previously available for issuance under the 2012 Plan that were not then subject
to outstanding &#x201c;Awards&#x201d; (as defined in the 2012 Plan), and (iii) &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z25uuN8xGTCc" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"&gt;220,897&lt;/span&gt; unallocated shares previously available for
issuance under the 2009 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2009 Plan). Any
shares subject to outstanding options or other equity &#x201c;Awards&#x201d; under the 2019 Plan, the 2012 Plan and the 2009 Plan
that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for
cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered
or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which
those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance,
again be available for delivery with respect to Awards under the 2019 Plan. As of March 31, 2020, there were non-qualified stock
options to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--PlanNameAxis__custom--Plan2019Member_zbPiaDrJqWS9" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"&gt;4,292,501&lt;/span&gt; shares of Common Stock outstanding under the 2019 Plan, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--Plan2019Member_z4AxfPTi3V2j" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;3,584,245&lt;/span&gt; restricted stock awards and &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--Plan2019Member_zY5W37PTsAS5" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"&gt;2,384,245&lt;/span&gt;
performance stock awards outstanding under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmiZZrXoInTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and
2019 are set forth in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKT3HpcC3Ctk" style="width: 12%; text-align: right" title="Weighted average grant date fair value"&gt;0.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKCm4GBhbZ64" style="width: 12%; text-align: right" title="Weighted average grant date fair value"&gt;3.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAoURtu9Slh2" style="font: 10pt Times New Roman, Times, Serif"&gt;1.32&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrhE696UcnGe"&gt;1.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zclHBCYrH4Y8" style="text-align: right" title="Risk-free interest rate"&gt;2.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKbbd5VICeke" title="Volatility - minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyNJb5gWKHf9" title="Volatility - maximum"&gt;65.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zp37dwdC0gd" style="text-align: right" title="Volatility"&gt;61.85&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zBqThQyn9EH2" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zI3qCxPIUrU9" title="Term"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm4RzCP1iPK" style="text-align: right" title="Term"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRCbPvXZsR1g" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z97xFrXVFlxg" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zr8Sxn6nkEO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCouQC6ZD5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Contractual &lt;br/&gt;Life
    in Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 39%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF74Vd7stZY6" style="width: 11%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg5erwQ0O0H1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlNh1WMeN8Tk" style="width: 11%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nHUxpATmu4" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIrW2Q4UU0yl" style="text-align: right" title="Number of shares under options, granted"&gt;636,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKkPU4yQi8b" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPDM0gLWg4I4" style="text-align: right" title="Number of shares under options, exercised"&gt;(350,666&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEkpJ98J88v9" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKMQTcpYeBii" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;725,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9eD9aqL6MO8" style="text-align: right" title="Number of shares under options, expired"&gt;(50,472&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gOKEtgi3Al" style="text-align: right" title="Weighted average exercise price, expired"&gt;0.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;&#160;&#160;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyA0VXRGp0Xc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(110,375&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HEMrytqGP7" style="text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR85TrJIPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;25,155,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35NKobVHVH5" style="text-align: right" title="Weighted average exercise price, ending"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvu9zkcQx5pg" style="text-align: right" title="Weighted average remaining contractual life"&gt;5.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjmPJFz78dti" style="text-align: right" title="Aggregate intrinsic value, ending"&gt;787,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTP5Y15iGVAc" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,258,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7MNd8qOHPMd" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ye87I9gl87" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_uUSD_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zucj29CP0SH6" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;787,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHbMwgnL9hrg" style="text-align: right" title="Number of shares under options, unvested ending"&gt;5,896,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKAsY49mCuXg" style="text-align: right" title="Weighted average exercise price, unvested ending"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3rZDaT0F483" style="text-align: right" title="Weighted average remaining contractual life, unvested"&gt;9.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_za27Ur5hVJU" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
March 31, 2020, our outstanding options had exercise prices ranging from $&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MinimumMember_z2zcK2shnuD8" title="Range - exercise price of options"&gt;0.19&lt;/span&gt; to $&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_pii_uUSDPShares_c20200331__srt--RangeAxis__srt--MaximumMember_zsWv4cXD5p69" title="Range - exercise price of options"&gt;8.92&lt;/span&gt; per share. Share-based compensation expense
related to options recognized in our results of operations for the three months ended March 31, 2020 and 2019 was approximately
$&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8Oalng9xOC3" title="Share-based Payment Arrangement, Noncash Expense"&gt;1,836,630&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_uUSD_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8ophyRUIDAl" title="Share-based Payment Arrangement, Noncash Expense"&gt;2,143,239&lt;/span&gt;, respectively, and it is based on awards vested. At March 31, 2020, total unrecognized estimated compensation
expense related to unvested options was approximately $&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_uUSD_c20200331_zRML7RPGHnm5" title="Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"&gt;9,800,000&lt;/span&gt;, which may be adjusted for future changes in forfeitures. This
cost is expected to be recognized over a weighted-average period of &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaONmS9Je3Ak" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"&gt;2.3&lt;/span&gt; years. No tax benefit was realized due to a continued
pattern of operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified
number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on
the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested
portion is forfeited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Performance
stock awards will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award
will convert into common stock at a defined ratio depending on the degree of achievement of the performance target designated
by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. Based upon the expected
levels of achievement, stock-based compensation is recognized on a straight-line basis over the awards&#x2019; requisite service
periods. The expected levels of achievement are reassessed over the requisite service periods and, to the extent that the expected
levels of achievement change,
stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based
compensation is recognized over the remaining requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended March 31, 2020 and 2019, we recorded $&lt;span id="xdx_907_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20200101__20200331_zymRAM7dloi3" title="Restricted Stock or Unit Expense"&gt;503,377&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--RestrictedStockExpense_pp0p0_uUSD_c20190101__20190331_z55Q3WhfHaLb" title="Restricted Stock or Unit Expense"&gt;346,414&lt;/span&gt;, respectively, in share-based compensation expense
related to restricted stock units and performance stock awards. At March 31, 2020, total unrecognized estimated compensation expense
related to unvested restricted stock units and performance stock awards was approximately $&lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_uUSD_c20200331_zGZpPEt96H98" title="Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"&gt;9,830,000&lt;/span&gt;, which may be adjusted if
certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of &lt;span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7TixGtmu7T2" title="Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"&gt;2.6&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8Mso4923Ztl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock and performance stock awards (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Restricted
Stock Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Performance
Stock Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
                                         Average Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
                                         Average Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfs80wXB0Y6" style="width: 12%; text-align: right" title="Number of shares, beginning"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1gikQdahEX7" style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;3.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="Number of shares, beginning"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDPV5o0aOG94" style="text-align: right" title="Number of shares, granted"&gt;3,384,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgCPBNvZ4a9i" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8L3oT6dXQG6" style="text-align: right" title="Number of shares, granted"&gt;2,384,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhdvXun1r73j" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Vested/Released&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsSLdiyKRYI7" style="text-align: right" title="Number of shares, vested/released"&gt;(150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znw5y3XsKQba" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1kzQucs7e08" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;4,474,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKxgxHQZES9d" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zCUDguZmo065" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;2,384,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5SxZglFc9d2" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"/&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">271677742</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">271677742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">350666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">72109</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">276383</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">100107</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1832571</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2020-01-01to2020-03-31">P1Y8M12D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-03-31_custom_WarrantsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-03-31_custom_WarrantsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">5.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.608</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.0252</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-01-012019-03-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-03-31_us-gaap_WarrantMember348335407"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2019-01-012019-03-31_custom_WarrantsCashlessExerciseMember"
      decimals="INF"
      unitRef="Shares">471184</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-03-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">26446</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-03-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">85716</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">14546246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">6316474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-03-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">4970994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-03-31_custom_NewSharesMember"
      decimals="INF"
      unitRef="Shares">2354764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-03-31_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2395333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-03-31_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">220897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">4292501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">3584245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">2384245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmiZZrXoInTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires
the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life
of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 and
2019 are set forth in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKT3HpcC3Ctk" style="width: 12%; text-align: right" title="Weighted average grant date fair value"&gt;0.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKCm4GBhbZ64" style="width: 12%; text-align: right" title="Weighted average grant date fair value"&gt;3.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAoURtu9Slh2" style="font: 10pt Times New Roman, Times, Serif"&gt;1.32&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrhE696UcnGe"&gt;1.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zclHBCYrH4Y8" style="text-align: right" title="Risk-free interest rate"&gt;2.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKbbd5VICeke" title="Volatility - minimum"&gt;63.53&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyNJb5gWKHf9" title="Volatility - maximum"&gt;65.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zp37dwdC0gd" style="text-align: right" title="Volatility"&gt;61.85&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zBqThQyn9EH2" title="Term"&gt;6&lt;/span&gt;-&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zI3qCxPIUrU9" title="Term"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm4RzCP1iPK" style="text-align: right" title="Term"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRCbPvXZsR1g" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20190101__20190331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z97xFrXVFlxg" style="text-align: right" title="Dividend yield"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCouQC6ZD5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of activity under the 2009, 2012 and 2019 Plans and related information during the three months ended March 31, 2019 is
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Contractual &lt;br/&gt;Life
    in Years&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 39%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF74Vd7stZY6" style="width: 11%; text-align: right" title="Number of shares under options, beginning"&gt;25,030,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg5erwQ0O0H1" style="width: 11%; text-align: right" title="Weighted average exercise price, beginning"&gt;4.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlNh1WMeN8Tk" style="width: 11%; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7nHUxpATmu4" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;3,668,171&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIrW2Q4UU0yl" style="text-align: right" title="Number of shares under options, granted"&gt;636,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKkPU4yQi8b" style="text-align: right" title="Weighted average exercise price, granted"&gt;1.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPDM0gLWg4I4" style="text-align: right" title="Number of shares under options, exercised"&gt;(350,666&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEkpJ98J88v9" style="text-align: right" title="Weighted average exercise price, exercised"&gt;0.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKMQTcpYeBii" style="text-align: right" title="Aggregate intrinsic value, exercised"&gt;725,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9eD9aqL6MO8" style="text-align: right" title="Number of shares under options, expired"&gt;(50,472&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4gOKEtgi3Al" style="text-align: right" title="Weighted average exercise price, expired"&gt;0.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;&#160;&#160;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyA0VXRGp0Xc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(110,375&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HEMrytqGP7" style="text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR85TrJIPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares under options, ending"&gt;25,155,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z35NKobVHVH5" style="text-align: right" title="Weighted average exercise price, ending"&gt;4.65&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvu9zkcQx5pg" style="text-align: right" title="Weighted average remaining contractual life"&gt;5.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_uUSD_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjmPJFz78dti" style="text-align: right" title="Aggregate intrinsic value, ending"&gt;787,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vested and Exercisable at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTP5Y15iGVAc" style="text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;19,258,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7MNd8qOHPMd" style="text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;5.02&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Ye87I9gl87" style="text-align: right" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_uUSD_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zucj29CP0SH6" style="text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;787,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pii_uShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHbMwgnL9hrg" style="text-align: right" title="Number of shares under options, unvested ending"&gt;5,896,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pii_uUSDPShares_c20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKAsY49mCuXg" style="text-align: right" title="Weighted average exercise price, unvested ending"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3rZDaT0F483" style="text-align: right" title="Weighted average remaining contractual life, unvested"&gt;9.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25030234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3668171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">636500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">350666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">725199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">50472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">110375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25155221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">787178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">19258556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">P4Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">787178</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">5896665</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.42</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">P9Y18D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.19</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2020-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1836630</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-03-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">2143239</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">9800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-03-31_us-gaap_EmployeeStockOptionMember">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedStockExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">503377</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">346414</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">9830000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockUnitsRSUMember">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z8Mso4923Ztl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Restricted stock and performance stock awards (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Restricted
Stock Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Performance
Stock Awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
                                         Average Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
                                         of Shares&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b/&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
                                         Average Grant Date Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfs80wXB0Y6" style="width: 12%; text-align: right" title="Number of shares, beginning"&gt;1,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1gikQdahEX7" style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;3.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="Number of shares, beginning"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted average grant date fair value, beginning"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDPV5o0aOG94" style="text-align: right" title="Number of shares, granted"&gt;3,384,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgCPBNvZ4a9i" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z8L3oT6dXQG6" style="text-align: right" title="Number of shares, granted"&gt;2,384,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zhdvXun1r73j" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;1.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Vested/Released&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsSLdiyKRYI7" style="text-align: right" title="Number of shares, vested/released"&gt;(150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_znw5y3XsKQba" style="text-align: right" title="Weighted average grant date fair value, vested/released"&gt;2.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;&#160;&#160;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1kzQucs7e08" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;4,474,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKxgxHQZES9d" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_uShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zCUDguZmo065" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, ending"&gt;2,384,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_uUSDPShares_c20200101__20200331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z5SxZglFc9d2" style="text-align: right" title="Weighted average grant date fair value, ending"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">3384245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">2384245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-03-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">4474245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="Shares">2384245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-03-31_us-gaap_PerformanceSharesMember"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zOK9h2MmOi8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
12 &#x2013; INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. We do not expect to pay any significant federal or state income tax for 2020 as a result of (i) the losses recorded
during the three months ended March 31, 2020, (ii) additional losses expected for the remainder of 2020, and/or (iii) net operating
loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax
assets if it is &#x201c;more likely than not&#x201d; that some component or all of the benefits of deferred tax assets will not
be realized. As of March 31, 2020, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements,
no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the
reporting period.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrEhlWxw6pSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
13 &#x2013; RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;In
July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to
time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements
with Catalent have been reviewed by independent directors of our company, or a committee consisting of independent directors of
our company, since July 2015. During the three months ended March 31, 2020 and 2019, we were billed by Catalent approximately
$&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20200101__20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z3oFfM9nGANh" title="Amount billed"&gt;1,303,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zpJg8liN9Tx8" title="Amount billed"&gt;1,397,000&lt;/span&gt;&lt;span style="background-color: white"&gt;,
respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation
testing. As of March 31, 2020 and December 31, 2019, there were amounts due to Catalent of approximately $&lt;/span&gt;&lt;span id="xdx_90C_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zQme2UgDxVZj" title="Amounts due to related party"&gt;755,000&lt;/span&gt; &lt;span style="background-color: white"&gt;and
$&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zE9PfebzlMbc" title="Amounts due to related party"&gt;35,000&lt;/span&gt;&lt;span style="background-color: white"&gt;, respectively. In addition, we have minimum purchase requirements in place
with Catalent as disclosed in Note 15, Commitments and Contingencies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2020-01-012020-03-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">1303000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-01-012019-03-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">1397000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2020-03-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">755000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2019-03-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_80C_eus-gaap--ConcentrationRiskDisclosureTextBlock_z4loBUXUHMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
14 &#x2013; BUSINESS CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
purchase our prescription products from several suppliers with approximately &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zbhYELJlr5Uh" title="Concentration risk"&gt;32&lt;/span&gt;%, &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zQ1XMiUXW4Id" title="Concentration risk"&gt;28&lt;/span&gt;%, &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zthVxpVKaYK5" title="Concentration risk"&gt;24&lt;/span&gt;% and &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zaoS24yqS4B5" title="Concentration risk"&gt;13&lt;/span&gt;% of our purchases supplied by
four vendors each, respectively, during the three months ended March 31, 2020 and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierOneConcentrationRiskMember_zg5SqwrrnO57" title="Concentration risk"&gt;33&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z65UES1vk0k4" title="Concentration risk"&gt;29&lt;/span&gt;%, &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zkyrP7FmlPm9" title="Concentration risk"&gt;27&lt;/span&gt;% and &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierFourConcentrationRiskMember_zgtlqNsGTzW5" title="Concentration risk"&gt;11&lt;/span&gt;% of our purchases supplied
by four vendors each, respectively, during the three months ended March 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores
that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months
ended March 31, 2020, &lt;span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zJWaOaYw1Hrj" title="Number of customers - revenue"&gt;four&lt;/span&gt; customers each accounted for more than &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzqivXVzo4Og" title="Concentration risk"&gt;10&lt;/span&gt;%
of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zxsFXqJcYeb6" title="Concentration risk"&gt;70&lt;/span&gt;%
of our prescription revenue for the three months ended March 31, 2020. During the three months ended March 31, 2019, &lt;span id="xdx_909_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvuebnY3r9V1"&gt;five&lt;/span&gt;
customers each generated more than &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziYlqDFn7kfh" title="Concentration risk"&gt;10&lt;/span&gt;%
of our prescription revenues. Revenue generated from the five customers combined accounted for approximately &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FiveCustomersConcentrationRiskMember_z4D7kWoziI3c" title="Concentration risk"&gt;83&lt;/span&gt;%
of our prescription revenue for the three months ended March 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended March 31, 2020, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90F_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zK3o0Jfpg52" title="Revenues"&gt;3,199,000&lt;/span&gt; of our prescription revenue,
McKesson Corporation accounted for approximately $&lt;span id="xdx_90C_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zzWQDVF6dl7b" title="Revenues"&gt;2,259,000&lt;/span&gt; of our prescription revenue, Cardinal Health accounted for
approximately $&lt;span id="xdx_90E_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_z15vUxEeXY27" title="Revenues"&gt;1,886,000&lt;/span&gt; of our prescription revenue and Pharmacy Innovation PA accounted for approximately $&lt;span id="xdx_90D_eus-gaap--Revenues_pp0p0_uUSD_c20200101__20200331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zJ6qWO7XUeI4" title="Revenues"&gt;1,234,000&lt;/span&gt; of our
prescription revenue. During the three months ended March 31, 2019, PI Services accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zS9jKAOiH47h" title="Revenues"&gt;967,000&lt;/span&gt; of our &lt;/span&gt;prescription
revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_908_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zv2ESvX08fr2" title="Revenues"&gt;787,000&lt;/span&gt; of our prescription revenue, Pillpack, Inc. accounted for
approximately $&lt;span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_z1teRsXY3Nid" title="Revenues"&gt;534,000&lt;/span&gt; of our prescription revenue, Cardinal Health accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zk56pYPfTsmd" title="Revenues"&gt;525,000&lt;/span&gt; of our prescription
revenue and McKesson Corporation accounted for approximately $&lt;span id="xdx_900_eus-gaap--Revenues_pp0p0_uUSD_c20190101__20190331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zQqIFZ9wbowk" title="Revenues"&gt;457,000&lt;/span&gt; of our prescription revenue.&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_custom_SupplierOneConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_custom_SupplierFourConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_custom_SupplierOneConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_custom_SupplierFourConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">5</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_FiveCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">3199000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember"
      decimals="0"
      unitRef="USD">2259000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">1886000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-012020-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember"
      decimals="0"
      unitRef="USD">1234000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember"
      decimals="0"
      unitRef="USD">967000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">787000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">534000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">525000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember"
      decimals="0"
      unitRef="USD">457000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKjfzAFxO555" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
15 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Operating
Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities
represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease
liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased
asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use
asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct
costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is
initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the
same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease
payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured
using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments
based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications
result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period
that were not included in the initial lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a &lt;span id="xdx_90C_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_z49Hc1Gs7cjb" title="Non-cancelable operating lease term"&gt;63&lt;/span&gt;-month term. On February 18, 2015, we entered into an agreement with the same lessors to
lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes &lt;span id="xdx_90E_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zdnTAIJYtIbe" title="Net rentable area"&gt;56,212&lt;/span&gt; rentable square
feet, or the full premises, of which the lease on &lt;span id="xdx_908_ecustom--RentedAreaLease_iI_usqft_c20181002_zavPAji6Zzr7" title="Rented area lease"&gt;7,561&lt;/span&gt; square feet commenced in 2018 and the lease on the remaining &lt;span id="xdx_901_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zuk9U7TpcpOk" title="Additional area of lease occupied"&gt;48,651&lt;/span&gt; square
feet commenced in August 2019, or the full premises commencement date. The lease will expire &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_c20190801_zooqb9Fp7uQ3" title="Lessee, Operating Lease, Term of Contract"&gt;11 years&lt;/span&gt; after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term
of the lease for &lt;span id="xdx_90B_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200331_zGKl8cgGsoKh" title="Number of options to extend lease"&gt;two&lt;/span&gt; additional consecutive periods of &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_c20200331_z7m3STSvPd17" title="Lease renewal term"&gt;five years&lt;/span&gt;. The extension option is not included in the determination of
the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods.
We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June
2019, we entered into an agreement with the same lessors to lease additional &lt;span id="xdx_90B_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zGsNAQs5rXtf" title="Lease not yet commenced (area)"&gt;6,536&lt;/span&gt; square feet of administrative office space
in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the second quarter of 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_pp0p0_zNY6Q43yVFNk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental lease information at:&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20200331_zxV04oRYF49a" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20191231_zmdyR94QUFKl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXsktDN2sUf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,757,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zMvBIFJAm8nk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zgc1gXR5vOgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,782,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20200331_zgpKv29c3Da5" style="text-align: right"&gt;9
years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zkV39ZTLEp8j" style="text-align: right"&gt;9
years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_zUc06LuSM8O2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;Supplemental cash flow information &lt;br/&gt;
for the three
    months ended:&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"/&gt;&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&#160;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"/&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March
                                         31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: -10pt; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200331_zuL23QaCMZd5" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;327,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeasePayments_pp0p0_c20190101__20190331_zuzqDRbG7V09" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;279,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20200331_zThhmozWlRkf" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20190101__20190331_zLBPQS6oYC3c" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;3,760,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMfhD1if9rfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities
recorded on the balance sheet:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20200331_zhIW313Tinf5"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz43w_zCAZN4lRQIi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 44%"&gt;2020 (9 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,239,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz43w_zpNF4VUEvJbk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,198,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz43w_zbebADZ5EjO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,262,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz43w_zsChrp9u3jZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,293,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz43w_z5JX4iD4rHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz43w_zEuArkid0XZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,036,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPz43w_z3WEFqQI4RUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,357,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zW2oDb4PO6sd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,821,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zidasaTE7p9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,535,773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zuXTlzE5dyei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;During
the three months ended March 31, 2020 and 2019, operating lease expense related to our real estate leases was $&lt;span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20200101__20200331_zllAgsvvtDMc" title="Operating lease expense"&gt;563,764&lt;/span&gt; and $&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20190331_zFemHXpOi1c7" title="Operating lease expense"&gt;295,109&lt;/span&gt;&lt;span style="background-color: white"&gt;,
respectively, and variable lease expense was insignificant.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Intellectual
Property Licenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of revenue as described in Note 3, Summary of Significant Accounting Policies&lt;span style="background-color: white"&gt;,
to these consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent &lt;/span&gt;&lt;span id="xdx_90A_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20200331_zaLFiVzssxN9" style="font: 10pt Times New Roman, Times, Serif" title="Significant supply commitment percentage payable"&gt;50&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. In addition, we have a manufacturing and
supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year. As of
March 31, 2020, we have met our purchase commitments with Catalent.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Legal
Proceedings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Off-Balance
Sheet Arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of March 31, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or
future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Employment
Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2013-06-302013-07-01">P63M</txmd:CapitalLeaseObligationsTerm>
    <txmd:NetRentableAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">56212</txmd:NetRentableAreaLease>
    <txmd:RentedAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">7561</txmd:RentedAreaLease>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-08-01">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber contextRef="AsOf2020-03-31" decimals="INF" unitRef="Pure">2</txmd:LesseeOperatingLeaseExistenceOfOptionToExtendNumber>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-03-31">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea contextRef="AsOf2019-06-01" decimals="INF" unitRef="sqft">6536</txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_pp0p0_zNY6Q43yVFNk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental lease information at:&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20200331_zxV04oRYF49a" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20191231_zmdyR94QUFKl" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXsktDN2sUf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,757,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,109,154&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zMvBIFJAm8nk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,753,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,501,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zgc1gXR5vOgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8,782,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,145,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted average remaining term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20200331_zgpKv29c3Da5" style="text-align: right"&gt;9
years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zkV39ZTLEp8j" style="text-align: right"&gt;9
years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_zUc06LuSM8O2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&lt;b&gt;Supplemental cash flow information &lt;br/&gt;
for the three
    months ended:&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"/&gt;&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31,&#160;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"/&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March
                                         31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: -10pt; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200331_zuL23QaCMZd5" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;327,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeasePayments_pp0p0_c20190101__20190331_zuzqDRbG7V09" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;279,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20200331_zThhmozWlRkf" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x97;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20190101__20190331_zLBPQS6oYC3c" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;3,760,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">9757167</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1753499</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">8782274</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-03-31">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-03-31" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">327386</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">279742</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">3760171</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMfhD1if9rfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities
recorded on the balance sheet:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20200331_zhIW313Tinf5"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz43w_zCAZN4lRQIi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 44%"&gt;2020 (9 months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,239,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz43w_zpNF4VUEvJbk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,198,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz43w_zbebADZ5EjO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,262,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz43w_zsChrp9u3jZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,293,859&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz43w_z5JX4iD4rHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,326,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz43w_zEuArkid0XZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,036,931&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPz43w_z3WEFqQI4RUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,357,069&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zW2oDb4PO6sd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(4,821,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zidasaTE7p9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,535,773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1239230</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2198541</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1262302</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1293859</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1326206</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">8036931</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">15357069</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">4821296</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">10535773</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      unitRef="USD">563764</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">295109</us-gaap:OperatingLeaseExpense>
    <txmd:SignificantSupplyCommitmentPercentagePayable contextRef="AsOf2020-03-31" decimals="INF" unitRef="Pure">0.50</txmd:SignificantSupplyCommitmentPercentagePayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-03-31">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zR17Y1wtVQ08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
16 &#x2013; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Paycheck
Protection Program Loan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 27, 2020, we received a loan pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security Act, or the CARES Act, as administered by the U.S. Small Business Administration, or the SBA. The loan in the principal
amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_uUSD_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zR5vIxPGLC1j" title="Principal amount"&gt;6,477,094&lt;/span&gt;, or the PPP Loan, was disbursed by Bank of America, NA, a national banking association, or BofA, pursuant
to a promissory note issued by the Company, or the Promissory Note.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The PPP
Loan matures on the two-year anniversary of the funding date and bears interest at a fixed rate of&lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zE0HdnO9pnyj" title="Interest rate"&gt; 1.00&lt;/span&gt;%
per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (discussed below), will
commence after the six-month anniversary of the funding date. We did not provide any collateral or guarantees for the PPP Loan,
nor did we pay any facility charge to obtain the PPP Loan. The Promissory Note provides for customary events of default,
including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material
adverse effects. We may prepay the principal of the PPP Loan at any time without incurring any prepayment charges.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
or a portion of &lt;span title="Description of PPP loan forgiven"&gt;the PPP Loan may be forgiven by the SBA and BofA upon application by us beginning 60 days but not later than 90
days after the funding date of the PPP Loan. Under the CARES Act, loan forgiveness is available for the sum of documented payroll
costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan.
For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $&lt;span id="xdx_900_ecustom--IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zXo2YmzCzxuh" title="Individual employee annual compensation maximum for payroll costs under loan"&gt;100,000&lt;/span&gt;, prorated annually.
Not more than &lt;span id="xdx_90D_ecustom--MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zKijJPzNxrDd" title="Maximum percentage of forgiven amounts for nonpayroll costs under loan"&gt;25&lt;/span&gt;% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines,
or if salaries and wages for employees with salaries of $&lt;span id="xdx_907_ecustom--IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness_pp0p0_uUSD_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zCVCWquAIq24" title="Individual employee maximum salary reduced by specified percentage for reduction of loan forgiveness"&gt;100,000&lt;/span&gt; or less annually are reduced by more than &lt;span id="xdx_900_ecustom--IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness_pii_dp_c20200426__20200427__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramLoanMember_zyBYuvBoUsLj" title="Individual employee salary reduction specified percentage for reduction of loan forgiveness"&gt;25&lt;/span&gt;%.&lt;/span&gt; Although we currently
believe that our use of the PPP Loan will meet the conditions for forgiveness of the loan, we cannot assure that the PPP Loan
will be forgiven, in whole or in part.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Amendment
No. 2 to Financing Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with incurring the PPP Loan, we, together with our subsidiaries, amended the Financing Agreement to, among other things,
permit us to incur the PPP Loan and add certain affirmative covenants relating thereto.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="0"
      unitRef="USD">6477094</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="INF"
      unitRef="Pure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <txmd:IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan
      contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="0"
      unitRef="USD">100000</txmd:IndividualEmployeeAnnualCompensationMaximumForPayrollCostsUnderLoan>
    <txmd:MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan
      contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="INF"
      unitRef="Pure">0.25</txmd:MaximumPercentageOfForgivenAmountsForNonpayrollCostsUnderLoan>
    <txmd:IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness
      contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="0"
      unitRef="USD">100000</txmd:IndividualEmployeeMaximumSalaryReducedBySpecifiedPercentageForReductionOfLoanForgiveness>
    <txmd:IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness
      contextRef="From2020-04-262020-04-27_us-gaap_SubsequentEventMember_custom_PaycheckProtectionProgramLoanMember"
      decimals="INF"
      unitRef="Pure">0.25</txmd:IndividualEmployeeSalaryReductionSpecifiedPercentageForReductionOfLoanForgiveness>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6822360720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 6,087,359<span></span>
</td>
<td class="nump">$ 8,040,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">10,712,171<span></span>
</td>
<td class="nump">10,316,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">893,332<span></span>
</td>
<td class="nump">3,285,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">1,874,036<span></span>
</td>
<td class="nump">1,463,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Accrued wholesale distributor fees</a></td>
<td class="nump">3,897,398<span></span>
</td>
<td class="nump">2,347,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">909,137<span></span>
</td>
<td class="nump">422,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,179,065<span></span>
</td>
<td class="nump">1,049,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,753,499<span></span>
</td>
<td class="nump">1,501,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">4,794,794<span></span>
</td>
<td class="nump">3,916,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">823,694<span></span>
</td>
<td class="nump">1,480,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 32,924,485<span></span>
</td>
<td class="nump">$ 33,823,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6820444848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of the following:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z9HcyPKJavwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49E_20200331_zJ6OnGfW0RJ1" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20191231_zy54QoRqwAMl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_402_eus-gaap--InventoryFinishedGoods_iI_z1MWAvfmBMF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Finished products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,956,900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,976,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_zHqBoUQfxH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,554,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,182,059</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InventoryRawMaterialsAndSupplies_iI_zeAitBvwQ9qa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,095,662</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,701,747</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_iI_zJDL3HUjRQP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,607,453</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,860,716</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806287264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKjfzAFxO555" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
15 &#8211; COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities
represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease
liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased
asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use
asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct
costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is
initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the
same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease
payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured
using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments
based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications
result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period
that were not included in the initial lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1,
2013 and originally provided for a <span id="xdx_90C_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_z49Hc1Gs7cjb" title="Non-cancelable operating lease term">63</span>-month term. On February 18, 2015, we entered into an agreement with the same lessors to
lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April
26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location.
This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.
On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the
same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_90E_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zdnTAIJYtIbe" title="Net rentable area">56,212</span> rentable square
feet, or the full premises, of which the lease on <span id="xdx_908_ecustom--RentedAreaLease_iI_usqft_c20181002_zavPAji6Zzr7" title="Rented area lease">7,561</span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_901_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zuk9U7TpcpOk" title="Additional area of lease occupied">48,651</span> square
feet commenced in August 2019, or the full premises commencement date. The lease will expire <span id="xdx_903_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_c20190801_zooqb9Fp7uQ3" title="Lessee, Operating Lease, Term of Contract">11 years</span> after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term
of the lease for <span id="xdx_90B_ecustom--LesseeOperatingLeaseExistenceOfOptionToExtendNumber_iI_dc_uPure_c20200331_zGKl8cgGsoKh" title="Number of options to extend lease">two</span> additional consecutive periods of <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_c20200331_z7m3STSvPd17" title="Lease renewal term">five years</span>. The extension option is not included in the determination of
the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods.
We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June
2019, we entered into an agreement with the same lessors to lease additional <span id="xdx_90B_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zGsNAQs5rXtf" title="Lease not yet commenced (area)">6,536</span> square feet of administrative office space
in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the second quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_pp0p0_zNY6Q43yVFNk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information at:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_495_20200331_zxV04oRYF49a" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20191231_zmdyR94QUFKl" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zXsktDN2sUf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Right-of-use asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,757,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,109,154</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zMvBIFJAm8nk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Short-term operating lease liability (included in Other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,753,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zgc1gXR5vOgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,782,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,145,049</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Weighted average remaining term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20200331_zgpKv29c3Da5" style="text-align: right">9
years</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zkV39ZTLEp8j" style="text-align: right">9
years</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_zUc06LuSM8O2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.25</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"><b>Supplemental cash flow information <br/>
for the three
    months ended:</b></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"/><td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March 31,&#160;2020</b></span></td><td style="text-align: center; padding-bottom: 1pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"/><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>March
                                         31, 2019</b></span></td><td style="padding-bottom: 1pt; text-align: center"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200331_zuL23QaCMZd5" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease">327,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeasePayments_pp0p0_c20190101__20190331_zuzqDRbG7V09" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease">279,742</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20200101__20200331_zThhmozWlRkf" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#151;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pp0p0_c20190101__20190331_zLBPQS6oYC3c" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligation">3,760,171</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zMfhD1if9rfe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table reconciles the undiscounted cash flows for all operating leases at March 31, 2020 to the operating lease liabilities
recorded on the balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><b>Year Ended December 31,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_49D_20200331_zhIW313Tinf5"><b>&#160;</b></td></tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPz43w_zCAZN4lRQIi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 44%">2020 (9 months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,239,230</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPz43w_zpNF4VUEvJbk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,198,541</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPz43w_zbebADZ5EjO2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,262,302</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPz43w_zsChrp9u3jZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,293,859</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPz43w_z5JX4iD4rHNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,326,206</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPz43w_zEuArkid0XZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,036,931</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_mtLOLLPz43w_z3WEFqQI4RUd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,357,069</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zW2oDb4PO6sd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,821,296</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zidasaTE7p9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,535,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A2_zuXTlzE5dyei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the three months ended March 31, 2020 and 2019, operating lease expense related to our real estate leases was $<span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20200101__20200331_zllAgsvvtDMc" title="Operating lease expense">563,764</span> and $</span><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20190331_zFemHXpOi1c7" title="Operating lease expense">295,109</span><span style="background-color: white">,
respectively, and variable lease expense was insignificant.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Intellectual
Property Licenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies.
In addition, we pay royalties as a percent of revenue as described in Note 3, Summary of Significant Accounting Policies<span style="background-color: white">,
to these consolidated financial statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Purchase
Commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels
during the first contract year and a higher number of softgels after the first contract year. If the minimum order quantities
of specific products are not met, we are required to pay Catalent </span><span id="xdx_90A_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20200331_zaLFiVzssxN9" style="font: 10pt Times New Roman, Times, Serif" title="Significant supply commitment percentage payable">50</span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and
the sum of all purchases of our products from Catalent during the contract year. In addition, we have a manufacturing and
supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year. As of
March 31, 2020, we have met our purchase commitments with Catalent.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Legal
Proceedings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved
in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations,
or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 31, 2020 and 2019, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or
future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Employment
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits.
Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments,
if those circumstances occur during the term of the employment agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813839440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities consist of the following:</a></td>
<td class="text"><p id="xdx_895_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zARa1nt0YMu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Other
current liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_493_20200331_zXU6bS3Y7usf" style="border-bottom: Black 1pt solid; text-align: center"><b>March 31, 2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" id="xdx_491_20191231_zUXEzD95cGAb" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr id="xdx_407_eus-gaap--AccruedSalariesCurrent_iI_maOLCzu3r_zu7w3AR93IA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify">Accrued payroll, bonuses and commission costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,087,359</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,040,278</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_pp0p0_maOLCzu3r_zYayDvE07DA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,712,171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,316,298</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedMarketingCostsCurrent_iI_pp0p0_maOLCzu3r_z5SyHQzqD0Xh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued sales and marketing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">893,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,285,662</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maOLCzu3r_zDCcuIpSRXeb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued compensated absences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,874,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,463,878</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_pp0p0_maOLCzu3r_zBtGcJ050cz9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,897,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,347,122</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzu3r_zby3Z8amvHs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">909,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">422,336</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maOLCzu3r_zSmzDQRsKmFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,179,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,049,603</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLCzu3r_zteRE5GZDNH7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,753,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,501,539</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--AccruedRebates_iI_pp0p0_maOLCzu3r_zEqtw8txrvNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accrued rebates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,794,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,916,672</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maOLCzu3r_zGmyUO6kHg4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">823,694</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,480,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_mtOLCzu3r_zB9nSjMyVn86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,924,485</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,823,613</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
